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ABSTRACT
Non-compliance with antipsychotic medication is one of the main causes of relapse in
people with psychotic illnesses such as schizophrenia. In controlled trials, medication
management interventions such as compliance therapy and behavioural tailoring have
been shown to be effective in enhancing adherence. Community Psychiatric Nurses
(CPN5) are ideally placed to deliver such interventions but require additional training to
equip them with the necessary knowledge and clinical skills.
An initial investigation, a national survey of 250 CPNs, confirmed that current
medication management practice was generally poor but was enhanced if CPNs had
attended psychosocial intervention training (the Thom course). An 80 hour medication
management training package was developed, based on the available literature and expert
consensus opinion, and was piloted on fifteen CPNs. Following training there were
significant improvements in knowledge and clinical skills suggesting that further
investigation within the context of a randomised controlled trial was warranted.
A randomised controlled trial compared medication management training with routine
CPN care. It was hypothesised that medication management training would lead to
clinically significant improvements in patients' psychopathology, as a result of enhanced
treatment compliance, compared to routine care at week 26 assessment.
Sixty CPNs were organised into geographical clusters (to minimise the risk of
contamination) and randomised to either the experimental or waiting list control group.
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Each CPN identified two patients on their caseload who were assessed at baseline, week
26 and week 52. The primary outcome measure was the Positive and Negative Syndrome
Scale (PANSS).
Forty-four CPNs completed the trial. At the week 26 assessment, the patients of 48% of
CPNs in the experimental group and 26% of CPNs in the control group showed
improvements on the primary outcome measure. Response was maintained in the
experimental group at the week 52 assessment. Medication management training was also
superior to routine care in improving patients' attitudes towards treatment and
compliance, which were clinically significant. Intention to treat analysis did not
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CHAPTER ONE: BACKGROUND
1.1 OVERVIEW OF SCHIZOPHRENIA
Schizophrenia is a debilitating mental disorder characterised by a range of symptoms
including: delusions, formal thought disorder, hallucinations, abnormal affect, passivity
phenomena, motor abnormalities, cognitive deficits, lack of volition and lack of insight
(WHO, 1992). The presentation of the illness varies tremendously not only between
individuals but within the same individual at different stages of their illness.
Schizophrenia occurs in all cultures and has a lifetime incidence of about one per-cent.
The average age of onset is around 27 years in men and 31 years in women (Jones et a!.,
1994).
A number of studies have examined the premorbid and prodromal phases of
schizophrenia (Shepherd et a!., 1989; McGlashan, 1998; DeQuardo, 1998) and seem to
highlight that patients show evidence of developing schizophrenic symptoms months or
even years before they have contact with psychiatric services. In a study by Jones et al.
(1994) prospective data were collected on 4,746 individuals born in the UK during one
week in 1946. The results demonstrated subtle motor, linguistic and social dysfunction in
children who later developed schizophrenia. They showed increased deviance with age,
and cognitive decline became progressively more marked in early adolescence. The
premorbid phase merges into the prodromal phase in which actual functional decline may
be accompanied by eccentric ideas and interests, changes in affect, unusual speech and
bizarre perceptual experiences.
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Until recently the course of schizophrenia was considered to be one of continuous
deterioration (Shepherd et a!., 1989). However, very few studies have followed people
with schizophrenia beyond the middle decades of life. Long-term studies that have been
carried out suggest that schizophrenia tends to have a prolonged course with the greatest
variability in the initial stages (Bleuler, 1974; Ciompi, 1980).
The aetiology of schizophrenia is complex. Although the genetic contribution is well
established (Gotesman et al., 1987) other, probably environmental, factors clearly play a
role. Environmental factors that have been studied include pregnancy and birth
complications (Rifkin et a!., 1994; O'Callaghan et a!., 1994; McNeil, 1995), life events
(Bebbington eta!., 1993) and family interactions (Bebbington and Kuipers, 1994).
1.2 PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIA
Antipsychotic medication has been the mainstay of treatment for schizophrenia since the
1950s when it was discovered that the dopamine antagonist's haloperidol and
chiorpromazine exert antipsychotic effects. The dopamine hypothesis of schizophrenia is
supported by reports that the clinical potency of antipsychotics is proportional to the
extent to which they block dopamine receptors (Creese et a!., 1976). These observations
led to the widespread belief that excessive dopamine activity or hyperdopaminergia is
associated with the pathophysiology of schizophrenia.
According to the dopamine hypothesis, antipsychotic agents ameliorate the positive
symptoms of schizophrenia through dopamine D 2 blockade in the mesolimbic system. In
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fact, in vitro studies have shown a linear relationship between antipsychotic potency and
D2 blockade (Pilowsky et a!., 1992). Developments in imaging techniques such as
Positron Emission Tomography (PET) and Single Photon Emission Tomography (SPET)
have made it possible to carry out in vivo studies visualising receptor binding sites in the
brain. One PET study showed that a relatively modest dose of haloperidol (2mg/day)
resulted in 5 3-74% occupancy of available D2
 receptors (Farde et al., 1992). This
observation carries important clinical implications. It may suggest that there is a
maximum effective dose, above which there is no improvement in efficacy and a possible
decline in tolerability.
An inadequate response to treatment with neuroleptics may be encountered in more than
30% of patients with schizophrenia (Kane, 1989). It has been hypothesised, but not
confirmed, that a poor response to antipsychotic medication is due to inadequate
occupancy of central D 2 receptors. One SPET study showed no significant difference in
striatal D2 receptor availability among antipsychotic responders (n10), antipsychotic
non-responders (n=8) and normal controls (n20) (Pilowsky et a!., 1993). This suggests
that a poor clinical response cannot be attributed to inadequate striatal D 2 occupancy.
Other reports suggest that a high affinity for D 2
 receptors may not be the only basis for
efficacy in antipsychotic agents. Although these drugs typically occupy these receptors
within a few hours of administration, there is often a 1-3 week delay before therapeutic
benefits are reported (Gray, 1 998a). This suggests that these drugs act via a series of
secondary, and as yet unknown, processes that evolve over days to weeks. There are
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suggestions that a number of other neuroreceptors, peptides, and amino acid systems may
be involved. This is further supported by the fact that changes in systems other than the
dopamine system have been implicated in the aetiology of schizophrenia these include;
serotonin, glutamate, noradrenaline, neurotensin, and aminobutyric acid.
Chlorpromazine, the first effective pharmacological treatment for the symptoms of
schizophrenia was introduced during the I 950s. Since then, a variety of antipsychotic
agents have been developed. Controlled clinical trials have repeatedly shown that these
drugs are generally efficacious for the positive symptoms of schizophrenia. However,
tolerability problems, especially acute extrapyramidal symptoms (EPS; dystonias,
akathisia, and Parkinsonism), encountered with these so called conventional agents has
prompted further research into the development of improved novel and atypical agents
such as risperidone, olanzapine, and quetiapine.
Conventional antipsychotic agents are often associated with a high incidence of
extrapyramidal symptoms. In a much-cited study, Ayd (1961) surveyed 3,775 patients
treated with both high and low-potency conventional antipsychotic drugs and reported
that 38% of the sample developed acute EPS. However, subsequent studies have
produced wide variations in the incidence of EPS. For example, the incidence of akathisia
varies from 10% to 75% in different studies (Adler, 1989) and dystonia from almost zero
to 90% (Casey and Keepers, 1988). The incidence of Parkinsonism is more consistently
observed in approximately 50% of patients treated with conventional antipsychotics
(Keepers et al., 1983). Much of this variation can be explained by methodological and
diagnostic variations in study design. However, there does appear to have been a steady
increase in the prevalence of acute EPS in the past 30 years. This is almost certainly due
to the increased use of higher doses of high potency antipsychotics (Casey, 1996).
Although EPS are typically perceived as the most troublesome side effects associated
with antipsychotic agents, other side effects are also encountered with their use.
Antipsychotic agents have complex receptor binding profiles that may underlie these
effects. Hyperprolactinemia, caused by dopamine blockade in the tuberoinfundibular
dopamine pathway, may cause sexual dysfunction, amenoreah, galactorrohoea, or
gynacomastia. The blockade of muscarinic receptor may cause anticholinergic symptoms
(dry mouth, blurred vision, constipation) whilst the blockade of histamine receptors may
induce sedation. Little trial evidence exists on how to manage many of these symptoms,
although the management of acute EPS have been investigated in a number of studies.
1.2.1 Management of acute EPS
The treatment of acute dystonia and Parkinsonism is broadly similar and is generally
treated in two ways, dose titration, or more commonly, via the addition of other
pharmacological therapies. The recognition that EPS, at least in part, results from
dopamine/acetycholine imbalance secondary to dopamine blockade (Borrison, 1985) has
led to the widespread clinical use of anticholinergic drugs that reduce cholinergic activity
or, less frequently, dopamine agonists that enhance dopamine activity. Although early
studies, which were not methodologically robust, failed to confirm the superiority of
anticholinergics over placebo as anti-Parkinsonian agents (Mindham, 1976). A number of
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controlled studies have established the efficacy of anticholinergics in the treatment of
acute Parkinsonism (Mindham et a!., 1977; Korsgaard and Friis, 1986) and dystonia
(Goff eta!., 1991; Winslow eta!., 1986).
Although anticholinergic drugs are commonly used prophylactically to prevent the onset
of EPS, the evidence for this strategy is weak. In a review of the use of anticholinergics
Lavin and Rifkin (1991) found few data to support their use prophylactically, although
they did conclude that in young patients receiving high potency antipsychotics such a
strategy might be useful.
Anticholinergics are themselves associated with a range of side effects including dry
mouth, blurred vision, constipation, tachycardia, urinary hesitancy or retention, and
erectile dysfunction in men or failure of vaginal lubrication in women (Barnes and
McPhillips, 1996). There are also data which suggest that anticholinergics may provoke
or exacerbate tardive dyskinesia (TD) and that if withdrawn symptoms of TD improve
(Chouinard et al., 1988; Gerlach and Casey, 1988). Rebound phenomena, including
nausea, abdominal pain, restlessness and insomnia (Gardos et aL, 1978; Jellinek et a!.,
1981), and more recently akinetic depression (Bermanzohn and Stris, 1994) have been
reported following the rapid cessation of anticholinergics. Drachman (1977) also
observed that anticholinerics produce cognitive deficits similar to those observed in
normal ageing. In a double blind study of the effects of benzatropine on cognitive
functioning in people with chronic schizophrenia, Baker et a!. (1983) found that when
patients were switched to a placebo treatment their scores on tests of cognitive
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functioning improved significantly. Results suggest that anticholinergics may have
specific effects on patients' short-term memory and their ability to sustain attention.
Dopamine agonists, such as amantadine, restore the dopamine/acetyicholine balance and
have been shown in a number of controlled trials to be as effective as anticholinergics in
treating EPS (DiMascio et a!., 1976; Fann and Lake, 1976; Stenson et a!., 1976).
However, whilst avoiding the side effects of anticholinergics, dopamine agonists have
been shown to have their own problematic side effects including mood disturbance (Rego
and Geller, 1989), exacerbation of psychotic symptoms (Nestelbaum et al., 1986) and the
potential to be fatal in overdose (Cook et a!., 1986). Perhaps as a result they are rarely
used clinically.
Acute Parkinsonism and dystonia respond relatively well to treatment with
anticholinergics. Akathisia, however, responds in a less than satisfactory way (Boodhoo
and Sandler, 1991). In a series of studies, 3-b1ockers (e.g. propranolol) have been shown
to be effective in treating akathisia (Flischhacker, 1991; Kramer et al., 1988; Yassa et a!.,
1988). Trials have also shown that benzodiazapines are an effective treatment for
akathisia (Kabes et a!., 1982), although their mode of action, again, remains unclear.
The evidence for the efficacy of dose titration as a strategy for managing acute EPS is
also uncertain. Data from studies using Positron Emission Tomography (PET) suggest
that, in vivo, clinical response is achieved when 5 0-60% of striatal D2 receptors are
blocked, but EPS only emerges when >80% are blocked (Nordstrom et a!., 1993). This
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suggests that a reduction in the dose of an antipsychotic to within this therapeutic window
of D2 blockade should minimise acute EPS. This hypothesis has not, however, been
tested in large-scale clinical trials.
1.2.2 Atypical antipsychotics
Perhaps the most effective way of minimising the risk of EPS is via the use of atypical or
novel antipsychotics that, by definition, have a low propensity to induce EPS. The early
1 990s saw the introduction of clozapine the first of a new generation of antipsychotic
drugs. However, clozapine is not a new drug. When it was first introduced into Europe
during the 1 970s it was met with great hope. This drug overcame many of the limitations
of the conventional neuroleptics in that it appeared to reduce negative symptoms, it was
associated with little or no EPS, and it was effective for patients with refractory illness.
However, in 1975 agranulocytosis developed in 18 of 3,200 clozapine-treated patients in
Finland, and 4 of 2,900 in Switzerland (Gray, 1998a). The serious nature of this side
effect led to the voluntary withdrawal of clozapine from the market. Nonetheless, the
advent of clozapine marked an important advance in the treatment of schizophrenia.
In 1988, results of a multicentre study revealed that clozapine was more effective than
conventional neuroleptics for patients with treatment-resistant schizophrenia (Kane,
1988). A number of controlled (Claghorn et al., 1987) and uncontrolled (Meltzer, 1989;
Matted, 1989; Owen et a!., 1989; Clozapine Study Group, 1993) studies have
demonstrated that clozapine is a clinically useful drug that reduces both the positive and
negative symptoms of schizophrenia with a low incidence of EPS. In 1990, it was
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introduced in the U.K. with strict guidelines for haematological monitoring because of
the associated risk for agranulocytosis. Clinical experience with clozapine has led to the
development of other novel antipsychotic agents including risperidone, olanzapine,
sertindole, quetiapine and ziprasidone.
Phase III and IV clinical trials of these agents have repeatedly shown that they have
placebo levels of EPS (around 7-16%; Gray, 1999). However, there is a great deal of
variability in the mode of action of these drugs. For example, risperidone and ziprasidone
are potent dopamine D 2 and serotonin 5HT2a
 antagonists, whilst clozapine, olanzapine
and quetiapine are multireceptor antagonists (Moore, 1999).
In practice, because of their classical affinity for dopamine D 2
 receptors, risperidone and
ziprasidone will, at high doses, induce EPS. The same is not true of clozapine, olanzapine
and quetiapine which have a much weaker affinity for D 2
 receptors and as a result do not
have the propensity to induce EPS at higher doses (Bigliani and Pilowsky, 1999). It has
been proposed, but not confirmed, that risperidone and ziprasidone have a low incidence
of EPS because of serotonin-dopamine interactions in the basal ganglia. Serotonin
blockade appears to reverse the effects of dopamine D2
 blockade, but only in the
nigrostriatal system and not in the mesolimbic system (Kapur and Remington, 1996).
Clozapine, olanzapine, and quetiapine in contrast appear to have a naturally high affinity
for dopamine receptors in the mesolimbic system (Bigliani et a!., 1998) and consequently
a low propensity to induce EPS.
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There is convincing evidence for the efficacy of conventional antipsychotics. However.
they may tend to be used in higher than necessary doses and are generally poorly
tolerated. There are few data to assist in the management of many of these symptoms and
the evidence suggests that the management of acute EPS is challenging. Novel and
atypical antipsychotics are generally very well tolerated and have a low propensity to
induce many of the problematic side effects associated with conventional treatments
(Gray et al., 1999). Guidelines have been published to guide clinicians on how to
effectively use antipsychotics and minimise side effects (Taylor et a!., 1999) although
concern has been repeatedly expressed that clinicians fail to follow such guidance.
1.3 THE PROBLEM OF NON-COMPLIANCE
There is good evidence that the prophylactic use of antipsychotic medication reduces the
risk of relapse (Marder et a!., 1999; Kane 1989). However, a number of studies have
demonstrated that compliance with antipsychotic medication is generally poor and not
taking medication is associated with a substantial increase in relapse rates, more frequent
hospitalisations and a generally poorer outcome in people with psychotic illnesses (Gabel
and Piezcker, 1985; Helgason, 1990). Kemp et al. (1997) have proposed that the so called
'revolving door phenomena' can be almost exclusively attributed to repeated non-
compliance. Kisling (1994) has argued that if patients were completely compliant with
their medication, relapse rates would fall to about 15% (currently 50% of patients relapse
within a year of achieving remission). However, the assumption that poor compliance can
be attributed solely to the patient's failure to do what clinicians have told them to must be
juxtaposed with evidence that professionals often do not carry out their own
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responsibilities regarding medication. For example, Taylor et a!. (2000) showed that
prescriptions for antipsychotics are often inappropriate resulting in unwanted and
unnecessary side effects.
It has been proposed that either 'concordance' or 'adherence' should replace the use of
the word 'compliance'. Concordance emphases patient rights, the need for information
and the importance of two-way communication and decision making (although, this has
to be considered in light of the cognitive deficits and behavioural problems that are
common in people with schizophrenia). However, it is clinicians' practice rather than the
language that they use that is important, and it is practice that is the focus of this thesis.
1.3.1 How common is non-compliance?
Estimating compliance rates in people with schizophrenia has proved difficult for two
reasons. Firstly, there is no agreed definition of compliance - definitions vary from
complete cessation or verbal refusal, to any significant deviation from prescription,
including dosage errors or failure to attend appointments. Secondly, there is no valid way
of measuring compliance. Rates of compliance have been measured using a number of
different methods none has proved satisfactory. These include physicians' assessment
and patients' self-report, pill counts, and urine and blood assays. These methods of
assessment are not always reliable. Patient self-report and physician assessment are
inaccurate, both consistently overestimating compliance (Churchill, 1985). Pill counts are
more reliable, but it is impossible to tell whether the patient has actually ingested the
medication. Urine testing for a drug with a long half-life will tend to overestimate
30
compliance. Since most neuroleptics have a relatively long half-life, blood assay is likely
to prove more reliable. However, the degree of compliance is impossible to determine
and therefore blood assays can only be used as a criterion for current compliance
(Babiker, 1986).
The problem of accurately measuring adherence explains inconsistencies in the incidence
of non-compliance reported in people with schizophrenia. For example, Quitkin et a!.
(1978) used clinician judgement to determine compliance and observed that only 10% of
patients were non-compliant with their medication over a twelve month period. In
contrast Wolff and Colacino (1961) using patient interview over a six-month period
reported that 73% of patients were non-compliant. However, in a review of the world
literature Cramer and Rosenheck (1998) proposed an average non-compliance rate of
approximately 42% a finding that is similar to rates in other mental and physical
disorders.
1.3.2 Why are patients non-compliant?
Difficulties in reliably measuring compliance not only make it challenging to quantify the
incidence but also to produce a model to explain how patients make decisions about
taking antipsychotic medication. Studies have attempted to identify factors that affect
compliance, but are characterised by serious methodological problems over and above the
measurement of compliance.
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Several of the studies reviewed divide patients into two groups, compliant or non-
compliant, even though compliance is often partial rather than an all-or-nothing
phenomenon (Cramer and Rosenheck, 1998).
There is a risk that the assessment procedure itself may influence the behaviour under
investigation. Poor adherence tends to disappear under scrutiny and the findings are
therefore likely to reflect recent rather than overall compliance (Blackwell, 1996).
• It is difficult to ensure the participation of all patients in a given population. By
definition, non-compliant patients may not want to participate in a research project.
Given these limitations, what factors influence compliance in people with schizophrenia?
Patients with a physical disorder who accept that they have an illness and perceive it as
serious ('are insightful') tend to be more compliant (Haynes, 1976). This is consistent
with the Health Belief Model, which hypothesises that individuals reach decisions on
health actions based on their perception of the seriousness of the illness, their
susceptibility to it and the benefits of adherence (Babiker, 1986). In studies of non-
psychiatric patients this model generally shows a modest ability to predict/explain
treatment compliance (Meichenbaum and Tusk, 1987).
In schizophrenia, insight - defined as, awareness of illness, an ability to recognise
symptoms as part of an illness and acceptance of treatment - has also been associated
with compliance. A number of studies have examined the relationship between insight
and compliance with generally consistent results, despite substantive differences in
operational definitions of insight. Lin et a!. (1979) showed a significant relationship
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between insight and compliance in a prospective study. Marder (1983), Buchanan (1992)
and Kemp and David (1996) have all produced similar results. Some contradictory
findings have, however, been reported (McEvoy et al., 1989).
A number of interpersonal (such as the therapist's ability to listen and empathise with the
patient) and relationship factors (liking and trusting the therapist; and the patient's level
of involvement in treatment decisions including discussion of the patient's beliefs,
concerns and expectations) have been shown to correlate with compliance in patients
with physical disorders (Haynes, 1976). Patient interactions with the therapist, including
the process of formulating perceptions, therapist-influence and the patient's evaluation of
the treatment are incorporated into the 'Theory of Reasoned Action' (Cochran and Gitlin,
1988). However, the ability of this model to explain or predict compliance has not been
tested.
Psychotic psychopathology, especially paranoia, suspiciousness, grandiosity and
delusional beliefs about medication, were highlighted as influencing compliance in a
study by Appelbaum and Gutheil (1980) who interviewed 40 patients who refused
antipsychotic medication during a three month period. Similar results were reported by
van Putten et al. (1976) and Bartko et a!. (1988) who both observed that grandiose
delusions were more common in non-compliant patients. The more severe a patient's
psychopathology the worse their compliance. Renton et a!. (1963) examined this
relationship in a study of 132 patients. They reported that the severity of patients'
symptoms at the time of discharge was significantly associated with future adherence.
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Two studies have shown that when asked, patients indicate that, subjectively, side effects
have a significant impact on compliance (Weiden et a!., 1986; Renton et a!., 1963).
However, when this is examined more objectively findings are equivocal. Mutsatsa et a!.
(under review), for example, showed that contemporaneous side effects had a weak but
significant impact on compliance, van Putten et a!. (1974) demonstrated an increased
incidence of bradykinesia, dystonia and tremor, but not akathisia, in patients who were
reluctant to take medication. In this study akathisia was not associated with non-
compliance probably because of the difficulty in distinguishing it from anxiety. In a
further prospective study a strong correlation between akathisia and compliance was
found (van Putten et al., 1984). However, these findings have not been consistently
replicated. In a two-year prospective study Buchanan (1992) found no correlation
between akathisia and compliance although the study only examined side effects reported
at discharge from hospital. Flischhacker et a!. (1994) also failed to establish a link
between EPS and compliance in patients receiving long-term treatment with either
clozapine or haloperidol. Non-compliance with either drug was not predicted by the
incidence of Parkinsonian symptoms or akathisia during the first four weeks of treatment.
There is some evidence that a number of other factors may influence compliance:
McEvoy et a!. (1989) suggested that compliance was substantially higher in patients
whose medication was supervised by a family member; Swofford et a!. (1996) found that
compliance rates were much lower in patients with a co-morbid substance misuse
diagnosis. Other factors that are suggested within the literature as affecting compliance
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but lack any empirical evidence include the complexity of treatment regimes (Parkin et
al., 1976), and the patient's sociocultural background (Piatkowska and Famill, 1992).
1.3.3 Factors that enhance compliance
Adams and Howe (1993) examined factors that were likely to predict good compliance in
44 psychotic inpatients. The greater the number of indirect benefits of medication (i.e.
"keeps me out of hospital" or "it allows me to make new friends"), the more compliant
patients were. Similar results were reported by Chan (1984) who observed that compliant
patients had generally derived positive benefits from medication.
These data suggest that a number of pragmatic interventions may be potentially useful in
improving compliance, and consequently the health, of people with schizophrenia.
1.4 INTERVENTIONS TO ENHANCE COMPLIANCE
Given the relationship between good compliance and outcome it is perhaps surprising
how little research effort has been devoted to devising and testing interventions to
improve the taking of prescribed antipsychotic medication. A range of interventions has
been evaluated in patients with both physical and mental disorders although much of the
research has focused on schizophrenia or acute psychosis. The interventions that have
been tested include patient education (Seltzer et a!., 1980; Stricker et a!., 1986; Brown et
a!., 1987; Smith et a!., 1992; Macpherson et a!., 1996a; Gray, 2000), behavioural
interventions (Boczkowski et a!., 1985) and cognitive behavioural interventions
(Hayward et a!., 1995; Lecompte and Plec, 1996; Kemp et al., 1996; 1998). Although the
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number of patients in these studies was generally quite small, statistically significant
increases in medication adherence were found following some of the interventions. Very
few of the trials reported the impact of the intervention on clinical outcomes. Because of
the small sample sizes in these studies, the possibility of a false-negative (type II) error is
quite high.
1.4.1 Educational interventions
Educational interventions aim to provide information to patients about both their illness
and medication with the goal of increasing understanding and promoting compliance.
Group and individual patient education has been evaluated using a variety of
methodologies including a number of randomised controlled trials.
Group educational interventions were tested by Stricker et a!. (1986) and Smith et al.
(1992). The curriculum for the Stricker et al. (1986) medication education groups was
divided into two parts. The first part consisted of six, weekly, didactic presentations about
the major drugs used in psychiatry, the risks associated with substance misuse and the
biochemical theory of schizophrenia. During the second part, over a four-week period,
weekly discussions took place about the importance of taking medication,
communication with physicians, and the benefits of long-term medication adherence. The
groups were large with up to fifteen patients attending each.
The groups were evaluated by randomly assigning 75 chronic psychiatric patients to
receive either the educational package or standard care. Patients were then assessed
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before and after attending the educational groups and at 35 week follow-up using three
measures developed specifically for the study; a self report attitudes towards treatment
questionnaire, a multiple choice knowledge questionnaire, and a dichotomous observer
rating of compliance. Although the authors stated that these measures had been tested for
validity and reliability these data were not reported.
At follow up no difference in compliance or attitudes towards treatment were observed
between the experimental and control groups. However, significant improvements in
patients' knowledge were observed between the groups at post-treatment assessment and
at follow-up. Patients also reported a high degree of satisfaction with the intervention.
In a study examining the effect of residual psychotic symptoms on knowledge acquisition
by people with schizophrenia, Smith et al. (1992) evaluated a group educational
intervention based on material developed for family psychoeducation (Smith and
Birchwood, 1992). The intervention was delivered fortnightly over an eight-week period.
The concept, symptoms and treatment of schizophrenia, in addition to basic symptom
management strategies were discussed with small groups of patients (5-6 per group) in
four fortnightly sessions. A booklet backed up the information presented in the groups.
Twenty-eight patients were divided into two groups, those with and those without
residual positive symptomatology, whom both received the same educational
intervention. Patients were assessed prior to and immediately after, the educational
intervention using valid measures of knowledge, insight, and compliance. It was not
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reported whether the researcher who was collecting the data was blind to the treatment
condition. Findings were similar to those reported by Stricker et al. (1986), no significant
improvement in patients' compliance or insight was observed in either group, though
both groups showed an increase in knowledge about their medication. The authors
observed that although significant improvements in knowledge were found in both
groups, patients who had no residual symptoms absorbed more information than those
who were still symptomatic.
Both of these studies suggest that whilst educational interventions are effective in
improving patients' knowledge they have little impact on compliance with medication.
One explanation for this finding may be that group interventions are not the most
effective method of providing patients with information about their treatment.
Macpherson et al. (1996a), Brown et a!. (1987), Gray (2000) and Seltzer et al. (1980) all
examined whether individual patient education was effective in improving compliance
with medication. The intervention devised by Macpherson et al. (1 996a) consisted of
either one or three individual sessions of education about medication. All sessions were
individually tailored around an information booklet that was derived from the
psychoeducation literature (Smith and Birchwood, 1987).
Sixty-four patients were randomised to receive either one session or three sessions of
patient education or standard care. They were assessed by the clinician who delivered the
intervention, using a battery of standardised valid measures, including the Positive and
Negative Syndrome Scale (PANSS Kay et al., 1989a) and the Schedule for the
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Assessment of Insight (SAl, David, 1990). The Understanding of Medication
Questionnaire (UMQ), a measure of patients knowledge about treatment was developed
specifically for the study and validity and reliability data are reported in a separate paper
(Macpherson et al., 1996b). Compliance was determined using a single item sub-scale of
the SAT. These were administered at baseline, immediately post intervention (or after four
weeks in the control group), and at eight-week follow up.
Again, patient knowledge about medication improved immediately after both the one and
three sessions of education. However, at follow up, three sessions of education were
significantly superior to one session. As in the study by Strickner eta!. (1986) and Smith
et al. (1992), compliance did not improve post-intervention or at follow up, in any group.
However, in contrast to Smith et a!. (1992) insight was enhanced in patients who received
three, but not one, sessions of education.
Individual patient education was also examined by Brown et a!. (1987) who randomly
assigned 30 patients to receive one of four treatment conditions: verbal information about
their medication but not about side effects; verbal and written information about their
medication but not about side effects; verbal information about medication and about side
effects; or verbal and written information about medication and side effects. A
psychiatrist, who was not blind to the treatment condition, assessed patients on a monthly
basis for four months using measures of knowledge, side effects and compliance.
Compliance was measured using pill counts, patient self-report, and observer rating.
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Again patient education improved patients' knowledge about their medication but failed
to enhance compliance.
Gray (2000) examined the effect of three sessions of structured patient education in a
randomised controlled trial of 44 patients with schizophrenia taking clozapine. Once
again the intervention had no effect on patients' insight into their illness or their attitudes
towards treatment.
Although limited by some methodological considerations, most notably assessment of
patients by assessors who were not blind to the treatment condition, the evidence from
studies evaluating both group and individual educational interventions seems to suggest
that whilst they are effective in improving patients' understanding of their treatment they
are not effective in enhancing compliance with medication. However, confounding data
have been reported by Seltzer eta!. (1980).
Sixty-seven inpatients were divided, but not randomised, into experimental and control
groups. The experimental group received 9 lecture and discussion sessions about the
nature of mental disorder and its pharmacological management. Within these sessions
specific attention was given to drawing a link between relapse and stopping medication.
At discharge patients were given written drug information. The control group received
standard care.
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Patients were assessed at baseline and at five-month follow up by an independent, but not
blind, assessor. Compliance was assessed using pill-counts and FPN phenothiazaine
urine tests - both measures of current, not long-term, compliance. Patients' knowledge
about, and attitudes towards, medication were determined using a 14 item scale
developed specifically for the study. At follow up, patients in the experimental group
were significantly more compliant than those in the control. However, compliance data
for more than half of the patients in the study were missing at follow up which casts
severe doubt on the validity of the findings.
Although Seltzer et al. (1980) provide some confounding data, this was flawed because
compliance was assessed in so few patients at follow up. It is therefore reasonable to
conclude that simple educational interventions, whilst effective in improving patients'
knowledge about medication, are generally not effective in enhancing compliance.
1.4.2 Behavioural interventions
If improving patients' understanding about their medication does not improve adherence
then interventions may need to address some of the other factors that influence
compliance. Boczkowski et a!. (1985) hypothesised that helping patients to tailor their
medication so that it fitted in with their daily routine would be effective in enhancing
compliance. This was evaluated in a controlled trial of 36 patients who were randomly
assigned to receive one session, lasting up to 50 minutes, of either behavioural tailoring,
psychoeducation or a control intervention. Patients were assessed pre-intervention and at
one month and three month follow-up. Patients' knowledge and attitudes were
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determined using a self-report scale. Compliance was determined using pill counts and
ratings from patients and carers.
Patients who received the behavioural tailoring intervention were informed of the
importance of taking their medication. They were also encouraged to link taking
medication with specific routine behaviours (e.g. making breakfast, turning off the
television at night). Patients were also given a calendar with a dated slip of paper for each
dose of antipsychotic. Patients were told to keep the calendar with the medication and
remove the appropriate strip when they took their medication. The educational
intervention was similar to that describe by Seltzer et al. (1980), and the control
intervention focused on themes not related to medication or diagnosis.
The evidence that behavioural tailoring was effective in enhancing compliance is
inconclusive. Compliance, as measured by pill count, was significantly improved in
patients who received behavioural tailoring compared to either of the control
interventions. However, compliance measured using patient and observer self-report did
not improve. This suggests that either self-report was inaccurate or patients had learned to
adjust the number of tablets returned for the purposes of pill counting to falsely
demonstrate improved compliance.
1.4.3 Cognitive-Behavioural Interventions
Whilst behavioural tailoring attempts to address some of the factors affecting compliance,
patients' reasons for not taking their medication are diverse. Several studies have
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examined the use of cognitive behavioural interventions to involve patients in their
treatment and encourage them to examine the range of factors affecting compliance
(Lecompte and Pelc, 1996; Hayward et al., 1995; Kemp et al., 1996; 1998).
Lecompte and Peic (1996) tested a cognitive behavioural programme based around five
therapeutic strategies: engagement; psychoeducation; identifying prodromal symptoms
and developing coping strategies; behavioural strategies for reinforcing compliant
behaviour; and correcting false beliefs about medication. Sixty-four non-compliant
psychotic patients were randomly assigned to receive either the cognitive behavioural
intervention or a control intervention (unstructured conversation). The duration of the
intervention is not reported.
The duration of hospitalisation one year before and one year after the intervention was
reported as an indirect measure of compliance that was not directly observed. Patients
who received the cognitive behavioural intervention spent significantly less time in
hospital than those in the control group. However, it is unclear whether this improvement
can be attributed to improved compliance or to other factors such as increased use of
coping strategies.
A more robust evaluation of a cognitive behavioural intervention is described by
Hayward et a!. (1995). Medication self-management was based on motivational
interviewing and aimed to allow patients and clinicians to work collaboratively to
examine medication issues.
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Twenty—one patients were randomly assigned to receive three 30 minute sessions of
either medication self-management or a control intervention (non-directive discussion on
any issue except medication). Patients were assessed pre- and post-intervention using
measures of attitude toward medication, insight and psychopathology. The doctor in
charge of the patient's outpatient treatment rated compliance on a three-point scale
ranging from 1 (totally non-compliant) to 3 (good compliance). Although differences
between groups in insight, attitude toward treatment, and compliance were observed,
none reached statistical significance. This may, in part, be because of the small number of
patients in the study, the short duration of the intervention, and an unsophisticated
measure of compliance. However, the pilot work led to the development of a longer more
structured intervention, compliance therapy.
Kemp et al. (1996; 1998) devised compliance therapy based on motivational interviewing
and cognitive behavioural techniques. Key principles include working collaboratively,
emphasising personal choice and responsibility, and focusing on patients' concerns about
treatment. The intervention was divided into three phases which acknowledges that
readiness to change is on a continuum. Phase 1 deals with patients' experiences of
treatment by helping them review their illness history. In phase 2 the common concerns
about treatment are discussed and the good and the bad things about treatment are
explored. Phase 3 deals with long-term prevention and strategies for avoiding relapse.
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The intervention was evaluated in a large-scale randomised controlled trial (Kemp et a!..
1996; Kemp et al., 1998). Seventy-four psychotic inpatients were randomly assigned to
receive either compliance therapy or non-specific counselling. Patients received 4-6
sessions with a research psychiatrist lasting, on average, 40 minutes and were assessed at
baseline, post-treatment arid three, six, twelve, and eighteen month follow-up, using a
battery of standardised measures, including an observer rated measure of compliance.
Although an assessor blind to the treatment condition performed the latter assessments
the person conducting the therapy undertook the initial interviews. Treatment adherence
was significantly better in the compliance therapy group and was sustained through
follow-up. Unexpectedly, there was no significant difference in psychopathology
between the groups. However, the improvements in compliance did result in enhanced
community tenure, with patients in the compliance therapy group taking longer to relapse
than those who received non-specific counselling.
1.4.4 Implications for clinical practice
Non-compliance with aritipsychotic medication is clearly a major preventable cause of
relapse in patients with psychotic disorders. The causes of non-compliance are unclear
but the evidence does suggest that a number of factors have a role to play and that
individuals reasons for stopping medication are idiosyncratic. A range of different
pragmatic interventions to enhance compliance have been tested. However, many lack
sufficient methodological rigor: none offered any statistical justification for their sample
size; raters were often not blind to the treatment condition; there was an unnecessary
reliance on specially developed measures; and therapist time was often not controlled for.
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Based on the available evidence, medication management aimed at enhancing treatment
concordance should consist of the following:
• A collaborative approach to working with patients.
• Use of valid and reliable assessment tools to measure psychopathology, antipsychotic
side effects, attitudes towards treatment, insight and compliance.
• Giving patients information about their illness and treatment.
• Tailoring medication regimes to suit the patient.
Use of compliance therapy techniques.
1.5 MEDICATION MANAGEMENT PRACTICE IN THE BRITISH NATIONAL
HEALTH SERVICE
Standards four and five of the National Service Framework for mental health
(Department of Health, 1999) aim to ensure that people with severe mental illnesses
receive care and treatment that has a sound empirical basis. Good medication
management, as described above and including the use of rigorous assessments with valid
and reliable measures and the application of compliance therapy techniques, is clearly
identified within the framework as being integral to achieving these standards.
Much of the care and treatment that people with schizophrenia receive is delivered by
Community Psychiatric Nurses (CPNs). The most recent national survey reported that in
1996 there were approximately 6,700 CPNs working in England and Wales treating
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around 49% (122,723) of the patients with serious mental disorders (Brooker and White,
1997).
Brooker and White (1997) reported that CPNs were generally experienced nurses
employed on a senior grade and spent almost 50% of their time in direct face to face
contact with patients. On average they carried a caseload of 38 patients of which half had
a serious mental disorder and 21% were receiving long acting depot antipsychotic
medication. CPNs tended to specialise in using counselling or psychodynamic therapy. A
minority (15.9%) of CPNs surveyed reported that they specialised in the use of
psychosocial interventions that would include the application of cognitive behavioural
techniques such as compliance therapy. The Brooker and White (1997) survey suggests
that CPNs may play a substantive role in helping patients to manage their medication.
However, it is unclear whether current practice is adequate to achieve the standards set
out in the National Service Framework (Department of Health, 1999).
There are no data that directly examine the way in which CPNs promote compliance in
their patients. The evidence that does exist seems to suggest that routine CPN practice
relies on the unsophisticated use of basic counselling skills and not the application of
more technical skills such as those used within compliance therapy. For example, in a
randomised controlled trial of patients with predominantly neurotic disorders allocated to
either treatment by a CPN or standard GP care there were no differences in outcomes
between the groups (Gournay and Brooking, 1994). Gournay and Brooking (1994)
suggest that these results can be explained by a lack of clinical skills among CPNs.
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Devane et al. (1998) seem to support this conclusion. They demonstrated, in a study
examining tape recorded CPN sessions, that although general clinical skills were
satisfactory their ability to apply more complex technical cognitive therapy techniques
was poor.
As has already been discussed, part of good medication management is the rigorous
assessment of psychopathology, side effects and subjective factors such as beliefs about
treatment and insight. CPNs practice, especially in the assessment of side effects has been
explored. For example, in a small survey of CPNs practice Bennett et a!. (1995) observed
that on average CPNs screened patients for only 3-4 of the possible side effects they
might experience and there was no evidence of assessment using techniques other than
unstructured self-report. Gray (1998b) observed that CPNs do not ask patients about
certain side effects, such as sexual dysfunction, that may have a substantial impact on
patients' decisions about taking medication. There are no published data on CPNs
practice in assessing psychopathology, beliefs about treatment, and insight, which are
part of a good medication management assessment.
Examining the impact of using valid and reliable assessment tools on the detection of
EPS Wieden et a!. (1987) demonstrated that clinicians trained in using such measures
were significantly more accurate at detecting side effects than clinicians in routine
practice. There are, however, no published data on the use of such measures by CPNs in
the NHS.
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Although research evidence describing current CPN practice is weak, it seems reasonable
to propose that routine care in terms of medication management, is inadequate to meet
the high standards established by the National Service framework. These findings may be
explained by the relatively small amount of time that CPNs spend in staff development
and training. In the Brooker and White (1997) survey clinical supervision was provided
to 87% of respondents. However, only 2% of CPNs had received any substantive training
in using psychosocial interventions (which would include the use of side effect
assessment tools) and only 36% had received any additional education to prepare them
for working in the community.
1.6 THE EFFICACY OF CPN TRAINING
Training CPNs to use medication management techniques including the use of valid and
reliable measures and compliance therapy may be one way of utilising CPNs more
effectively and achieving the standards set out in the NSF. There has only been one
published medication management training study (Bennett et al., 1995). A number of
studies have explored the impact on patients' clinical outcomes of training nurses in more
sophisticated psychological interventions including: cognitive behavioural therapy
(Marks et al., 1977); schizophrenia family work (Brooker et a!., 1992a; 1994);
psychosocial interventions (Lancashire et a!., under review); and the management of
violence (Whittington and Wykes, 1996). The duration of the training varied
considerably from one-day workshops (Whittington and Wykes, 1996) to 18-month full-
time academic courses (Marks et a!., 1977).
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Marks et al. (1977) were the first to demonstrate that mental health nurses could be
trained to deliver complex cognitive behavioural interventions initially for patients with
neurotic disorders. The intensive, full-time, training programme (English National Board
ENB-650 behavioural psychotherapy) lasted for eighteen months and centred around a
behavioural treatment rationale and the extensive use of closed circuit television (CCT) to
monitor therapy sessions and provide trainees with detailed feedback on the development
of their clinical skills. There is good evidence that the nurses who had received training
produced good clinical outcomes in the patients they were treating (Marks et a!., 1977).
A twenty-five year follow-up survey of the 274 nurse therapists trained in using these
techniques (Goumay et a!., 2000) found that trainees reported a high degree of fidelity to
the behavioural techniques they were taught to use during the course. However, such a
programme is expensive and time consuming and is therefore impractical as a model for
enhancing the practice of the 6,700 CPNs currently working in England and Wales.
Shorter, and therefore more cost effective, models for disseminating psychosocial
interventions needed to be developed, building on the teaching techniques that have been
shown to be effective.
Brooker and Butterworth (1993) examined whether a short 26 week day release course
delivered over a six month period would be effective in enhancing psychosocial
intervention skills, specifically in working with families, in a cohort of nine CPNs. The
course focused on the acquisition of specific clinical skills, including engagement with
the family, family education, and problem solving, which were taught using role-play.
CPNs were also trained to perform a series of standardised assessments and submitted
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audiotapes of sessions with families for clinical supervision. The blind rating (using the
cognitive therapy scale; Vallis et al., 1986) of tapes submitted at the end of the course
suggested that CPNs were able to demonstrate competent skills in delivering
psychosocial interventions to families. However, as no baseline scores are reported the
level of improvements in skills, if any, cannot be established. Published in two parts, a
quasi-experimental study describing the impact of this model of training on clinical
outcomes was reported by Brooker et al. (1992a) and Brooker et a!. (1992b). Nine CPNs
received training and each identified a partner CPN to act as a control. The CPNs in the
control group were trained to administer the assessments but not the family work
intervention. Forty-seven families entered the study and were allocated to either the
experimental (n17) or control (n13) condition depending on the geographical location
of their home. Data were only reported on the thirty who completed the trial. Patients and
families were assessed pre-training, post-training and at six month follow-up by the
CPNs treating them using a battery of valid and reliable outcome measures.
Brooker et a!. (1 992a) reported that based on CPN ratings of the Knowledge about
Schizophrenia Interview (KASI; Barrowclough et aL, 1987) there was a significant
improvement in families understanding of the illness in the experimental but not the
control group. Significant improvements in psychopathology and, to a lesser extent,
social functioning were also reported (Brooker et a!., 1992b) in patients treated by CPNs
trained in family work compared to those treated by CPNs delivering standard care.
However, the findings of both studies may be confounded by the use of the trainees, who
were not blind to the treatment condition, to collect data. Although the findings of this
51
study have been replicated by Brooker et al. (1994), this second quasi-experimental trial
had many of the methodological weaknesses of the original trial.
Lancashire et a!. (under review) reported the results of a multi-centre uncontrolled trial to
evaluate the impact of training professional mental health workers to deliver psychosocial
interventions such as family work and cognitive behavioural therapy. The programme,
that included a medication management component, was commonly referred to as the
Thom course after Sir Jules Thom who funded the development of the training. Sixty-
four trainees were selected following a screening interview, to receive 40 days classroom
training over a single academic year and engage in an equivalent number of days clinical
practice with a minimum of four patients with psychotic illnesses. Training was divided
into three modules: problem orientated case management, family work and cognitive
behavioural interventions for psychosis. To ensure acquisition of the skills necessary to
implement the psychosocial treatments, trainees were given a clear treatment rationale,
participated in weekly group supervision of their clinical work, engaged in role play
exercises to rehearse skills prior to use, and audiotaped their treatment sessions for
review by course tutors. Patient outcomes were determined by asking each mental health
worker to identify at least two patients on their caseload who were assessed by
independent evaluators pre-training and at twelve month follow-up. One-hundred and
twenty patients consented to participate in the trial and significant improvements in
patients' psychopathology and social functioning were observed at follow-up. Partly
because of the success of this study Thom training has become one of the major training
initiative for CPNs. However, because the design of the trial was naturalistic and not
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controlled it is difficult to attribute the gains observed to the application of psychosocial
interventions by trainees, rather than improvements that would have occurred naturally
over time.
There is also some evidence that short courses, which are targeted at specific needs, can
be beneficial. For example Bennett et al. (1995), in the only study evaluating a
medication management training intervention, showed a significant increase in the
detection rates of antipsychotic side effects following a brief one day training session in
which CPNs learned to use a specific side effect rating scale. Similarly, Whittington and
Wykes (1996) demonstrated a substantial reduction in the number of violent incidents
experienced by those who had received management of violence training compared with
those who had not attended training.
The training interventions that have been tested, and shown to be effective, all rely on the
presentation of an intervention with a good evidence base followed by rehearsal in vitro
using role play of skills prior to putting them into practice. Such tecimiques may be
effective in enhancing the medication management practice of CPNs and ultimately
improving patients' mental health. Surprisingly, there appears to be little association
between the duration and outcome of training. However, longer courses are obviously
more expensive and perhaps therefore do not lend themselves to the rapid dissemination
of interventions into routine clinical practice throughout the NHS. Pragmatically
therefore, any medication management training initiative targeted at CPNs must be brief.
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1.7 MEDICATION MANAGEMENT: UNANSWERED QUESTIONS
Although the quality of the data are far from satisfactory the key components of good
medication management seem clear. However, there are a number of important, and as
yet unanswered, questions that have emerged from the literature.
• To what extent do CPNs see medication management as part of their role?
Do CPNs utilise recognised valid and reliable medication management outcome
measures in their routine practice?
Have recent training initiatives, such as Thorn, improved medication management
practice?
These questions will be addressed in chapter two. If there are apparent deficits in current
practice it would be useftil to develop a pragmatic brief training intervention to address
these needs. Chapter three will therefore address whether a medication management
course can be effective in enhancing CPNs' skills and knowledge in this area?
However the most important question to answer is whether such training would lead to
improvements in patients' psychopathology and compliance with antipsychotic
medication? This is the most complex question to answer and will be the main emphasis
of this thesis.
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CHAPTER TWO: SURVEY OF CPN PRACTICE
2.1 BACKGROUND
As has already been established it is unclear whether CPNs are receptive to becoming
more involved in helping patients manage their medication and to what extent recent
training initiatives, such as Thorn, have addressed the poor practice that is alluded to
within the literature. A number of important questions need to be addressed.
Do trained and untrained CPNs:
1. Indicate that medication management is part of their role?
2. Believe that they have been adequately trained to deliver medication management
interventions?
3. Routinely and comprehensively assess patients for antipsychotic side effects?
4. Utilise valid and reliable measures to evaluate pharmacological interventions?




A power calculation was performed to determine the number of CPNs that would need to
be surveyed to detect the proportion who utilise standardised antipsychotic side effect
scales in clinical practice. Assuming a population of 6,700 CPNs (Brooker and White,
1997) and that an estimated 40% use at least one recognised assessment tool (Gray,
1998b) a sample of 91 CPNs would be necessary to achieve a confidence level of 95%.
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Assuming a non-response rate of 40-60% a survey sample size of 240 was estimated as
likely to meet the requirements of the power calculation.
2.2.2 Sample selection
As no comprehensive national database of CPNs working in the UK exists, the sample
for this study was generated using two different methods. Thom graduates were
identified by contacting the course leaders in both London and Manchester to request a
list of the names and addresses of all trainees who had successfully completed training.
CPNs were identified by inviting six representative urban and rural NHS Trusts in
England, where Thom training was not currently provided, to participate. Those Trusts
who agreed to take part provided a list of CPNs currently in clinical practice. From these
lists of 227 CPNs and 246 Thom graduates the sample was selected. Each nurse was
allocated a number, which was then sorted into a random order. The first 120 nurses in
each group (total 240) were then selected and sent a brief questionnaire to complete and
return.
2.2.3 Questionnaire (Appendix 1)
A 38-item questionnaire was developed based on previous research (Bennett et a!., 1995)
and consultation with a group of clinical and academic experts. The questionnaire, which
was intended to be brief and easy to complete, was designed to elicit information about
practitioner demographics, caseload composition, use of assessment tools, knowledge
about psychopharmacology and perceived training requirements.
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Information about the composition of caseloads was obtained by asking CPNs to
calculate the proportion of their patients who were suffering from different disorders.
Respondents were also asked to list all the assessment tools they regularly used in their
clinical practice. Knowledge about psychopharmacology was determined by asking
respondents to give an agree, disagree, or unsure response to nine statements about
psychopharmacology. A score of 2 was given for a correct answer, 1 for unsure, and 0 for
an incorrect answer. Producing a total score ranging from 0-18. The expert group paid
considerable attention to devising a list of questions that a CPN should ideally be able to
answer given appropriate training. This method of examining knowledge has been used
before and has been shown to be reliable and easy to administer (Gamble et a!., 1994).
The questionnaire was piloted on a cohort of 58 CPNs (Gray, 1 998b) and the analysis of
these responses allowed the questionnaire to be further refined, by removing unnecessary
items and rephrasing certain questions.
Questionnaires were sent out in November 1998, together with a covering letter
explaining the nature and purpose of the study. A reminder letter was sent eight weeks
later if CPNs had not responded. Respondents were asked to sign and return a consent
form with the questionnaire. If written consent was not obtained questionnaires were
excluded from the study.
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2.2.4 Statistics
Data were analysed using SPSS for windows, version 8.0. To identify between group
differences independent sample t-tests were used with two-tailed significance as the most
conservative method of analysis. The chi-square test (x 2) was used to test for association.
2.3 RESULTS
2.3.1 Response rates and non-response bias
Of the 240 questionnaires that were sent out 144 (60%) were returned. Of these 30 were
invalid because respondents either had never or were not currently working as CPNs - an
adjusted response rate of 54%. Completed consent forms accompanied all returned
questionnaires. There was no significant difference in the adjusted response rate from
Thorn graduates (53%) and CPNs (54%). A response rate of 54% may represent a
significant non-response bias. However, given that 30 respondents were not currently, or
had never worked as CPNs it is likely that the same was true for a proportion of the non-
responders which may reduce the bias.
2.3.2 Demographics
Of the 114 respondents 51% were female, 90% classified themselves as white, and had a
mean age of 40 years (range 24 - 57, s.d. 7.5). There was no significant difference in the
demographic profile of the two groups. The majority of CPNs (69%) and Thorn graduates
(64%) were employed at grade 'G'. Both CPNs and Thorn graduates had, on average, 15
years post registration experience and there was no significant difference in time spent
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working in the community (CPNs 8 years; Thorn graduates 7 years). All Thorn graduates
and 69% of CPNs were qualified to at least an undergraduate diploma level.
2.3.3 The role of the CPN
Although Thom graduates had significantly smaller caseloads than CPNs (24 vs. 37;
t4.53, d.f.110, p<.001), there was no significant difference in the proportion of patients
with serious and enduring mental disorders, such as schizophrenia. All respondents
indicated that they gave information and advice to both patients and carers about their
illness and medication.
Respondents were asked to indicate whether a range of commonly used therapeutic
techniques and skills were an important part of their role as a CPN. The list included the
following medication management interventions: assessing patients' mental state,
monitoring antipsychotic side effects and enhancing compliance. The results are
presented in table 2.1. No significant difference between the two groups was observed
both groups indicating that medication management interventions were an important part
of their role. Significantly more Thom graduates did report that the use of cognitive
behavioural and family work interventions were an important part of their role.
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Table 2.1. The role of the CPN
	
CPN	 Thorn graduate
Assessing mental state 	 96.9	 100
Risk assessment	 90.6	 95.8
Monitoring side effects 	 87.3	 95.8
Suicide prevention	 87.3	 91.7
Crisis intervention	 71.9	 85.7
Case management 	 65.6	 77.6
Enhancing compliance	 61.9	 75.5
Mental health promotion	 58.7	 58
Giving depots	 50	 60.4
Anxiety management 	 40.6	 44.7
Cognitive behaviour	 31.3	 65.3
therapy'	 __________________ ___________________
Counselling	 30.6	 25
Family work2	 7	 61.2
Relaxation therapy	 18	 20.8
= 13.98, df2, p=.00l. 2.x2 =15.46, df=2, p<.00l
2.3.4 Assessing side effects
There was no significant difference in the frequency with which Thorn graduates and
CPNs reported asking patients about antipsychotic side effects, with 80% of both groups
assessing side effects at least once a month. The majority of both groups reported that
they routinely asked patients about extrapyramidal symptoms (73% of Thorn graduates
60
vs. 65% of CPNs). Both groups reported that they were less likely to ask patients about
anticholinergic effects, although Thorn graduates were significantly more likely to assess
them than CPNs (56% vs. 30%; 2=734, d.f.=l, p=.007). Of the prolactin related side
effects, sexual dysfunction was the most frequently assessed, but by a minority of both
Thorn graduates (42%) and CPNs (24%). Amenorrhoea was assessed by 14% of Thorn
graduates and 6% of CPNs. Less than 6% of CPNs in both groups reported that they
routinely asked patients about other prolactin related side effects such as galactoria or
gynocomastia. Just over half (52%) of the Thorn graduates but less than a third (3 1%) of
CPNs indicated that they assessed weight gain, a difference that was statistically
significant ( 2=5 d.f.=1, p=.O34).
2.3.5 Use of side effect assessment tools
Side effect assessment tools were routinely used by significantly more Thorn graduates
than CPNs (62% v 25%; X2=8.6l, d.f.=1, p=.O03). The most widely used measure of
antipsychotic side effects, in both groups, was the LUNSERS (Liverpool University
Neuroleptic Side Effect Rating Scale; Day et a!., 1995). Significantly more Thorn
graduates than CPNs reported using it in clinical practice (56% vs. 25%; C=l 1.38.
d.f.=1, p=.001). The Simpson Angus Extrapyramidal Side Effect Rating Scale (Simpson
and Angus, 1970) was also used by a small, though significantly greater, number of
Thorn graduates than CPNs (10% vs. 0%; x 2 = 6.69, df.=l, p=.Ol). Fewer than 5% of
both Thorn graduates and CPNs reported using the AIMS (Abnormal Involuntary
Movement Scale; Guy, 1976). The use of self-developed measures to assess side effects
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was also reported by significantly more Thorn graduates (24% vs. 5%,	 16, d.f.= 1.
p=.002). No other measures were reported as being used.
2.3.6 Use of measures to assess psychopathology
The only recognised assessment of psychopathology reported to be used by respondents
in either group was the K.G.V. (Krawiecka, Goldberg and Vaughn, 1977). Thorn
graduates were significantly more likely to report using it in clinical practice than CPNs
(40% vs. 5%, 2=2l73 d.f.=1, p<.00l).
2.3.7 Use of measures to assess patients' beliefs about treatment and insight
None of the CPNs surveyed indicated that they routinely used any recognised measures
of patients' beliefs about treatment or insight into their illness.
2.3.7.1 Factors that influenced practice
The effect of gender, ethnicity, experience, nursing grade, and level of educational
attainment, on the use of the KGV and the LUNSERS were explored. There were no
significant differences in any of these variables between Thorn graduates and CPNs who
reported that they did or did not use either measure. CPNs who used the LUNSERS had
significantly smaller caseload sizes (29 vs. 40; p.O22) and were slightly younger (36
years vs. 41 years; p=.O31) than those who did not. This pattern was not found in Thorn
graduates.
62
2.3.8 Knowledge about medication management
No significant difference in mean total scores on the knowledge questionnaire were
observed between Thorn graduates (mean 14.64; range 8-18; s.d. 1.92) and CPNs (mean
13.58; range 9-17; s.d. 1.85). Scores were at the upper end of the 0-18 scale and suggest
that CPNs in both groups had a reasonable understanding about psychopharmacology and
the management of antipsychotic side effects.
2.3.9 Perceived need for training
Respondents were asked to rate their individual training needs on a 1 (low priority) to 9
(high priority) scale and results are shown in table 2.2. Generally a perceived need for
training in all proposed areas was reported with the exception of anxiety management and
relaxation. Both groups rated medication management interventions, risk assessment and
suicide prevention as high priorities for training. However, Thorn graduates placed a
significantly greater emphasis on the need for training in compliance and cognitive
behavioural interventions. In contrast, CPNs placed significantly more emphasis on
training in counselling.
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Table 2.2. Perceived priorities for training
CPN	 Thorn
Suicide prevention	 8.4	 8.38





Crisis intervention	 7.49	 7.88
Care programme approach	 7.37	 7.42
Case management	 7.29	 7.77
Mental health promotion 	 7.23	 7.55
Enhancing compliance' 	 6.77	 7.58
Cognitive behaviour therapy 2	 6.57	 7.78.
Family work3	6.48	 8.02
Giving depots	 6.24	 6.61
Counselling4
	6.07	 5.14
Relaxation therapy 	 5.18	 5.63
Anxiety management 	 5.6	 6.06
't107, p.OlO; 2 t 108, p<.001; 3 t=109, p<.O01; 4 t2.3, p.O22
2.4 DISCUSSION
The aim of this study was to explore the impact of a recent training initiative on CPNs'
medication management practice and knowledge. Both groups indicated that medication
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management was part of their role. Thorn graduates reported using more standardised
side effect and mental state measures than CPNs but were no more knowledgeable about
psychopharmacology. The sample meets the requirements of the power calculation and
the profile of respondents is generally comparable with the national survey of CPN
services (Brooker and White, 1997). Although a greater proportion of respondents were
educated to diploma level, the results may be cautiously generalised.
The majority of CPNs indicated that evaluating the effects of antipsychotic medication
was part of their role. However, despite evidence from Wieden et al. (1987) that
clinicians fail to detect a substantial proportion of side effects if they do not use
assessment tools, only a minority of CPNs reported that they made use of such
procedures in their practice. This suggests that respondents are failing to properly
evaluate how well their patients are tolerating antipsychotic medication, a finding that is
consistent with Bennett et al. (1995) arid Gray (1998b). The small number of CPNs who
reported using measures of psychopathology also appears to indicate that a regular review
of the efficacy of medication is not being performed. The failure of CPNs to evaluate
both the tolerability and efficacy of medication is incongruent with the standards set out
in the National Service Framework (Department of Health, 1999) and may expose a lack
of training in the use of such assessment tools. The high priority respondents, particularly
Thorn graduates, placed on medication management training may indicate an awareness
of the deficits in their current practice.
65
Respondents in both groups primarily used self-report scales such as the LUNSERS to
detect side effects. Whilst self-report is useful it relies on patients being aware of side
effects. This is not always the case, for example, patients may not always be aware of
tremor, stiffness or abnormal body movements, and highlights the importance of other
types of assessment tools which use observation and physical examination as a basis for
rating.
Although the results from the knowledge component of the questionnaire should be
treated with caution, no significant differences in knowledge about psychopharmacology
were reported between the two groups. However, important deficits in knowledge among
both groups, particularly about novel treatments, were observed. This may reflect the
comparatively small amount of time within the Thorn programme that is devoted
specifically to psychopharmacology. It is possible that a poor understanding about
psychopharmacology may limit the strategies used by both groups to help patients
manage antipsychotic side effects.
The results from this study suggest that training is, potentially, effective in enhancing
certain aspects of CPNs' medication management practice. Although Thorn graduates
reported using more standardised measures of psychopathology and side effects, only half
stated that they were currently using such measures in their clinical practice. This finding
is disappointing given that a considerable amount of time during the Thorn course is
devoted to producing clinicians that are able to use the KGV reliably. The failure of
Thorn graduates to routinely use the KGV suggests that they do not believe that it is
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relevant to their clinical work or find it too time consuming to complete and score. It is
also possible that external factors such as lack of clinical supervision following training
may also have an important influence on practice. In this survey the effect of caseload
size on practice was complex. CPNs who reported using the LUNSERS had a smaller
caseload than those who did not. This may suggest that if the size of CPNs caseloads
were reduced practice would improve. This may be true for simple self-report measures
such as the LUNSERS. However, it seems unlikely that caseload size would increase the
use of more complex measures to assess patients' psychopathology (such as the KGV)
which require training to be able to use proficiently.
It is surprising that demographic factors such as grade and educational attainment did not
explain variation in CPN and Thorn graduates practice. The finding that younger CPNs
who have not attended Thorn training are more likely to use the LLTNSERS would not be
anticipated, and may suggest that younger, but not less experienced, staff are more
motivated to seek out new skills. More research with a larger sample size is needed to
explore factors that influence the practice of CPNs and Thorn graduates.
More Thom graduates reported using the LUNSERS than the KGV in practice. This
might suggest that measures that are quick and easy to complete are more likely to be
incorporated into practice following training. The LUNSERS takes approximately 15
minutes and the KGV 90 minutes to complete. Alternatively, Thorn graduates may find
the LUNSERS more relevant to the problems that their patients present with.
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2.5 CONCLUSION
As discussed in chapter one, the evaluation of both the efficacy and tolerability of
antipsychotic treatment is critical if side effects are to be minimised and compliance
enhanced. The results of this study confirm previous research and suggest that CPNs do
not use standardised measures to evaluate pharmacological interventions. Training does
seem to be effective. Thorn graduates report using more assessment tools in routine
clinical practice but they tend to prefer self-report checklists to identify side effects. As a
model for enhancing CPNs' medication management skills, Thom training has been
partially successful, although more emphasis within the programme on
psychopharmacology and the use of other side effect assessment tools may be warranted.
However, the course is relatively time consuming and consequently it will not be possible
to train all of the 6,700 CPNs currently in practice. An alternative model is needed to
achieve widespread changes in practice rapidly and cost effectively. Delivering brief
manualised training packages, which can be disseminated to entire community mental
health teams, may be a more realistic approach to achieving this objective. A useful next
step would be to develop a brief medication management training package based on the
available evidence and test the impact of such an intervention on CPNs' knowledge and
skills.
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CHAPTER 3: DEVELOPMENT AND PILOTING OF THE MEDICATION
MANAGEMENT TRAINING PROGRAMME
3.1 BACKGROUND
Antipsychotic medication is the mainstay of the treatment of schizophrenia. However, in
chapter one it was demonstrated that compliance with antipsychotic medication is
generally poor, and as a result relapse is common. The reasons for non-compliance are
complex but there is good evidence that careful assessment, thoughtful prescribing and
the use of psychological interventions that focus on working collaboratively with patients
are effective in improving treatment concordance. CPNs are ideally placed to deliver
such interventions in conjunction with the rest of the multi-disciplinary team. Training
may be the most effective method of disseminating this knowledge and enhancing
practice. Previous studies have shown that there is no apparent relationship between the
duration of the training and clinical outcome. However, training that presents a clear
treatment rational, gives trainees the opportunity to rehearse skills using role play and
provides structured clinical supervision seems to be most effective.
Chapter two confirmed that without training practice is poor. CPNs make little use of
valid and reliable assessment tools to assess patients' psychopathology or side effects,
although their knowledge of psychopharmacology is reasonable. Thorn graduates, who
had had some medication management training, were more likely to report using valid
and reliable measures. However, there appears to be a preference among Thorn graduates
for self-report tools that can be completed by patients and quickly scored. Because of the
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relatively low proportion of Thorn graduates who report using measures such as the
KGV, there is concern about the ability of training to enhance practice in the long-term.
Based on the evidence presented in chapters one and two there is a clear need for a
medication management training course targeted at CPNs. As there is no apparent
advantage, in terms of clinical outcomes, to intensive training courses such as Thorn, the
medication management course should be relatively short. If the training is shown to be
effective there is the added advantage of facilitating more rapid and cost effective
dissemination of the intervention throughout the NHS.
Based on the evidence presented in chapters one and two the core components of the
curriculum should be:
Assessment of factors likely to affect compliance. This should include response to
treatment, antipsychotic side effects, beliefs about medication and awareness of
illness. This will allow the trainee to develop an individual patient formulation and
target interventions more effectively. To maximise the impact of training it is
pragmatic to use measures that are self report and/or quick to complete.
Compliance therapy. There is good evidence from randomised controlled trials that
compliance therapy techniques are effective in enhancing patients' beliefs about
treatment and insight. Training in compliance therapy skills should form a substantive
part of the programme.
Behavioural tailoring. Although the quality of the evidence is weak such techniques
may be useful and should form a small part of the training.
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Patient education. The evidence suggests that patient education is unlikely to enhance
compliance. However, patients generally have a poor understanding of treatment and
it would be unethical not to emphasise, within training, the importance of education
in enabling informed decisions to be made.
Psychopharmacology. In chapter two, CPNs' knowledge about psychopharmacology
was found to be reasonable. However, in chapter one it was noted that there is a
tendency to use higher than necessary doses of antipsychotic medication and that
many side effects are undetected by clinicians. It is therefore important to ensure that
training provides an overview of the safety and efficacy of antipsychotic and related
pharmacological therapies (such as the use of anticholinergic medication to treat drug
induced Parkinsonism). Training should also include information on the management
of antipsychotic side effects to enable trainees to propose plans for treating them.
Clinical supervision. In previous studies where training has been shown to be
effective (Lancashire et al., in review) structured supervision is cited as a critical
method of changing trainees' clinical practice. Clinical supervision should therefore
be an integral part of a training programme.
The curriculum outlined above is drawn from the evidence presented in chapters one and
two. The methods used to train CPNs will be important in ensuring that they have
acquired appropriate skills and knowledge. In chapter one, role-play rehearsal of new
clinical skills prior to use in practice was a teaching method common to effective training
interventions. Skills based medication management training may benefit from adopting
such an approach to developing trainees' clinical skills.
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A preliminary investigation would be useful in establishing whether a brief training
package is effective in enhancing clinicians skills and knowledge to a level likely to
produce clinically meaningful outcomes. If the training was shown to be effective, further
exploration, within the context of a randomised controlled trial, would then be warranted.
3.2 THE MEDICATION MANAGEMENT INTERVENTION AND COURSE
A group of clinical and academic specialists met to review the literature and finalise the
curriculum for the medication management intervention and training course. This group
developed medication management training and treatment manuals to ensure consistency
of training and enhance fidelity to the intervention (the final version of the training and
treatment manuals can be found in appendices 2 and 3).
3.2.1 Treatment procedure
All patients were seen individually and the duration and frequency of sessions was
defined by individual CPNs according to each patient's level of cognitive function. It was
recommended that the intervention would initially involve approximately 20 hours of
individual work followed by ongoing, monthly, top-up sessions. The aim of the
medication management intervention was to help patients examine the use of
pharmacological interventions to treat their illness and also to provide them with skills to
help them manage their medication in the future.
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The first stage of the intervention, which normally lasted several sessions, was the
completion of formal clinical measures of psychopathology, insight, attitudes towards
treatment and antipsychotic side effects. During this stage of the intervention CPNs
helped patients to identify specific problems and targets for treatment as well as engaging
the patient in discussing their medication. A clear treatment rationale, that the CPN
wanted to work collaboratively with the patient in addressing issues around medication.
was presented. A formulation and plan of therapeutic tasks and homework was then
discussed with the patient. Considerable time was devoted to the careful assessment and
review of the patient's medication as it was hoped that this would not only aid
engagement but also have some therapeutic benefit.
3.2.2 Structure of sessions and general therapeutic skills
At the beginning of each session CPNs set an agenda with the patient with specific and
relevant areas for discussion. Time limits were established and the CPN carefully planned
and structured each session appropriately for each patient dependent on their level of
functioning. General therapeutic approaches included: carefully eliciting and responding
to verbal and non-verbal feedback; understanding the patient's views of medication and
treatment; and encouraging the patient to take an active role during the sessions. Guided
discovery was a central skill with the CPN helping the patient to explore problems and
draw their own conclusions. These general skills and structure formed the foundations for
the application of more specific medication management and compliance therapy
techniques.
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3.2.3 Medication management/compliance therapy techniques
3.2.3.1 Providing information
Providing patients with information about their illness and treatment was an important
part of the intervention. Misconceptions and lack of understanding about any aspect of
treatment were clarified at any opportunity.
3.2.3.2 The illness timeline
Patients identified when they, or significant others, first realised they had psychiatric
problems and the course of their illness and the positive and negative effects of treatment
over time were then plotted. Close attention was paid to helping the patient identify when
their mental health had been particularly good and when it had been not so good. The
purpose of this exercise was two-fold; firstly to help the patient make any links between
stopping medication and worsening psychopathology, and secondly to identify and
examine negative experiences of treatment, particularly where medication had been
forcibly administered.
3.2.3.3 Normalising rationales
Drawing an illness timeline was linked to the use of normalising rationales to explain
both psychotic pathology and the need for maintenance treatment. A rationale was
discussed with the patient and the typical symptoms of, and possible genetic
predisposition to, schizophrenia were described. The vulnerability-stress model (Zubin,
1987) was then explained in detail, with the CPN making specific links to the work done
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in reviewing the illness timeline, to help the patient identify that their psychotic
symptoms may be caused by an increased susceptibility to stress. If the patient accepted
this rationale then further work could be undertaken with the CPN helping the patient to
draw analogies to other physical illnesses, such as diabetes or asthma, where maintenance
treatment is necessary to prevent relapse.
3.2.3.4 Drawing up a balance sheet
Patients were helped to draw up a balance sheet to highlight both the positive and
negative aspects of treatment. Emphasis was placed on identifying the less obvious
effects of medication. Dependent on the patient's level of functioning this activity could
be done as homework with the CPN expanding and clarifying the work that the patient
had already undertaken.
3.2.3.5 Testing beliefs about illness and medication
Patients' beliefs about their illness and medication were tested by adapting the cognitive
behavioural procedures for examining delusions (Chadwick et al., 1996). Beliefs about
illness and medication were challenged: the plausibility of the beliefs was questioned; the
beliefs were reformulated as being an understandable response to, and way of making
sense of, specific experiences; and a personally meaningful alternative was constructed.
Finally, the patient's original belief and the alternative were assessed in light of the
available information.
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3.2.3.6 Spe/Ic problems with medication
Specific problems with medication, such as side effects, were examined using a problem
solving strategy (Hawton and Kirk, 1989). A problem was selected and a target was
agreed. The broad steps necessary to achieve this goal were identified and the patient
decided, in detail, the practical and realistic tasks that would be necessary to achieve this
goal. Progress was reviewed in subsequent sessions.
3.2.3.7 Examining the consequences of stopping medication
Patients were asked to project the positive and negative aspects of stopping medication.
Again this was a potential homework task dependent on the patient's level of functioning.
3.2.3.8 Long term plans
Patients were asked to look six to twelve months into the future and identify a goal they
wanted to achieve. A problem solving strategy was utilised to identify tasks needed to
achieve this objective.
3.3 Medication management training course
The course was designed for rapid dissemination and teaching activities were carefully
structured and planned to mirror the treatment manual. It was delivered as a day release,
nine week, 72 hour programme consisting of four major components, with the aim of
providing mental health nurses with practical skills in working with patients
collaboratively on medication issues. Eight weeks after the end of the course a follow-up
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day was held to review the application of skills to clinical practice (a total of 80 hours
contact time). The four key components of the training were assessment, cognitive and
medication management skills, psychopharmacology, and clinical supervision. A multi-
disciplinary team, including a combination of academic and clinical staff, provided
teaching.
In the first component of the course, trainees were taught to use a battery of valid and
reliable assessment tools to evaluate treatment with antipsychotic medication and derive a
formulation of the patient's problems or concerns about their medication. The formulation
was used to guide the selection of targeted medication management interventions. In
order to evaluate the efficacy of antipsychotic treatment regimes trainees learned to
assess patients' psychopathology using the Positive and Negative Syndrome Scale
(PANSS; Kay et a!., 1 989a), a comprehensive and widely used measure, the completion
of which is based on the clinician undertaking a Structured Clinical Interview (Sd). The
PANSS was selected because it is extensively used in the UK, training materials are
available, and it is relatively quick to complete.
Trainees also learned to use a range of specific self-report measures. Self-report measures
were used because, as discussed in chapter two, clinicians appear to prefer them and are
more likely to continue to use them following training. Two measures were selected to
assess patients' beliefs about treatment. The Hogan Drug Attitude Inventory (DAI-30;
Hogan eta!., 1983) and the Insight Scale for Psychosis (IP; Birchwood eta!., 1994). The
DAI-30 is a 30-item scale used to determine patients' beliefs about antipsychotic
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medication and takes approximately 30 minutes to complete and score. The IP is an
eight-item scale exploring the three components of insight (awareness of illness, ability to
relable symptoms and acceptance of the need for treatment). These measures were
selected because they are widely used, have good validity and reliability and are quick to
complete and score.
Selecting a measure to detect antipsychotic side effects was more complex. The
advantages of self-report measures have already been stated. However, as discussed in
chapter two, a reliance on the use of self-report may mean that some side effects go
undetected. However, introducing clinicians to multiple measures to detect side effects
may make the assessment overly complex and time consuming, reducing the likelihood
that it would be completed and appropriate targets for treatment selected. Therefore, the
main side effect measure which trainees learned to use was the Liverpool University
Neuroleptic Side Effect Rating Scale (LUNSERS; Day et a!., 1995) a fifty-one item scale
to screen for unwanted side effects based on the UKU side effect measure (Lingjaerde et
a!., 1987). Each item is rated on a five-point scale and scoring involves grouping items
into side effect clusters (EPS, prolactin, anticholinergic, allergic, etc.). The measure takes
approximately 15 minutes to complete and 10-20 minutes to score, has been shown to be
valid and reliable and, as demonstrated in chapter two, is widely used.
Trainees practised using these measures through role-play and ratings of videotaped
patient interviews. Within the role-plays the measures were used to identify specific
problems and areas of concern that the trainees role-play partner wanted to address.
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The second component of the course focused on developing trainees' skills in using
psychological interventions (compliance therapy, behavioural tailoring, patient
education) to enhance compliance. Trainees were given an overview in compliance
research and the medication management treatment rationale. To facilitate teaching,
discrete clinical interventions were described (reviewing illness history, testing beliefs
about treatment, exploring ambivalence, and giving information). Video role-play was
used to allow trainees to rehearse each discrete intervention and receive feedback from
the rest of the group about what they did well within the role-play and what they could
have done differently (Gask, 1999).
The psychopharmacology component of the course provided a comprehensive overview
of the mode of action and use of antipsychotics to supplement trainees more specific
medication management work. The Bethlem and Maudsley NHS Trust Prescribing
Guidelines (Taylor et a!., 1999) were used as a basis for teaching and to provide trainees
with evidential clinical practice guidelines. Teaching, using the guidelines as a template,
focused on effective treatment strategies, the management of antipsychotic side effects,
and the treatment of refractory illnesses.
Regular, weekly, clinical supervision formed a critical component of the course
integrating skills learnt in the classroom into clinical practice. Each trainee presented a
patient they were working with, concluding the presentation by suggesting a supervision
question for discussion within the group. Following the discussion, an action plan was
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agreed. On the follow-up day trainees presented an update on their progress, having
implemented the action plan.
3.4 AIMS OF THE PILOT INTESTIGATION
The aim of this study was to establish whether the model of medication management
training described above has sufficient impact on CPNs' clinical skills and knowledge to
warrant further investigation. This was established by testing the hypotheses that
medication management training would:
Enhance trainees' compliance therapy skills as measured using the Cognitive Therapy
Scale (Vallis et a!., 1986; appendix 4 and 5).
Increase trainees' knowledge about medication management as measured using the
Knowledge about Medication Management Questioimaire (appendix 6).
• Demonstrate that trainees can reliably evaluate pharmacological interventions by
rating patients' mental state using the Positive and Negative Syndrome Scale
(PANSS; Kay et a!., 1989a).
Because the other measures (DAI-30; IP; LUNSERS) taught during the course were self-
report, it is not necessary (or possible) to establish trainees' reliability in using them.
Feedback from trainees on the relevance of training to their clinical practice, their ability
to apply what they had learned in practice and their overall satisfaction with training was




The study has a within-subjects repeated measures design. Trainees were recruited from
three mental health Trusts in south London and were accepted on to the course if they
were registered mental health nurses currently working predominantly in the community
with patients with serious and enduring mental disorders.
3.5.2 Primary outcome measure
3.5.2.1 Cognitive Therapy Scale (CTS; Vallis et a!., 1986; appendix 4)
A ten-minute standardised role-play task (appendix 5) derived from the method described
by Scott et a!. (1999), focusing on a patient's specific problem with antipsychotic
medication, was performed pre- and post-training. An experienced third party 'actor'
role-played the patient. These were videotaped and blind rated by a trained cognitive
therapist using the cognitive therapy scale at the end of training. The CTS is extensively
used in both North America and the United Kingdom and is a valid and reliable 10-item
measure of clinicians' general and specific clinical skills. Each of the items - agenda
setting, feedback, understanding, interpersonal effectiveness, collaboration, pacing and
efficient use of time, guided discovery, strategy for change, application of specific
medication management techniques and an overall clinician rating - were rated on a
seven-point scale ranging from poor (0) to excellent (6) producing a total score of
between 0 and 60. A satisfactory score for each item is defined as 3, and for the total as
30. Each item has four anchor points to facilitate rating.
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3.5.3 Secondary outcomes measures
3.5.3.1 The Knowledge about Medication Management Questionnaire (Appendix 6)
The 16-item multiple-choice Knowledge about Medication Management Questionnaire
was administered pre- and post-training. The questionnaire was specifically developed
for the study as no appropriate measure could be identified within the literature that
reflected the medication management course curricula and recent developments in
psychopharmacology, including the introduction of new drugs. Trainees were presented
with 16 questions that related to case vignettes with five possible responses, of which
only one was correct. The questionnaire produces a total score ranging from 0 to 16. The
questionnaire was designed to have content validity by including questions on key
aspects of the medication management intervention taught within the course. To test this
a Consultant Psychiatrist and a Clinical Pharmacist completed the questionnaire and were
able to get 100% of the questions correct. Test re-test reliability was established by
correlating scores on the Knowledge about Medication Management Questionnaire in a
group of 10 mental health nurses not associated with the project. Questionnaires were
completed twice with a ten-week interval between assessments to mirror training, and
good test re-test reliability was demonstrated.
It is possible that testing trainee knowledge may in itself influence the outcome of
training by enhancing trainees' motivation to study for the test. To minimise this effect
trainees were not given advance notice of the test and were not allowed to keep copies of
the assessment.
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3.5.3.2 Positive and Negative Syndrome Scale (PANSS; Kay eta!., ]989a)
Reliability in assessing patients' mental state using the PANSS was established using the
method described by Peuskens et a!. (1995). Trainees' ratings of a video of a patient
being interviewed using the structured clinical interview (SCI; Kay et a!., 1989b) were
compared to a gold standard. A rating to within ±1 point of the gold standard for 80% of
the items demonstrated satisfactory inter-rater reliability (Peuskens et al., 1995).
3.5.3.3 Satisfaction, relevance and application of training (appendix 7)
At the end of the course trainees completed a questionnaire asking them to rate how
satisfied they had been with the content of the course and the quality of the teaching.
They also rated how relevant the course was to their clinical practice. Each rating was
made on a four-point Likert type scale. Trainees also indicated if they were able to
incorporate the skills that they had learnt into their routine clinical practice.
3.5.4 Statistical analysis
To identify within group differences post-training the Wilcoxon test for related samples
was used. Two-tailed tests were used as the most conservative method of analysis even
when the comparisons were supported by a specific hypothesis. Standard parametric
statistics also produced the same result. The McNemar test was used to test for changes in




3.6.1 Demographic characteristics of the trainees
Although fifteen trainees completed the two courses, eight in cohort one and seven in
cohort two, three trainees did not complete the measures because they were absent when
they were administered. Data are therefore reported on the twelve trainees who
completed all the assessments. There were no significant differences in the demographic
profile of trainees who did or did not complete all the assessments.
The mean age of the 12 trainees who completed the course was 32 years (range 26-41),
50% were male and the majority (5 8%) classified themselves as being of white ethnic
origin. All trainees were mental health nurses working in the community with a mean
length of experience of six years. The majority of trainees (75%) held diploma level
qualifications or higher. There were no significant differences between the two cohorts.
Trainees who completed the course had an average attendance of 88% of the taught
components. The demographic profile of trainees is generally similar to that reported in
other training studies (Lancashire et al., under review; Brooker et al., 1994) and the most
recent survey of Community Mental Health Nurses in England and Wales (Brooker and
White, 1997). Trainees in this study have, however, received more post-registration
training and are from a more diverse ethnic background than the national average
(Brooker and White, 1997).
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3.6.2 The Cognitive Therapy Scale
Table 3.1 shows mean CTS total and item scores pre- and post-training. At post-training
the CTS total score had doubled and, with the exception of guided discovery, significant
improvements in each of the items were also observed. A mean improvement from barely
adequate to satisfactory was observed for the application of medication management
techniques.
Table 3.1. CTS total and item scores pre- and post-training
-rrni ___
Si1Thj,j	 s1
Agenda setting	 .77	 .83	 2.08	 .86	 =003
Feedback	 1.31	 1.18	 2.92	 1.12	 <.001
Understanding	 1.54	 .97	 3.23*	 1.24	 <.001
Interpersonal effectiveness	 2.15	 .69	 3.38*	 1.12	 .001
Collaboration	 1.77	 .73	 3.00*	 .82	 =.001
Pacing and efficient using of 	 1.31	 1.11	 2.69	 .85	 =002
time
Guided discovery	 1.85	 1.07	 2.77	 .93	 Ns
Strategy for change	 .85	 .80	 3.00*	 .82	 <.001
Application of medication	 .92	 .86	 3.00*	 1.15	 <.001
management techniques
Clinician rating	 1.62	 .96	 2.85	 1.07	 .003
Total score	 16	 8.75	 30.6**	 9.07	 <.00 1
*Satisfactory standard defined as 3
	
**satistactory total score defined as >30
ns=not significant
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One of the trainees had satisfactory CTS scores pre-training, five (42%) achieved a
satisfactory total score of>30 post-training. However, this difference was not statistically
significant. Table 3.2 shows the proportion of trainees achieving a satisfactory standard
on each item of the CTS.
Table 3.2. Proportion of CPNs who were rated as satisfactory on the CTS pre- and
post-training
•i
Agenda setting	 2	 17%	 2	 17%	 Ns
Feedback	 2	 17%	 7	 58%	 [.063]
Understanding	 2	 17%	 8	 67%	 .031
Interpersonal effectiveness
	 4	 33%	 9	 75%	 [.063]
Collaboration	 1	 8%	 8	 67%	 .016
Pacing and efficient using of 	 2	 17%	 7	 58%	 [.063]
time
Guided discovery	 4	 33%	 7	 58%	 Ns
Strategy for change	 0	 0%	 8	 67%	 .008
Application of medication 	 0	 0%	 6	 50%	 .031
management techniques
Clinician rating	 2	 17%	 8	 67%	 .031
Total score	 1	 8%	 5	 42%	 Ns
ns=not significant, []trend
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3.6.3 Knowledge about Medication Management
Pre-training, the mean score on the Knowledge about Medication Management
Questionnaire was 7.9 with trainees getting just under half of the questions correct. Post-
training the mean score increased to 10.5 with trainees getting two thirds of the questions
correct. This equates to a mean improvement of 33% which is highly statistically
significant (p<.00l).
3.6.4 Mental state assessment
Eight (67%) trainees rated the video of a patient being interviewed to a satisfactory
standard. The mean number of errors (items not rated to within ±1 point of the gold
standard) per trainee was 4.8 (16%). No significant difference in trainees' concordance
with the gold standard was observed between positive symptoms (mean 1.1 errors),
negative symptoms (mean 1.8 errors) and general psychopathology (mean 2.0 errors).
3.6.5 Satisfaction, relevance and application of training
All trainees reported that they were either satisfied or very satisfied with the content of
the course and the quality of the teaching. All trainees also reported that they were able to
incorporate the assessment tools and skills into their day to day clinical practice. Trainees
did feedback that they would like less time spent on role-play and more on
psychopharmacology.
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3.6.6 Prediction of change
Linear regression was used to identify any predictors of improvements in clinical skills
and knowledge. CTS and Knowledge about Medication Management Questionnaire
change scores were used as the dependent variables and age, gender, ethnicity,
attendance, length of experience, clinical grade and highest level of previous academic
attainment were used as the independent variables. No predictors were found although
there was an association between attendance and change in CTS total score (r=.586,
p=.O45).
3.7 DISCUSSION
The results generally supported the hypothesis that brief training enhances trainees'
medication management skills and knowledge. The results also demonstrated that the
majority of trainees could reliably assess a patient's mental state using valid and reliable
assessments. A high degree of satisfaction with the training was reported.
The Cognitive Therapy Scale total and item scores were rated as being barely adequate-
to-mediocre pre-training. Knowledge about Medication Management Questionnaire
scores also suggested a poor pre-training understanding about medication management.
These findings demonstrate that trainees were not skilled in structuring sessions or
working collaboratively with patients using basic cognitive therapy skills. The
application of specific medication management techniques was also rated as being
'barely adequate'. The findings suggest that prior to receiving training, trainees were not
sufficiently skilled to apply techniques which have been shown to be effective in
88
enhancing compliance (Kemp et a!., 1997). The poor pre-training scores on the
Knowledge about Medication Management Questionnaire demonstrate that trainees had a
poor understanding of assessment measures, strategies for enhancing compliance and
antipsychotic side effects. This finding is consistent with the poor rates of detection of
antipsychotic side effects by mental health nurses reported by Bennett et a!. (1995) and
the findings reported in chapter two.
All trainees showed an improvement in CTS scores following training. Almost half of
the CPNs who received training were able to demonstrate satisfactory medication
management skills at the post training assessment compared to none pre-training. These
trainees may have acquired sufficient skill and knowledge to apply the training with
sufficient fidelity to improve patient outcome. This hypothesis will, of course, need to be
tested within the context of a randomised controlled trial. These improvements are
consistent with the satisfactory levels of clinical skills observed by Brooker and
Butterworth (1993) and may suggest that, as discussed in chapter one, brief targeted
programmes are as effective as more extensive courses in facilitating the implementation
of psychosocial interventions.
However, only just over half of the trainees achieved a satisfactory level of skill and
refinements to the programme will be needed to maximise the potential impact of training
on patient clinical outcomes. Improvements in some CTS items were found whilst others
did not change significantly. For example, post training 75% of trainees demonstrated a
satisfactory level of interpersonal effectiveness but only 17% in agenda setting. This
89
suggests that, in future, more time is spent on developing these skills. However,
increasing the amount of time spent rehearsing clinical skills is contradictory to the
feedback from trainees who wanted to spend less time in role-play.
The weak correlation between skills acquisition and attendance suggests that trying to
improve attendance may be useful in improving CTS post-training. Attendance in this
study was high although some level of absenteeism was unavoidable. However, careful
planning with service providers (e.g. running the course on days when there are no ward
rounds) and the involvement of trainees' line managers in facilitating and encouraging
participation may help improve attendance.
Training was effective in improving knowledge about medication management and was
consistent with Lancashire et al. (under review) who also found that training improved
trainees' knowledge. Skills in assessing patients' mental state were also demonstrated to
be satisfactory for the majority of trainees. These results suggest that trainees understand
the treatment rationale, are able to perform relevant assessments, derive a formulation
and target appropriate medication management interventions to address patients' specific
problems with their medication.
The high degree of satisfaction with the training and strong indication that trainees found
it to be both applicable and relevant to their clinical practice is consistent with the
findings reported in chapter two. Suggesting that the medication management
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intervention provides clinicians with the skills that they need but are not provided with
within current training initiatives.
The cost of providing medication management training was £1,474 per trainee, including
replacement costs (a detailed breakdown of costs can be found in appendix 9). Given that
the training is manualised and can potentially be facilitated by an appropriately trained
clinician there is a potential for rapid dissemination.
The improvements in clinician skills and knowledge and the reported satisfaction with,
and relevance to practice of, the medication management training suggest that an
investigation into the impact on clinical outcome may be warranted.
3.8 CONCLUSION
Brief targeted training that facilitates the rapid dissemination of psychosocial
interventions into routine clinical practice is needed to meet the requirements of the
National Service Framework (Department of Health, 1999). The results of this study
suggest that the medication management training programme leads to enhanced clinical
skills and knowledge. However, whilst skills are enhanced only half of the trainees were
able to demonstrate satisfactory levels. This suggests that the model of training may need
to be revised to ensure that a higher proportion of trainees achieve a satisfactory standard.
However, the improvements are sufficient to warrant a further large-scale investigation
into the impact of training on clinical skills and patient outcomes.
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CHAPTER 4: RANDOMISED CONTROLLED TRIAL
The first three chapters have established that non-compliance with antipsychotic
medication is a major preventable cause of psychiatric relapse. Psychological and
pharmacological interventions, such as compliance therapy and effective detection and
management of antipsychotic side effects (medication management), are effective in
enhancing treatment concordance. Training is potentially an effective method of
disseminating medication management interventions so that CPNs can deliver them in
routine clinical practice. A survey of CPNs confirmed that current medication
management practice is poor and that although training is enhanced in those who have
received training in psychosocial interventions, such models do not lend themselves to
the large-scale dissemination of medication management interventions throughout the
NHS. Based on the available evidence a pilot medication management training package
was developed and piloted. Significant improvements in CPNs' knowledge and skills
were found post training. It is reasonable therefore to progress from this pilot work to
address the central research question:
• Does medication management training result in improved clinical outcomes for
patients?
4.1 METHODS
The most robust method for answering this question is a randomised controlled trial
comparing the clinical outcomes of patients treated by CPNs who have received
medication management training with those delivering routine care. No previous studies
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have used such a methodology to evaluate the impact of a training intervention. This trial
will also therefore develop and test methodologies for undertaking such an investigation.
4.2 MAIN HYPOTHESES
The main hypotheses of this trial were to establish that compared to standard care, the
application of a medication management intervention for patients with schizophrenia
delivered by CPNs in routine clinical practice would produce significant improvements in
patients':
1. Psychopathology, because of increased treatment compliance
2. Functioning, because of increased treatment compliance
3. Aftitudes towards treatment
4. Compliance with antipsychotic medication
5. Insight into their illness
6. Antipsychotic side effects, because of more appropriate prescribing
7. Service utilisation, because of increased treatment compliance
8. Prescribed antipsychotic medication
4.2.1 Other issues investigated
The trial also aimed to establish that revised brief training was effective in providing
CPNs with the knowledge and skills necessary to effectively deliver the medication
management intervention. Three questions were asked:
1. Would CPNs' clinical skills be enhanced?
2. Could they reliably assess patients' psychopathology?
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3. Would knowledge about psychopharmacology be increased?
4.3 DESIGN
Sixty CPNs were recruited to the trial from two NHS Trusts. They were organised into 12
clusters based on the geographical location of the community mental health team or GP
surgery where the CPN was based. They were then randomised into either the
experimental or waiting list control groups. CPNs in the experimental condition received
80 hours of training to deliver a medication management intervention. Those in the
waiting period continued with their standard practice for 26 weeks and then received the
same training. Each CPN identified two patients on their caseload to participate in the
trial. These patients completed a battery of self-report and researcher rated outcome
measures at baseline and again after 26 and 52 weeks (Figure 4.1). Because patients are
not independent of each other (i.e. pairs share the same CPN), the most conservative
method of analysing the data is to take the mean of the scores from the CPNs' two















































































The design was chosen to compare clinical outcomes in patients treated by CPNs who
had been trained to deliver a medication management intervention with those of CPNs
delivering routine care during the control period. CPNs in the control group then received
training after the week 26 assessments had been completed, at which point they served as
their own controls. Comparison with a control group, where clinical outcome was being
monitored, was important because, as observed in chapter one, compliance tends to
improve under scrutiny. It was also important to assess patients after a follow up period,
rather than pre- and post-training only, because if improvements are not sustained the
durability of the intervention may be in question (Hickie eta!., 1995).
Alternative designs such as control groups made up of non-active or placebo training
were considered but rejected. Placebo training was rejected for two main reasons: firstly,
it would be unethical and expensive to train CPNs to deliver an intervention which was
known to be ineffective, secondly, it would have been difficult to get the support of the
CPNs in identifying suitable patients for the study. Standard care, as a control, was
rejected because of anticipated difficulties in recruiting CPNs to participate and facilitate
access to patients in a study for which they received no benefit.
4.5 POWER CALCULATION
The required sample size of 60 CPNs for this trial was based on the following
assumptions:
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1. The primary outcome of interest is improvement in patients' psychopathology.
2. The primary outcome measure is the total score for the Positive and Negative
Syndrome Scale (PANSS Kay eta!., 1989a).
3. The mean common standard deviation for the PANSS is 12.4. This is derived from
data from drug trials (Marder et al., 1997; Beasley et a!., 1997; Peuskin et al., 1995)
previous compliance interventions (Macpherson et al., 1 996a) and psychometric
testing of the PANSS (Kay 1990; Bell et a!., 1992; Peralta and Cuesta 1994).
4. The CPN is the unit of analysis.
5. No previous trials of compliance interventions have demonstrated a significant effect
of treatment on patients' psychopathology. A ten-point difference in the PANSS total
scores between the experiemental and control groups was considered to be clinically
important and feasible to achieve. This was based on evidence from the compliance
therapy trial (Kemp et a!., 1996; 1998) and previous studies that have evaluated the
impact of CPN training on patients' psychopathology (e.g. Brooker et al., 1994).
6. The most conservative method of analysis would be a comparison of the differences
in mean scores between the two groups at the week 26 assessment (controlling for
baseline scores) using an analysis of co-variance (ANCOVA).
7. The level of significance for detecting a training effect of 10 points on the PANS S
was set at 5%. The degree of certainty that a true difference between groups (if at
least 10 points) would be detected was 80%.
8. The patient drop out rate in a previous training trial was 20% (Lancashire et a!., under
review). A similar drop out rate was assumed in this trial.
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The power analysis was performed using NQuery advisor.
4.6 INCLUSION AND EXCLUSION CRITERIA
4.6.1 CPN inclusion criteria
CPNs were recruited to the trial if they met the following inclusion criteria:
Registered nurse on either part 3 or 13 of the UKCC (United Kingdom Central
Council) register.
• Have at least 12 months post registration experience.
Working in a community setting with a caseload of predominantly psychotic patients.
4.6.2 Patient inclusion and exclusion criteria
Each CPN who agreed to participate in the study identified two patients on their caseload
who they would be working with for the duration of the trial. These patients were then
visited by a researcher and screened to ensure that they met the trial inclusion/exclusion
criteria:
4.6.2.1 Inclusion criteria.
Currently on the caseload of a randomised CPN.
Gave written informed consent to participate in the trial.
• Had a recorded lCD- 10 diagnosis of a psychotic disorder (WHO, 1992).
• Currently, or a prescribing doctor recommended, taking antipsychotic medication.
• Known or suspected poor treatment adherence (reported by the CPN) or within the
previous twelve months at least one admission or relapse.
98
4.6.2.2 Exclusion criteria
Patients suffering from moderate or severe learning disabilities concurrent with
schizophrenia.
Patients being treated by forensic psychiatric services.
Inpatients who have remained in hospital for more than six months prior to the start
of the training period.
Patients suffering from organic brain disorders.
4.7 METHOD OF RANDOMISATION
CPNs were allocated to experimental or control groups using a restricted cluster
randomisation procedure to: 1. ensure equal numbers of trainees in each group; and 2. to
minimise the risk of contamination (caused by CPNs who work in the same office sharing
information about the training). Randomisation sequences were prepared from a table of
random numbers, in random permuted blocks (appendix 8). As randomisation was with
small numbers of clusters, blocks of four were used.
The prepared randomisation lists were then transferred to a set of sealed envelopes,
numbered from one to twelve, containing a card indicating which group the cluster had
been allocated to. Once twenty CPNs were recruited to the trial they were organised into
four clusters (numbered one to four) with five trainees in each (keeping those who
worked in the same building together). The randomisation envelope corresponding to
their cluster number was then opened and the CPNs were informed of the date when
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training would occur. The CPNs name, cluster number and training allocation were
entered into the trial logbook immediately after randomisation and prior to the
commencement of training. This process was repeated on two more occasions (cluster
numbers five-eight and nine-twelve). The researchers undertaking patient assessments did
not have access to the randomisation envelopes or log.
4.8 RECRUITMENT OF CPNs
Two mental health NHS Trusts were approached and agreed to participate in this trial. A
trial co-ordinator, a senior nurse within each NHS Trust, recruited CPNs, who met the
inclusion criteria, to participate in the trial. CPNs were recruited by advertising the course
within the Trust in three ways: writing directly to CPNs; putting posters on notice boards;
and placing advertisements in the local recruitment bulletin. CPNs who agreed to attend
the training were informed by the trial co-ordinator that they would be randomly
allocated to attend a training course starting on two different dates 26 weeks apart. It was
also explained that they would need to identify two patients on their caseload who they
would continue to work with during the trial and who met the inclusionlexclusion criteria.
They also had to facilitate patient assessments conducted at baseline, week 26 and week
52.
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4.9 RECRUITMENT OF PATIENTS
4.9.1 Obtaining informed consent
At the screening visit, patients were given a brief description of the trial and the
interventions that their CPN would be using. It was explained that the aim of the study
was to improve the case they received by providing additional training to the CPN who
was treating them. They were informed that the assessment procedure would include
questions about their mental health and their experiences of taking antipsychotic
medication. Patients were encouraged to ask as many questions as they wished which
were answered as comprehensively as possible by the research worker. Patients were also
given an information sheet (appendix 10). They were not asked to make an immediate
decision but if they were happy to take part the researcher would make another
appointment to visit them and complete the interview. At this second visit patients were
asked to sign a consent form (appendix 11).
4.10 PROCEDURES TO ADMINISTER OUTCOME MEASURES AND
PROTECT AGAINST SOURCES OF BIAS
All patient interviews were conducted by one of two trained research workers who were
blind to the training condition. Both researchers were psychology graduates and were
experienced at interviewing patients with psychotic disorders. They also received
additional training in using all of the patient assessments, including the PANSS. Training
included role playing the interview, performing the interview with patients under
supervision, and practice interviews with patients. Reliability in rating the PANS S was
achieved using the method described by Peuskens et al. (1995) and outlined in chapter 3
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A high degree of inter-rater reliability was achieved for both research workers (researcher
one, two errors 93% correct; researcher two, four errors, 87% correct).
The researcher was given the contact name, address and phone number of a CPN, by the
lead investigator, and asked to arrange to visit the two patients they had identified to
participate in the study. Both the research worker and CPN were instructed not to discuss
any aspect of the trial or training. After each visit the patient's case record was placed in a
locked filing cabinet to which the research worker did not have access. A third party who
was not involved in data collection entered the data from the patient's case record onto a
computerised database, which was password protected.
4.11 TIMETABLE FOR TRIAL
The timings of the medication management training, intervention and patient interviews
are shown in table 4.1. The courses were staggered to allow a reasonable amount of time
for patient interviews to be completed. The dates for the courses were agreed with the
trial co-ordinator well in advance of the start of the course and a meeting was held with
all CPNs participating in the study outlining what would be required of them.
Problems were anticipated in ensuring that all the assessments were completed on time. A
four-week window was therefore agreed for each of the three assessments phases. If the
assessment was not completed within this time then it was counted as missing data but






























At baseline all patients were assessed using the following outcome measures which were
then repeated at week 26 and 52 (table 4.2). Care was taken when selecting measures that
the total time taken to conduct each patient visit should be no more than 90 minutes.
Table 4.2 Assessment procedure
Positive and Negative 	 Patient interview
SyndromeScale (PANSS)
	 _______________ ________ _________ _________
Global Assessment of	 Researcher rating
Functioning(GAF)
	 _______________ ________ ________





Composite measure of 	 CPN rating	 S	 S	 S
compliance
Insight Scale for Psychosis 	 Patient self-report	 S	 S	 S
(IS)	 _________________ _________ _________ _________
Liverpool University Side
	 Patient self-report	 S	 S	 S
Effect Rating Scale
(LUNSERS)	 _____________ _______ _______ _______
Demographic information	 Case note review	 S
Prescribing information
	 Case note review	 S	 S	 S
Service utilisation	 Case note review	 S	 S	 S
• = assessment
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4.13 PRIMARY OUTCOME MEASURES
4.13.1 Positive and Negative Syndrome Scale (PANSS; Kay et a!., 1989a)
The Positive and Negative Syndrome Scale (PANSS) was chosen as a well researched
psychometric instrument for evaluating the symptoms of schizophrenia. Thirty-items are
rated on a seven point scale which follows the general format of the Brief Psychiatric
Rating Scale (BPRS; Overall and Gorham, 1962). However, the PANSS has strict
operational criteria for conducting the 30-40 minute patient interview, thorough
definitions for all 30 items and detailed rating criteria for each level of psychopathology
(Kay et al., 1988). Seven of the items which represent productive features constitute the
positive sub-scale; seven deficit items similarly constitute a negative syndrome sub-scale;
and the remaining 16 which cannot be linked decisively to either syndrome serve as a
general psychopathology sub-scale.
The psychometric properties of the PANSS have been studied extensively by the Kay
group which developed the measure. Good inter-rater reliability (Kay et al., 1988)
adequate construct validity (Kay et al., 1987, 1988), high internal reliability (Kay et al.,
1987), appropriate test-retest reliability (Kay et al., 1987) and external validity (Kay et
al., 1986; 1987; Kay and Singh, 1989) have all been demonstrated. The most recent study
(Opler et al., 1994) replicated findings on the internal reliability of the PANSS, reporting
a coefficients for the positive, negative and general psychopathology scales of 0.80, 0.82
and 0.82 respectively. An independent study (Bell et al., 1992) has also established inter-
rater reliability. The internal consistency coefficients for the positive negative and general
psychopathology scales were 0.74, 0.69 and 0.64 respectively. Peralta and Cuesta (1994)
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argue that the PANSS may be the most valuable instrument for clinical research in
schizophrenia.
The PANSS is the standard measure used in most drug trials of new antipsychotic agents
(Beasley et a!., 1997; Marder et a!., 1997) and is increasingly being used in studies
evaluating psychological interventions for schizophrenia (for example, Macpherson Ct al.,
1 996a). It offers a number of scientific and practical advantages over measures such as
the BPRS (Overall and Gorham, 1962) and the KGV (Krawiecka et a!., 1977). A
structured clinical interview, guide and videotaped training are available. Items are
clearly defined and there are detailed criteria for each level of symptom severity. Such a
comprehensive package enables research workers to be easily trained to perform very
accurate and consistent assessments of patients' psychopathology.
4.14 SECONDARY OUTCOME MEASURES
4.14.1 Global Assessment of Functioning (GAF; Endicot et aL, 1976)
The Global Assessment of Functioning (GAF) is a quick and simple measure of overall
psychological disturbance, which has been extensively used in studies evaluating
pharmacological interventions (Gomez et al., 2000; Schulzet et a!., 1999; Percudani et
a!., 1999). The GAF consists of nine behavioural descriptors ranging from "absent or
minimal symptoms (e.g. mild anxiety before an exam)" ... "no more than everyday
problems" to "persistent danger of severely hurting self or others" ... "or persistent
inability to maintain minimal personal hygiene or serious suicidal act with clear
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expectation of death". Patients are rated between 0 (most severe) and 100 (least severe).
Jones et a!. (1995) demonstrated satisfactory validity and reliability for the OAF.
4.14.2 Hogan Drug Attitude Inventory (DAI-30; Hogan et a!., 1993)
The Hogan Drug Attitude Inventory (DAI-30) is a 30-item self-report measure predictive
of compliance in people with schizophrenia. Each statement is rated as being true or
false. To minimise the possibility of acquiescence bias there are an equal number of items
to be scored true and false. The measure produces a total score ranging from +30 to -30.
A positive score is predictive of compliance, a negative score of non-compliance.
Statements were selected from an original pool of 100 based on the item's ability to
discriminate between compliant and non-compliant patients. The scale has been shown to
have a degree of discriminative validity, with 89% agreement between the DAI and
clinician rating of whether patients were compliant or non-compliant. The DAI-30 has
frequently been used in previous studies to evaluate the effectiveness of compliance
interventions (e.g. Kemp eta!., 1996; 1998).
4.14.3 Clinician rating of compliance (Kemp et aL, 1998)
An informant and observer rating of compliance on a seven point scale, ranging from I
(complete refusal) to 7 (active participation in treatment). Concurrent validity has been
established by correlating scores with the Hogan Drug Attitude Inventory (DAI-30;
Hogan eta!., 1983; Kemp et al., 1998).
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4.14.4 Expanded Schedule for the Assessment of Insight (SAI-E; Kemp and David
1997)
The expanded schedule for the assessment of insight is a ten-item researcher rated scale.
Items are rated on a three-point scale based on a mental state examination (such as the
structured clinical interview) and specific additional questions described in the measure.
Scores are expressed as a percentage of total insight. The schedule has been used in
previous trials (Kemp et a!., 1996; 1998; Macpherson et al., 1996a) and satisfactory
reliability and validity have been reported (Kemp and David, 1997).
4.14.5 Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS; Day et
a!., 1995)
The LUNSERS is a 51-item self-report measure of the side effects of antipsychotic
medication. Forty-one items covering psychological, neurological, autonomic, hormonal
and miscellaneous side effects were constructed by rephrasing items from the UKU
adverse events measure (Lingjaerde et al., 1987) so that they could be self-rated. The
remaining ten items were "red herrings" referring to symptoms which were not known
antipsychotic side effects (e.g. hair loss). Each item is rated on a 5-point scale ranging
from 'not at all' to 'very much' based on how frequently the patient has experienced the
side effect in the last month.
The LUNSERS is an efficient, reliable and valid method of monitoring antipsychotic side
effects. Day et a!. (1995) showed good test re-test reliability (r0.81) and concurrent
validity against the UKU (r=0.83). It has also been demonstrated that there is a significant
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but weak correlation between increasing doses of antipsychotic medication (measured in
chiorpromazine equivalent) and the number and frequency of side effects measured using
the LUNSERS (r=O.31; Day eta!., 1995).
4.14.6 Demographic information
Using a satadardised form constructed for this study age, gender, ethnicity, diagnosis and
duration of illness were collected from patients' medical notes at the baseline assessment
and confirmed with the patient at interview (appendix 12). It was assumed that
demographic information would not change dramatically over the duration of the trial.
4.14.7 Prescribing information
All the medication that patients were prescribed on the day of assessment was recorded
on a form (appendix 13). Data were recorded from the patient's drug chart and were
crosschecked with the CPN and patient. Data were also obtained on whether the patient
was receiving any non-pharmacological or alternative treatments such as Cognitive
Behavioural Therapy (CBT).
4.14.8 Number of inpatient bed days
At each visit the researcher recorded, from the patient's medical notes, the number of
days spent as an inpatient in the previous six months (appendix 14).
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4.15 ETHICAL ISSUES
Ethical approval for this study was granted by local research ethics committees (LRECs)
at the two study sites who reviewed the trial protocol.
4.16 STATISTICAL ANALYSIS
Parametric tests were used for most of the analyses, as the data were normally distributed
(histograms for baseline scores for all the primary and secondary outcome measures are
shown in appendix 15) and most of the measures used in the trial produced interval data
which is well suited to such analysis. Even when supported by a specific hypothesis, all
statistical tests performed were two tailed at a significance level of 0.05. The data were
analysed in three ways:
Analysis of mean scores. Mean scores were compared within and between groups.
The t-test was used for analysing within group changes. An analysis of co-variance
(ANCOVA) was used for between group comparisons of mean response to training.
The ANCOVA was selected because it avoids repeated significance testing (thus
reducing the risk of type I error), provides a simple clear summary of the response to
training, and takes into account variations in pre-training scores.
Categorical change. Analysis of mean scores can be a less useful determinant of
outcome than percentage response rate if there is the potential for variation in
response between subjects. A major component of the analysis therefore involved
categorical change. Within group changes were analysed with the McNemar test and
between group comparisons were analysed using the chi-square test or Fisher's exact
test for small expected numbers. As the primary aim of this trial was to improve
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patients' psychopathology, the determinant of outcome was the percentage of CPNs
whose patients showed a mean 10% reduction in total PANS S scores.
Clinically significant change. Clinically significant change was also analysed within
and between groups. This was determined using Jacobson and Traux's (1991) criteria
that a patient's post-treatment and follow-up scores extend to 2 standard deviations
beyond the pre-treatment mean score. The analysis of clinically significant change
was chosen because statistical significance offers little insight into the benefits of a
training intervention in the real world. Clinical significance tends to make treatments
look less effective than standard statistical comparisons imply (Jacobson et al., 1988).
Clinically significant change has not been reported in any of the previous trials of
compliance or training interventions.
SPSS version 8.0 was used for all statistical analyses.
4.17 TRAINING AND TREATMENT FIDELITY
Revised training and treatment manuals (appendix 2 and 3) were written for this trial
incorporating the results of the pilot study and feedback from trainees and trainers as well
as the trial steering committee. The training for CPNs to equip them with the necessary
skills to deliver the medication management intervention was broadly similar to the
model described in the pilot study (chapter 3), but with some amendments. Increased
time was devoted to practising each of the medication management interventions using a
variety of role-play techniques. There was also increased emphasis on clinical
supervision during and after the course to enhance fidelity to treatment.
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Each of the CPNs who participated in the trial received peer group supervision, for the
six-month duration of the intervention, with a clinician who was experienced in using
medication management techniques.
4.18 CLINICIAN OUTCOME MEASURES
In order to establish CPNs' ability to deliver the medication management intervention,
measures of knowledge and clinical skills were performed pre-, during- and post-training
(Table 4.3). The procedures used to assess clinicians were as described in chapter 3.
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Following a recruitment campaign in the two NHS Trusts participating in the trial, sixty
CPNs who met the inclusion criteria, were recruited, and organised into geographical
groups and randomised. Prior to recruiting patients eight CPNs withdrew from the trial, 3
in the experimental group and 5 in the control group. Four had found alternative
employment in a different NHS Trust and two withdrew because they reported that they
were too busy to attend the training. Fifty-two CPNs entered the trial and referred 89
patients who were assessed by the research worker. Seven patients did not meet the
inclusion/exclusion criteria. Of these, five had not been diagnosed as suffering from a
psychotic disorder or were not prescribed or recommended to take antipsychotic
medication and two were not on the caseload of the CPN who referred them. A total of 82
patients were eligible for inclusion in the trial. Of these, five (6%) refused to participate,
three gave no reason and two said they did not want to participate in a research project.
Seventy-seven patients gave written consent and entered the study, a mean of 1.48 per
CPN.
5.2 PATIENT DROP-OUTS
Of the 77 patients who entered the trial 8 (10%) left the caseload of the CPN who was
treating them, three prior to the week 26 and 5 prior to the week 52 assessments and were
classified as training drop-outs (table 5.la). Three of the non-completers were from the
experimental group and five from the control (this difference was not significant). The
reported reasons for patients dropping out of the trial did not appear to be related to the
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study. Six patients moved out of the geographical area covered by the CPN treating
them, one could not be traced and had also, presumably, moved out of the area and one
was sent to prison and their care was transferred to a forensic psychiatric team.
Table 5.1.a Number of patient drop-outs by group
5.3 CPN DROP-OUTS
Of the 52 CPNs who entered the study eight withdrew before the end of the trial, two
before the week 26 and 6 before the week 52 assessments (table 5.lb). Three were from
the experimental and five from the control group (this difference was not significant).
Seven CPNs left the NHS Trust and one was promoted and withdrew from clinical work.
If CPNs dropped out of the trial their patients were classified as drop-outs.
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Table 5.1.b Number of CPN drop-outs by group
In total twenty patients dropped out of the trial. Fifty-seven patients (74%) were on the
caseloads of the CPNs at the end of the trial and were defined as completers. Not all of
the patients that finished the trial completed all the assessments.
5.4 COMPLETED ASSESSMENTS
Fifty-one patients (66%) were assessed at week 26 and thirty-five (45%) at week 52.
Assessments were not completed because some patients refused to be interviewed (but
did not drop out of the trial) or the assessment could not be organised within the four-
week window allowed within the trial protocol. Two patients did not want to be
interviewed by the research worker but agreed to complete and return their self-rated
measures by post.
Complete data are presented for 52 trainees at baseline (27 in the experimental and 25 in
the control group), 42 at the week 26 assessment (23 in the experimental and 19 in the
control group) and 29 at the week 52 assessment (15 in the experimental and 14 in the
control group).
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5.5 CPN PRE-TRAINING CHARACTERISTICS
Pre-training variables in each training group were compared using the chi-square test
(reported with continuity correction, or Fisher's exact test) for categorical or dichotomous
variables. Continuous variables were compared using an independent samples t-test. All
tests were two-tailed.
5.5.1 Demographic variables (table 5.2)
Among the 52 CPNs who entered the trial there were more men than women, the
majority were of white ethnic origin with a mean average age of 39 years. The majority
of CPNs held senior clinical grades, were experienced clinicians, and were educated to at
least diploma level. There were no significant differences between the two groups except
that CPNs in the experimental group were more clinically experienced.
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Table 5.2. Demographic characteristics of trainees. Demographic characteristics of CPNs who
completed week 26 and week 52 assessments and the generic community mental health nurse sample
from the 4th Quinquennial census (Brooker and White 1997) are presented for comparison.
:cT;!;i, itiI1Z.(J.
Gender	 Male	 10 (37%) 9 (39%) 9 (60%) 13 (52%) 8 (42%) 5 (36%)	 43%
Female	 17(63%) 14(61%) 6 (40%) 12(48%) 11(58%) 9 (64%)	 57%
	
Ageinyears(s.d.)	 39	 40.2	 41.6	 38	 36.9	 35.8	 39
_________ ________	 (8.3)	 (8.5)	 (6.5)	 (7.7)	 (7.5)	 (7.7)	 _________
	
Ethnicity White	 13 (48%) 11(48%) 7 (47%) 10 (40%) 7 (37%) 5 (36%)
	 90%
	
Black	 6 (22%) 4 (17%) 4 (27%) 10 (40%) 7 (37%) 5 (36%)	 3%
	
Asian	 8 (3O%) 8 (35%) 4 (27%) 4 (16%) 5 (26%) 4 (29%)	 6%
	
Other	 0 (0%)	 0 (0%)	 0 (0%)	 1(4%)	 0 (0%)	 0 (0%)	 1%
	
Experience inyrs	 10.9	 11.1	 11.0	 5.6	 6.25	 6.8	 14
(s.d.)	 ________	 (6.6)	 (6.8)	 (6.7)	 (3.9)	 (5.01)'	 (5.4)	 __________
Grade	 D	 0 (0%)	 0 (0%)	 0 (0%)	 0 (0%)	 0 (0%)	 0 (0%)	 1%
	
E	 0 (0%)	 0 (0%)	 0 (0%)	 0 (0%)	 0 (0%)	 0 (0%)	 14%
	
F	 8 (30%) 5 (22%) 3 (20%) 10 (40%) 8 (42%) 6 (43%)	 13%
	
G	 19 (70%) 18 (78%) 12 (80%) 12 (48%) 8 (42%)	 8 (57%)	 61%
	
H	 0 (0%)	 0 (0%)	 0 (0%)	 3 (12%) 3 (16%)	 0 (0%)	 9%
	
I	 0 (0%)	 0 (0%)	 0 (0%)	 0 (0%)	 0 (0%)	 0 (0%)	 2%
Highest	 Cert.	 13 (48%) 10 (43%) 6 (40%) 13 (52%) 13 (68%) 9 (64%)
quali.	
Dip.	 7 (26%)	 6 (26%)	 4 (27%)	 6 (24%)	 5 (26%)	 5 (36%)
No data
BScIBA 7 (26%) 7 (30%) 5 (33%) 4 (16%)	 1(5%)	 0 (0%)
Masters	 0 (0%)	 0 (0%)	 0 (0%)	 2 (8%)	 0 (0%)	 0 (0%)
Case-load (s.d)
	
35.7	 33.6	 35.4	 34.6	 33.6	 36	 38.3
__________________	 (8.3)	 (8.6)	 (8.6)	 (9.3)	 (9.8)	 (2.8)	 _________
'significant difference found between the groups at week 0 assessment (p=.O02)
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5.5.2 CPN Pre-training scores on main and secondary outcome measures (table 5.3)
Pre-training CTS total scores were at the low end of the 0-60 scoring range, indicating
that CPNs' general cognitive and specific compliance therapy skills were poor. Scores on
the Knowledge about Medication Management Questionnaire were in the middle of the
0-16 range suggesting a moderate level of understanding about the use of medication
management interventions.
Table 5.3. CPN mean (s.d.) pre-training scores by group
igmncam airrerence rouna etween tne two groups p=.uu'i
CPNs in the experimental group had significantly lower scores on the Cognitive Therapy
Scale at the pre-training assessment. There were significant differences between the two
groups for items one (agenda setting; p=.0l6) and six (pacing and efficient use of time;
5.5.3 Comparisons between CPNs who completed, withdrew and dropped out of the
trial
Pre-training characteristics of CPNs who entered and those who withdrew before the start
of the trial were compared. No significant differences were found on any of the following
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variables: age, gender, ethnicity, years of experience, grade, highest academic
achievement, or case-load size. The demographic profile of trainees who completed the
week 26 assessment is no different to CPN characteristics at baseline. The same is true at
the week 52 assessment.
5.6 ANALYSIS OF CPN OUTCOMES
The dependent variables were three measures of CPNs' clinical skills and knowledge.
The primary CPN outcome measure (used to define overall improvement in clinical skill)
was a video-taped role-play session blind rated using the Cognitive Therapy Scale (Vallis
et al.,1986; Dobson et a!., 1985). The main secondary outcome measures (detailed in
chapter 4) were as follows:
1. The Knowledge about Medication Management Questionnaire.
2. The CPNs' reliability (using the Positive and Negative Syndrome scale) in rating a
video of a patient being interviewed using the structured clinical interview.
3. A trainee satisfaction questionnaire.
Higher scores indicate improvements in trainees' skills, knowledge and satisfaction with
training.
5.6.1 Statistical anaJyses
To identify within group differences post-training, paired t-tests were used (two-tailed).
The McNemar test was used to examine changes in the proportion of trainees who
achieved a satisfactory score on the CTS post-training.
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5.6.2 Changes in mean scores on the CTS (table 5.4)
Table 5.4 shows mean total and item scores for the CTS. Highly significant
improvements in both CTS total and item scores were found.
Table 5.4. Changes in mean (s.d.) item and total scores on the Cognitive Therapy
Scale pre- and post-training
Agendasetting	 0.6(0.8)	 3.0(.7)	 <.001	 1.3(1.0)	 2.9(1.2)	 <.001
Feedback	 1.1(1.1)	 3.2(1.1)	 <.001	 1.7(1.1)	 3.2(0.9)	 <.001
Understanding	 1.3 (0.9)	 3.4 (1.2) <.001	 1.1 (0.7)	 3.2 (0.8) <.001
Interpersonal	 1.6(0.8)	 3.1 (1.2)	 <.001	 1.7(1.0)	 3.1 (1.1)	 <.001
effectiveness
Collaboration	 1.4 (1.0)	 2.9 (1.3)	 <.001	 1.8 (0.9)	 3.1 (1.5)	 =.002
Pacing and efficient use	 1.0 (0.9)	 3.3 (1.1) <.001	 1.6 (0.9)	 3.0 (0.9) <.001
of time
Guided discovery	 1.3 (0.7)	 3.4 (0.9)	 <.001	 1.5 (0.9)	 3.3 (1.4)	 <.001
Strategyforchange	 1.2(0.9)	 3.3(1.2)	 <.001	 1.6(1.0)	 3.0(1.1)	 <.001
Application of	 1.3 (0.7)	 3.0 (0.8)	 <.001	 1.6 (0.9)	 2.6 (1.2)	 =.004
medication
management techniques
Clinician rating	 1.5 (0.9)	 2.8 (0.9)	 <.001	 1.7 (0.8)	 2.8 (0.9)	 <.001
Total score	 12.3 (4.1) 31.6 (5.4) <.00 1 15.8 (3.7) 30.5 (6.0) <.001
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Pre-training, none of the trainees demonstrated satisfactory skills on the CTS. Post
training 14 (56%) in the experimental and 10 (43%) in the control group achieved this
standard (table 5.5). Significant improvements in the proportion of trainees who achieved
a satisfactory standard on the CTS items were also found. The difference between the two
groups in the number of trainees who achieved a satisfactory standard was not
statistically significant.
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Table 5.5. Proportion of trainees who achieved a satisfactory standard on the
Cognitive Therapy Scale pre- and post-training
______	
smTrflri'D'ki
irr1	 r1fl1I	 rirn	 rrri
I	 I	 I
Agenda setting	 0 (0%)	 17 (68%) <.00 1	 2 (9%)	 14 (61%) <.00 1
Feedback	 3 (12%) 17 (68%) <.001 4 (17%) 16 (70%) =.002
Understanding	 2 (8%)	 15 (60%) <.001	 0 (0%)	 18 (78%) <.001
Interpersonal	 3 (12%) 17 (68%) <.001 5 (22%) 14 (61%) 	 .035
effectiveness
Collaboration	 3 (12%) 12 (48%) =.012 5 (22%) 15 (65%) =.007
Pacing and efficient use	 0 (0%)	 18 (72%) <.001 4 (17%) 16 (70%) 	 .002
of time
Guided discovery	 1(4%)	 19 (76%) <.001	 1(4%)	 18 (78%) <.001
Strategy for change	 2 (8%)	 15 (60%) <.00 1 4 (17%) 11(48%) 	 .039
Application of
	 0 (0%)	 16 (64%) <.00 1 3 (13%) 11(48%) =021
medication
management techniques
Clinician rating	 3 (12%) 17 (68%)	 .001	 2 (9%)	 13 (57%)	 .00l
Total score	 0 (0%) 14 (56%) <.001	 0 (0%) 10 (43%) =.008
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5.6.3. Changes in mean scores on the Knowledge about Medication Management
Questionnaire (table 5.6)
Significant improvements in trainees' knowledge were found from pre- to post-training
assessment.
Table 5.6. Changes in mean (s.d.) total scores on the Knowledge about Medication
Management Questionnaire pre- and post-training




5.6.4 Mental state assessment
Twenty-nine (60%) trainees rated the video of a patient being interviewed to a
satisfactory standard. The mean number of errors (items not rated to within ± 1 point of
the gold standard) per trainee was 6.2 out of 30 (2 1%). No significant differences in
trainees' concordance with the gold standard were observed between positive symptoms
(mean 1.8 errors) negative symptoms (mean 2.3 errors) and general psychopathology
(mean 2.1 errors).
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5.6.5 Ratings of CPN satisfaction with training (appendix 16)
Trainees reported that they were either very satisfied or satisfied with the content of the
course and the quality of the teaching. They also reported that they were able to apply the
skills they had learnt to the patients on their caseload.
5.7 PREDICTION OF CHANGE
Exploratory stepwise linear regression was used to identify factors predictive of trainees'
knowledge and skill following training in both groups combined. Post-training scores on
the CTS and the Knowledge about Medication Management Questionniare were the
dependent variables. Baseline scores were entered first and then the following variables
were entered on the second level using stepwise procedures: Trainees' caseload size,
experience, clinical grade, highest academic qualification and attendance.
A model that included trainees' highest academic qualification, grade and attendance was
predictive of CTS scores post-training. Baseline scores alone accounted for 67% of the
variance in CTS scores (R2=.67, F=l09.34, p<.001). Highest academic qualification,
grade and attendance accounted for an additional 29% of the variance (R2 .98 (adjusted
R2=.96), F=71.18, p<.001).
Baseline scores on the Knowledge about Medication Management Questionaire were
predicative of trainees' knowledge post-training (R2 .909, F109.3, P<.00l). No other
significant predictors emerged.
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5.8 PATIENT CHARACTERISTICS AT BASELINE ASSESSMENT
Patients' demographic and clinical characteristics and medication usage are presented in
their raw form and have not been averaged. The demographic profile of patients who
completed week 26 and week 52 assessments are presented as a comparison to show that
the two groups do not differ, taking into account drop-outs. Baseline variables in each
training group were compared using the chi-square test (reported with continuity
correction or Fisher's exact test) for categorical or dichotomous variables. Continuous
variables were compared using independent sample t-tests. All statistical tests were two-
tailed.
5.8.1 Demographic variables (table 5.7)
Of the 77 patients who entered the trial, men outnumbered women by about 2:1 and just
over half classified themselves as being of white ethnic origin. They were middle aged
and over half were not married or cohabiting. There was no significant difference in the
demographic profile of the two groups.
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Table 5.7. Demographic characteristics by group for patients who completed
baseline (week 0), week 26 and week 52 assessments
l,NiI,it') p 11 	 TTT7fl
I	 I
Gender Male	 29	 18	 10	 22	 17	 15
	
(72%)	 (67%)	 (67%)	 (59%)	 (71%)	 (75%)
Female	 11	 9	 5	 15	 7	 5
	(28%)	 (33%)	 (33%)	 (41%)	 (29%)	 (25%)
Marital	 Single	 25	 15	 9	 22	 16	 15
status	 (62%)	 (55%)	 (60%)	 (60%)	 (59%)	 (75%)
Married!	 4	 3	 1	 3	 2	 0
cohabiting	 (10%)	 (11%)	 (7%)	 (8%)	 (8%)	 (0%)
Widowed!	 11	 9	 5	 12	 6	 5
separated!	 (28%)	 (33%)	 (33%)	 (32%)	 (25%)	 (25%)
divorced
Ethnicity White	 23	 16	 9	 22	 14	 9
	
(58%)	 (59%)	 (60%)	 (60%)	 (58%)	 (45%)
Black	 7	 4	 3	 3	 1	 2
	
(17%)	 (15%)	 (20%)	 (8%)	 (4%)	 (10%)
Asian	 8	 5	 2	 12	 9	 9
	
(20%)	 (19%)	 (13%)	 (32%)	 (38%)	 (45%)
Other	 2	 2	 1	 0	 0	 0
	
(5%)	 (7%)	 (7%)	 (0%)	 (0%)	 (0%)
Age in years (mean!s.d.) 	 41.4	 44.2	 43.4	 39.5	 40.3	 39
	
(10.6)	 (9.3)	 (10.9)	 (12.5)	 (12.9)	 (11.6)
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5.8.2 Clinical characteristics (table 5.8)
The mean age of onset of illness was 27.6 (s.d. 10.7) years and patients had, on average,
been ill for 13 (s.d. 9.7) years. All patients had been diagnosed with a psychotic mental
illness and for the majority this was labelled as schizophrenia. Almost two-thirds of the
patients smoked cigarettes and half reported that they drank alcohol. The majority of
patients had had at least one previous psychiatric hospital admission, and over half of the
patients had been detained in hospital on at least one occasion under a section of the
mental health act. On average patients had been living in the community for over a year
and almost two thirds were registered on the Care Programme Approach (CPA). There
were no significant differences between the experimental and control groups on any of
these characteristics although there was a trend towards a longer duration of illness in
patients in the experimental group. There was also a trend in this group to having been
living in the community for longer.
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Table 5.8. Clinical characteristics by group for patients who completed baseline
(week 0), week 26 and week 52 assessments
l,NUI,itilfl	 TTI1fl
Mean duration of illness	 15.2	 16.6	 15.6	 10.9	 8.9	 8.4
(s.d.). In years	 (9.6)	 (9.9)	 (10.8)	 (9.5)	 (10.1)	 (6.5)
Ageofonsetinyears	 25.5	 26.6	 26.1	 29.5	 31.8	 30.8
(mean/s.d.)	 (7.3)	 (7.2)	 (7.7)	 (12.8)	 (13.4)	 (11.7)
Percentage of patients	 33	 22	 13	 34	 22	 18
previously admitted to	 (82%)	 (81%)	 (87%)	 (92%)	 (92%)	 (90%)
psychiatrichospital	 ________ ________ ________ ________ ________ ________
Number of previous	 2.8	 2.9	 3.6	 3.2	 3.0	 3.2
psychiatric admissions	 (2.3)	 (2.2)	 (2.3)	 (2.0)	 (2.1)	 (2.2)
Time since last admission	 17.7	 18.3	 18.4	 12.5	 11.9	 11.7
inmonths(s.d.) 	 (10.7)	 (8.6)	 (10.8)	 (12.9)	 (12.7)	 (12.3)
Diagnosis Schizophrenia	 33	 23	 13	 32	 21	 17
_______________ (83%) (85%) (87%) (87%) (88%) (85%)
Schizoaffective	 2	 1	 1	 2	 1	 1
______________ (5%)	 (4%)	 (7%)	 (5%)	 (4%)	 (5%)
Bi-polar	 5	 3	 1	 3	 2	 2
_________ _____________ (12%) (11%) 	 (7%)	 (8%)	 (8%)	 (10%)
Smoke cigarettes	 23	 14	 8	 22	 15	 15
__________________________ (58%) (52%) (53%) (61%) (63%) (75%)
Drink alcohol	 16	 11	 6	 18	 13	 9
________________________ (4 1%) (4 1%) (40%) (49%) (54%) (45%)
Registered on the Care	 35	 24	 13	 33	 22	 19
Programme Approach	 (8 8%) (89%) (87%) (89%) (8 1%) (95%)
(CPA)	 ______ ______ ______ ______ ______ ______
Ever detained in hospital 	 21	 13	 9	 17	 11	 11
under the mental health act 	 (53%)	 (48%)	 (60%)	 (46%)	 (46%)	 (55%)
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5.8.3 Psychotropic medication usage (table 5.9)
Antipsychotic medication had been recommend by a Psychiatrist for all patients and was
prescribed for the majority. Patients were receiving relatively high doses (in
chiorpromazine equivalents) of antipsychotic medication and the majority had been
taking it for at least 3 months. Half of the patients received their antipsychotic medication
via a long acting depot preparation. Polypharmacy was common, as was the long-term
prophylactic use of anticholinergic medication. Fourteen (18%) patients were treated with
atypical antipsychotics (risperidone, olanzapine or quetiapine) and six (8%) patients were
receiving clozapine therapy. A minority of patients were also prescribed antidepressants,
mood stabilisers, and benzodiazapines. Patients' medication histories were often complex
and difficult to quantify. Treatment with specialist non-pharmacological therapies (such
as family work or CBT) was rare.
Again, there were no significant differences between the experimental and control groups
on any of these characteristics.
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Table 5.9. Medication at trial entry by group for patients who completed baseline (week 0), week 26
and week 52 assessments
TTrrrnTTn
Treatment with antipsychotic 	 40	 27	 15	 37	 27	 20
medication recommended by	 (100%)	 (100%)	 (100%)	 (100%)	 (100%)	 (100%)
Psychiatrist__________ __________ __________ __________ __________ __________
Prescribed antipsychotic	 35 (88%) 25 (93%) 14 (93%) 33 (89%) 25 (93%) 18 (90%)
medication
Mean dose (mg) per day of	 418 (312) 372 (278) 554 (234) 480 (253) 510 (278) 513 (298)
antipsychotic in
chiorpromazine equivalents
(s.d.)	 _________ __________ _________ __________ __________ _________
Duration of treatment with 	 31(78%) 23 (85%) 12(80%) 27(73%) 20(83%) 18 (90%)
current antipsychotic
medication (j)ercentage greater
thanthree months) 	 ________ _________
Antipsychotic administered via 21(62%) 15 (5 6%) 9 (60%)	 15 (41%) 10 (42%) 10 (50%)
depot__________ __________ __________ __________ __________ __________
Patient receiving an atypical 	 6 (15%)	 3 (11%)	 3 (20%)	 8 (22%)	 6 (25%)	 5 (25%)
antipsychotic___________ ___________ ___________ ___________ ___________
Patient receiving clozapine	 4 (10%)	 2 (7%)	 1(4%)	 2 (5%)	 0 (0%)	 0 (0%)
therapy_________ _________ _________ _________ __________ __________
Mean number of	 1.1 (.6 1)	 1.2 (.6 1)	 1.2 (.56)	 1.2 (.63)	 1.3 (.46)	 1.3 (.56)
antipsychotics per patient
(s.d.)	 _________ _________ _________ _________ _________ _________
Prescribed anticholinergic 	 20 (50%) 14 (52%) 8 (53%)	 19 (5 1%) 13 (54%) 10 (50%)
medication
Prescribed antidepressant	 6 (15%)	 4 (15%)	 2 (13%)	 7 (19%)	 4 (17%)	 4 (20%)
medication
Prescribed a mood stabiliser	 7 (18%)	 3 (11%)	 2 (13%)	 4 (11%)	 1(4%)	 1(5%)
Prescribed benzodiazapines 	 3 (8%)	 1 (4%)	 1 (7%)	 2 (5%)	 1 (4%)	 0 (0%)
Family work
	
1 (3%)	 0 (0%)	 0 (0%)	 0 (0%)	 0 (0%)	 0 (0%)
Cognitive behavioural therapy 	 3 (8%)	 2 (7%)	 1 (7%)	 2 (5%)	 1 (4%)	 1 (5%)
(CBT)	 _______ _______ _______ _______ _______ _______
niorpromazine equivaienee UdL4 is 1101 dVd1IWI tur sulile ypicai dIlLLpSy!.d1uLH.S
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5.9 BASELINE SCORES ON PRIMARY AND SECONDARY OUTCOME
MEASURES (Tables 5.10 and 5.11)
Scores on primary and secondary outcome measures are presented with the CPN as the
unit of analysis. Trainee scores are the mean of the two patients they were treating. Mean
total and sub-scale scores on the PANSS (table 5.10) at baseline suggest that CPNs'
patients were experiencing a moderate level of psychopathology.
Table 5.10. Baseline mean (s.d.) scores by group for patients who completed the
primary outcome measure at baseline (week 0), week 26, and week 52 assessments
Baseline mean scores for secondary outcome measures are shown in table 5.11. Baseline
scores on the GAF suggest a moderate level of impairment. No significant differences
were found between groups. Scores, at baseline, on the DAI-30 were in the middle of the
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range of scores produced by the measure and suggests that patients were ambivalent
about treatment with antipsychotic medication. These findings are consistent with the
observer ratings of compliance which were also in the middle of the scale and suggests
that patients were reluctant to take, or regularly questioned the need for, medication.
Scores on the insight schedule were at the lower end of the percentage scale and suggest
that patients' insight was markedly impaired. Mean scores on the LUNSERS were at the
low and of the scale suggesting that patients were reporting some antipsychotic side
effects. No significant differences between the groups were found.
Table 5.11. Baseline mean (s.d.) scores by group for patients who completed
secondary outcome measures at the baseline (week 0), week 26 and week 52
assessments
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5.10 COMPARISONS BETWEEN TRIAL COMPLETERS, TRIAL REFUSERS,
AND TRIAL DROP-OUTS ON PRE-TRAINING VARIABLES
Baseline characteristics of patients entering the trial and those who refused to participate
were compared. No significant differences were found on any of the following variables:
age, gender, ethnicity, employment status, marital status, duration of illness, number of
previous psychiatric admissions, or dose of antipsychotic medication. As tables 5.7-5.11
show there was no difference in the baseline demographic and clinical profile of patients
who entered the trial or completed the week 26 or week 52 assessment. This suggests that
patients dropped out of the trial by chance.
5.11 ANALYSIS OF PATIENT OUTCOME
5.11.1 Primary and secondary outcome measures
The dependent variables comprised three research worker, two patient and one CPN rated
outcome measures and their sub-scales. Prescribing data were recorded by the research
worker from the patient's drug chart and checked with the CPN and patient. The primary
outcome measure (used to define overall improvement in patients' psychopathology) was
the Positive and Negative Syndrome Scale (PANSS), a thirty item scale divided into three
sub-scales (positive, negative and general psychopathology). Each item is rated on a 1-7
scale. Secondary outcome measures (detailed in chapter 4) were as follows:
I. Disability - The Global Assessment of Functioning disability scale (range 0-100)
with 10 defined anchor points relating to social competence.
2. Compliance - The Drug Attitude Inventory (range -30 to +30); Observer rating of
compliance (range 1-7).
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3. Insight - Expanded schedule for the assessment of insight. Scores expressed as a
percentage of insight.
4. Side effects - Liverpool University Neuroleptic Side Effect Rating Scale (total score
range 0-164 excluding red-herrings). Eight sub-scores; extrapyramidal (range 0-28);
anticholinergic (0-20); other autonomic (0-20); allergic (0-16); psychic (0-40);
hormonal (0-24); miscellaneous (0-16); and red herrings (0-40).
5. Prescribed medication - The chlorpromazine equivalent dose (in mg per day) of
antipsychotic was the main measure of prescribing.
6. Service utilisation - Measured in the number of psychiatric inpatient days during the
previous 26 weeks.
5.11.2 Statistical analyses
Data were normally distributed and parametric tests were therefore used for most of the
analyses. Outcome data were analysed in two ways. Firstly, between and within group
changes in mean scores were analysed. Secondly, levels of categorical and clinically
significant change were analysed within and between groups.
In this trial, as in previous training studies, some CPNs and patients did not complete the
trial. Both CPN and patient drop-outs were evenly distributed between training groups
and did not significantly differ from completers on any pre-training characteristics or
scores. It may be acceptable to restrict the analysis to trainees for whom complete data is
available (Everitt and Pickles, 2000). Alternatively Pocock (1983) proposes conducting
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two analyses: one for trial completers alone, and a second analysis which, where possible,
includes data for all subjects (intention to treat).
Intention to treat analysis is difficult when a quantitative measurement is the basis of
evaluation. In such cases, a common practice is to bring forward the last known value as
a substitute for data missing at later dates. This method has been criticised, chiefly for the
assumption that a patient's response remains frozen in time (Everitt, 1998). Nevertheless
this remains the most widely used and conservative method of managing the problem of
trial drop-outs.
The inclusion of drop-outs in analyses of qualitative outcome is less contentious. In the
analyses of categorical change and clinical significance, non-completers were categorised
as non-responders.
5.11.3 Changes in mean scores
The mean scores and standard deviations on all outcome measures and sub-scales at all
time points for both the experimental and control groups can be found in tables 5.12a-c.
Graphs of the mean scores by training group on primary and secondary outcome
measures for both groups are shown in figure 5.1.
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Table 5.12.a Mean scores and standard deviations for experimental and control
groups on primary and secondary outcome measures
ri'ui	 __
	Mean	 s.d.	 Mean	 s.d.
PANSS-total'
Baseline	 72.5	 11.9	 66.5	 10.7
Week26	 57.6	 9.1	 60.2	 11.45
Week 52	 56.8	 4.8	 56.8	 4.8
GAF'
Baseline	 53.0	 7.7	 58.3	 8.4
Week 26	 56.5	 9.7	 65.4	 73.2
Week 52
	
64.7	 10.1	 73.2	 14.7
DAI-302
Baseline	 0.4	 9.8	 2.7	 10.6
Week 26	 9.0	 9.5	 6.66	 11.8
Week 52	 9.8	 9.1	 9.2	 10.0
Compliance2_______________ ________________ ______________ _______________
Baseline	 4.0	 0.88	 4.3	 1.3
Week26	 5.2	 0.83	 3.8	 1.1
Week 52	 4.8	 0.75	 4.8	 1.2
SAI-E2
Baseline	 36.6	 22.1	 53.18	 19.7
Week 26	 43.5	 10.8	 47.1	 21.8
Week 52	 39.7	 8.8	 54.5	 14.4
LUNSERS-total'
Baseline	 35.5	 22.5	 26.4	 9.7
Week 26	 27.4	 22.1	 21.1	 9.8
WeekS2	 31.1	 20.4	 25.5	 8.4
Dosemg/day (cpz. equ.)' 	 _____________ ______________ ____________ _____________
Baseline	 400	 317	 469	 293
Week 26	 387	 253	 479	 237
Week 52	 383	 239	 456	 259
Service utilisation1
Week26	 7.5	 13.6	 13.0	 25.1
WeekS2	 13.3	 20.2	 11.0	 12.3
'reduction in scores suggests improvement 	 2 increase in scores indicates an improvement
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5.12b Mean scores and standard deviations for experimental and control groups on
PANSS sub-scales
Mean	 s.d.	 Mean	 s.d.
PANSS-positive sub-scale
Baseline	 17.4	 5.5	 16.9	 3.9
Week 26	 14.9	 4.3	 14.3	 4.2
Week 52	 14.3	 3.5	 11.8	 4.4
PANSS- negative sub-scale
Baseline	 18.3	 5.1	 16.6	 4.3
Week 26	 14.2	 2.7	 14.0	 3.7
Week 52	 12.7	 2.8	 10.9	 2.9
PANSS-general sub-scale
Baseline	 36.5	 7.2	 33.0	 6.9
Week 26	 28.6	 4.4	 32.2	 6.7
Week 52	 29.7	 2.8	 25.3	 4.9
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5.12c Mean scores and standard deviations for experimental and control groups on
LUNSERS sub-scales
F.PT:II
Mean	 s.d.	 Mean	 s.d.
LUNSERS - EPS sub-scale
Baseline	 10.8	 5.7	 8.2	 3.9
Week26	 11.2	 6.1	 6.0	 3.8
Week 52
	 12.5	 5.3	 6.8	 3.8
LUNSERS - anticholinergic sub-scale
Baseline	 6.1	 1.7	 4.3	 2.0
Week 26	 6.1	 2.1	 3.3	 1.9
Week 52	 5.4	 2.9	 3.7	 2.2
LUNSERS - autonomic sub-scale
Baseline	 1.3	 2.1	 0.4	 0.56
Week 26
	 1.4	 2.1	 2.5	 2.5
Week52	 0.9	 1.0	 2.0	 1.9
LUNSERS - allergic sub-scale
Baseline	 2.2	 1.8	 3.1	 2.8
Week 26
	 2.0	 2.0	 2.4	 2.6
Week 52	 2.8	 2.8	 2.8	 2.7
LUNSERS - Psychic sub-scale
Baseline	 12.3	 11.4	 12.2	 5.6
Week 26	 10.0	 12.7	 8.0	 7.9
WeekS2	 11.4	 8.2	 12.4	 5.4
LUNSERS - Hormonal sub-scale
Baseline	 2.2	 4.4	 2.0	 2.7
Week 26
	 2.1	 3.9	 0.9	 1.4
Week 52
	 3.1	 4.4	 0.8	 1.1
LUNSERS - Miscellaneous sub-scale
Baseline	 3.6	 2.3	 4.1	 2.0
Week 26	 4.3	 1.4	 3.6	 1.1
Week 52	 5.5	 1.9	 3.8	 0.96
LUNSERS - Red herrings sub-scale
Baseline	 4.4	 2.8	 4.2	 2.5
Week26	 5.1	 2.7	 3.5	 2.0
Week 52
	 6.6	 3.7	 4.0	 2.0
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5.11.4 Was there a difference between the experimental and control groups at the
week 26 assessment?
An ANCOVA showed that care from CPNs who had undergone medication management
training was superior to CPNs' routine care on the primary measure of clinical outcome,
the Positive and Negative Syndrome Scale (F=5.54, df= 1, p=.O26). Training was also
superior on two secondary outcome measures, the Drug Attitude Inventory (F=16.76,
df=1, p<.001) and clinician rating of compliance (F28.52, df=1, p<.001). There was no
significant difference between the groups on the Global Assessment of Functioning, the
Expanded Schedule for the Assessment of Insight, the dose of prescribed antipsychotic or
the LUNSERS. Care by CPNs who had received medication management training was
not superior to routine CPN care over time on any of the PANSS sub-scales. There was a
trend towards a difference in the EPS (p=.O57) and red-herring (P.063) sub-scales of the
LUNSERS.
An ANCOVA for the primary and secondary outcome measures was repeated using data
from all patients: trial drop-outs were assigned their last known value at all subsequent
time points. The same pattern of results was found on all main outcome measures.
Medication management training was superior to standard CPN care over time on
measures of psychopathology (F=4.79, df=1, r.O36), attitudes towards treatment
(F14.84, df=l, p=.00l) and compliance (F28.50, df=1, p<.001) but not functioning,
insight or side effects.
140
5.11.5 What was the effect of training in the experimental group (baseline to week
26)?
From baseline to week 26 assessment there were significant improvements in the primary
measure of patients' psychopathology (PANSS-total; t6.87, df=22, p<.001). Significant
improvements in patients' attitudes towards treatment (DAI-30; t-49, df22, p<.001)
and compliance (t=-7.09, df=22, p<.001) were also found.
5.11.6 Was the effect of training sustained at the follow-up (week 52) assessment?
At week 52 assessment patients' psychopathology remained significantly improved
compared to baseline (t4.42, df14, p.003). There was a strong trend towards sustained
improvement in patients' attitude towards treatment (t-2.43, df14, p=.052). The
improvement in the composite measure of compliance was not maintained.
5.11.7 What was the effect of being in the control group over the waiting period
(baseline to week 26)?
In the control group, significant improvements in patients' psychopathology (PANS S-
total; t=2.57, df=18, p<.001) over the waiting period were found. No significant changes
in any of the other measures were observed.
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5.11.8 What was the effect of training in the control group (week 26 to week 52
assessments)?
Following training in the control group (after the week 26 assessments) significant
improvements were observed in psychopathology (PANSS-total; t=5.67, df= l1, p<.001)
and in patients' attitudes towards treatment (DAI-30; t =-2.74, df=12, p=.Ol9). But not in
any other measures or sub-scales.
5.11.9 Did training have any effect on service utilisation?
Service utilisation was analysed using Mann-Whitney U test because data were not
normally distributed. There was no significant difference between the experimental and
control group in the number of days CPNs' patients spent in hospital during the first and
second 26-week phase of the trial (7.5 vs. 13.1 days and 13.3 vs. 11.0 days respectively).
5.12 CATEGORICAL CHANGE
The primary determinant of improvement was the proportion of CPNs whose patients
showed a mean 10% or more reduction in total PANSS scores at the week 26
assessment. Table 5.13 shows the proportion of CPNs whose patients responded to
training by group.
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Table 5.13 CPNs whose patients responded to training by group (complete cases)
* Fishers exact test
5.12.1 Was there a difference between the experimental and control groups at the
week 26 assessment?
At week 26 assessment 11 CPNs (48%) in the experimental and 5 CPNs (26%) in the
control group (who had not yet been trained) showed a response. This difference between
the two groups was significant (p.O35) suggesting that training had been effective. A
greater than 20% reduction in PANS S scores was found in the patients of 6 CPNs (26%)
in the experimental and 1 (5%) in the control group, this difference was not significant.
143
5.12.2 What was the effect of training in the experimental group (baseline to week
26)?
The McNemar test showed that, in the experimental group, the number of CPNs whose
patients met the criteria for improvement in the PANS S was significantly increased at the
week 26 (p=.0Ol) assessment.
5.12.3 Was the effect of training sustained in the experimental group at the week 52
assessment?
At the week 52 assessment patients of eleven (73%) of the CPNs met the criteria for
improvement. The same number as at the week 26 assessment. The McNemar test
showed that there was a significant increase in the number of training responders
(p=.034) from baseline assessment. Seven (47%) of the responders showed a greater than
20% improvement, from baseline, in total PANSS scores at the week 52 assessment.
5.12.4 What was the effect of being in the control group over the waiting period
(baseline to week 26)?
The patients of five CPNs in the control group met the criteria for improvement at the
week 26 assessment. This was a significant increase from baseline (p=.031).
5.12.5 Was the change in PANSS scores similar in training responders in the
experimental and control groups at the week 26 assessment?
Patients of CPNs in the experimental group who were classified as training responders
had a mean PANS S score of 77.1 at baseline and 57.2 at the week 26 assessment, an
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improvement of 26%. In the control group, CPNs' patients who had responded had a
baseline score of 66.9 and a week 26 score of 53, a improvment of 20%.
5.12.6 What was the effect of training in the control group (week 26 to week 52
assessments)?
At the week 52 assessment five additional CPNs (7 1%) in the control group showed
improvements in the patients they were treating. This was double the number who
improved at the week 26 assessment. Of the CPNs who were classified as responders at
week 52, five (3 6%) showed a greater than 20% improvement in the psychopathology of
patients they were treating.
5.12.7 Does the inclusion of trial drop-outs effect the impact of training?
The analysis was repeated to include trial drop-outs and missed assessments, who were
rated as unimproved (table 5.14). The proportion of CPNs in the experimental group
whose patients responded remained significantly greater than the proportion in the
control group at week 26. There was no significant difference between the two groups at
the week 52 assessment.
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Table 5.14. Proportion of CPNs who responded to training by group (all cases)
ns = not significant
5.13 DID TRAINING PREVENT RELAPSE?
The measure of relapse was defined as a mean 10% or more increase in total PANS S
scores. None of the patients in either the experimental or control group met the criteria
for relapse at either the week 26 or week 52 assessment. There were no patient suicides
or deaths during the trial.
5.14 CLINICALLY SIGNIFICANT CHANGES
The clinical significance of change on the primary outcome measure was determined
using Jacobson and Traux's (1991) criteria that a patient's post treatment and follow-up
score extends to two standard deviations beyond the baseline mean score.
5.14.1 PANSS (table 5.15)
There was no significant improvement in the proportion of CPNs in both the
experimental and control groups who showed a clinically significant change in the
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patients they were treating (a mean reduction in total PANSS scores of 25.2 or more) at
the week 26 and week 52 assessment. There were no significant differences between the
two groups.
Table 5.15 Number (%) of CPNs showing clinically significant change by group on
primary outcome measure (PANSS)
ns = not significant
5.14.2 Attitudes towards treatment (table 5.16)
There was a significant proportion of CPNs in the experimental group whose patients
showed a clinically meaningful improvement in attitudes towards treatment (a mean
increase in scores of 20.4) at week 26 (p=.039) but not week 52 assessments. The
proportion of CPNs in the control group whose patients showed meaningful
improvements was not significant at the 26 week assessment but was, following training,
at week 52 (p.031).
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Significantly more CPNs in the experimental group showed clinically meaningful
improvements in patients attitudes towards treatment at the week 26 assessment. When
the proportions were adjusted to include drop-outs and non-completers (rated as
unimproved) 44% in the experimental group and 12% in the control group showed
clinically meaningful improvments in attitudes towards treatment, a difference that was
not significant.
Table 5.16. Number (%) of CPNs whose patients showed clinically significant
change in attitudes towards treatment (DAI-30) by group
ns = not significant
5.14.3 Clinician rating of compliance (table 5.17)
There was a significant proportion of CPNs in the experimental group whose patients
showed a clinically meaningful improvement in compliance (an increase in scores of 2.2)
at week 26 (p=.021) but not week 52 assessments. The proportion of CPNs in the control
group whose patients showed meaningful improvements was not significant at the week
26 but was, following training, at week 52 assessment (p<.019).
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Significantly more CPNs in the experimental compared to the control group showed a
clinically meaningful improvement in patient compliance at the week 26 assessment.
When proportions were adjusted to include drop-outs and non-completers (rated as
unimproved) 33% in the experimental, and 0% in the control group showed clinically
meaningful improvements in compliance, a difference that was statistically significant
(p<.00 1).
Table 5.17. Number (%) of CPNs showing clinically signfficant change in patient
compliance, by group
ns = not significant
5.15 PREDICTION OF OUTCOME: LINEAR REGRESSION
Exploratory stepwise linear regression was used to identif' factors predictive of clinical
outcome (as measured using the PANSS-total score). Week 52 PANSS-total score was
the dependent variable. Baseline scores were entered first and the variables under
investigation were entered on the second level using stepwise procedures. Baseline scores
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alone explained 35% of the variance in PANSS-total scores at week 52 assessment
2=35 F
=7.50, p<.001).
5.15.1 Predicting outcome from trainee demographics
The following trainee variables were entered into the exploratory stepwise regression:
clinical experience, caseload size, age and attendance. No significant predictors emerged.
5.15.2 Predicting outcome from trainees' knowledge about medication management
and clinical skills
The number of errors trainees made in rating the PANS S video, and their post-training
scores on the Knowledge about Medication Management Questionnaire and the
Cognitive Therapy Scale were entered into the exploratory stepwise regression. No
significant predictors emerged.
5.15.3 Predicting outcome from patient characteristics
The following patient demographic and clinical characteristics were entered into an
exploratory stepwise regression: age, age at onset of illness, duration of illness, number
of inpatient admissions, and time since last admission. The final model incorporating
number of inpatient admissions, age and duration of illness was predictive of PANSS-
total scores at the week 52 assessment (R2=.66, F=9.53, p<.001), and accounted for an
additional 31% of the variance.
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5.15.4 Predicting outcome from secondary outcome measures
Patients' baseline scores on the secondary outcome measures were entered into an
exploratory stepwise regression. No significant predictors emerged. Scores at week 52
were also explored and, again, no significant predictors emerged.
5.16 PREDICTION OF OUTCOME: TRAINING RESPONDERS AND NON-
RESPONDERS
Differences between patient and trainee demographic and clinical characteristics were
explored in training responders and non-responders using the independent sample t-test.
At the week 52 assessment 21 out of 29 CPNs had responded to training (a 10%
reduction in total PANSS scores). Differences and associations in responder and non-
responder demographic and clinical characteristics were compared using the paired
sample t-test and the chi-square test.
5.16.1 Differences in CPN demographic and clinical characteristics
There were no significant differences between responders and non-responders on the
following demographic characteristics: gender, ethnicity, age, years of experience, or
academic qualifications. However, training responders were significantly more likely to
be employed at a higher grade (p<.032).
5.16.2 Differences in CPN clinical skills and knowledge
Training responders were likely to be more clinically skilled than non-responders. The
mean score on the CTS for trainees whose patients had responded to training was 33.0
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(s.d. 6.9) compared with 28.7 (s.d. 4.6) for trainees whose patients did not respond
(p=.O38). There was no difference in the number of errors made by trainees in rating
patients' psychopathology and clinical outcome.
There was no significant difference in the scores on the Knowledge about Medication
Management Questionnaire in trainees whose patients did (mean 13.1, s.d. 2.2) and did
not (mean 11.8, s.d. 2.7) respond to training.
5.16.3 Differences in patient demographic and clinical characteristics
Patients who had responded to training were likely to be younger in age than non-
responders. Responders had a mean age of 36.5 (s.d. 8.2) years, compared with a mean
age of 44.2 (s.d. 12.2) years in non-responders (p=.038).
There were no significant differences in the remaining personal or clinical characteristics
of gender, ethnicity, age of onset, number of previous psychiatric admissions, diagnosis,
smoking behaviour, alcohol consumption, registration on the care programme approach
or previous detention in hospital under the mental health act.
5.16.4 Differences in secondary outcome measures
No significant differences were found in the baseline scores of responders and non-
responders on any of the secondary outcome measures, or their sub-scales.
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5.16.4.1 Are training responders more compliant?
At the week 52 assessment, training responders had significantly lower scores on the
DAI-30 (7.9 vs. 21; t=2.42, df=28, p=<.001), indicating a more positive attitude towards
treatment, and a higher clinician rating of compliance (6.2 vs. 4.6; t2.12, df=26,
p=<.00 1), indicating more consistent adherence to treatment.
5.16.4.2 Differences in other secondary outcome measures
None of the scores, at week 52, for the secondary outcome measures were significantly




The primary aim of this trial was to demonstrate the efficacy of medication management
training for CPNs working with patients with schizophrenia taking antipsychotic
medication.
A number of studies have demonstrated that medication management interventions such
as compliance therapy (Kemp et al., 1996; 1998), behavioural tailoring (Boczkowski et
al., 1985) and patient education (Macpherson et a!., 1 996a; Gray, 2000) are effective in
improving compliance and the understanding of treatment in people with schizophrenia.
Many of these studies have focused on compliance as the primary outcome of interest.
However as Haynes et a!. (1999) argue, improving adherence per se may not benefit the
patient unless it is accompanied with improvements in clinical outcome. There have been
no trials that have established that clinicians in routine practice can be trained to produce
similar outcomes to those found in clinical trials.
The primary aim of this trial was, therefore, to test the hypothesis that compared to
standard care, the application of a medication management intervention delivered by
CPNs, post-training, would lead to significant improvements in the psychopathology of
the patients they were treating. The secondary aims were to test the hypotheses that
training would lead to significant improvements in patients' compliance with
antipsychotic medication, insight into their illness, antipsychotic side effects, and service
utilization.
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Two other issues were of interest. Firstly, the literature suggests that psychotropic
medication in the United Kingdom is generally poorly prescribed (Newton Ct a!., 1996)
and guidelines which promote good practice (such as the Maudsley Prescribing
Guidelines; Taylor et a!., 1999) are largely ignored by prescribers. The effect on
prescribing of training CPNs in the use of evidence based guidelines has not been
explored. Secondly, although previous studies have shown that training can lead to
improvements in patient outcomes (Brooker et al., 1992a; Brooker et a!., 1994;
Lancashire et a!., under review) the link between the clinicians' level of skill and the
patients' clinical outcome have not been established. This study therefore also explored
this relationship.
In order to test the primary hypothesis, sixty CPNs were randomly assigned to either an
experimental or waiting list control group. Each CPN identified two patients on their
caseload who had been (within the previous 12 months), or were currently, non-
compliant with their antipsychotic medication. A research worker blind to the training
condition assessed these patients at baseline and at week 26 and week 52 follow-up.
CPNs in the experimental group received 80 hours of training immediately following the
baseline assessment. CPNs in the control group continued with their routine care and then
received training following the week 26 assessment. The primary outcome measure was
the Positive and Negative Syndrome Scale (PANSS), a valid and reliable measure of
patients' psychopathology. The mean of the two patients' scores for each outcome
measure was used for the analysis. Response rate and clinical significance of change was
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analysed in addition to mean scores. As the data were normally distributed within and
between group analyses were made using parametric statistics. Patient and CPN drop-out
were managed using the intention to treat principle with the last known observation
carried forward.
6.2.1 Were CPNs and patients representative?
The CPNs were drawn from two large mental health Trusts in the South of England. Very
few of the CPNs who initially agreed to participate dropped out of the trial prior to
receiving training. Their demographic characteristics are broadly consistent with the 1997
survey of CPN practice in England and Wales (Brooker and White, 1998). The
proportion of female CPNs is similar (56% of CPNs were female in this trial compared
with in the National survey), as was the CPNs age (39 vs. 39 years). The majority of
CPNs (59%) in this trial and the National survey (61%) were employed at nursing grade
'G'. The mean length of CPNs' clinical experience in this study was slightly shorter (7.9
vs. 14 years). As expected, given the geographical location of the trial, CPNs in this study
were from a more diverse ethnic background: 66% of CPNs were from a non-white
ethnic background compared to 10% in the National survey. Compared to the national
average, a higher proportion of CPNs had attained at least a diploma level academic
qualification, again this would be predicted given the increased availability of training in
the geographical area where the trial was conducted (Gournay and Brooker, under
review). The number of patients on CPNs' caseloads was marginally higher in the
national survey (38.3 vs. 35.3).
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CPNs were randomised into geographical clusters to control for the possibility of
contamination. This method increased the risk that the two groups may have different
characteristics. However, the experimental and control groups were well balanced on
most demographic variables (with the exception of years of experience) and baseline
knowledge scores. The control group had slightly higher baseline scores on the Cognitive
Therapy Scale.
Patients in this trial were representative of patients currently in receipt of services in the
UK. The demographic and illness profiles of patients were similar to that seen in UK
trials of training interventions for CPNs (Brooker et al. 1994), patient education
(Macpherson et a!., 1996a), and compliance therapy (Kemp et a!. 1996; 1998). Mean age
in the present study (40.4 years) was within the range reported in the trials cited (35.5-
45.2 years). A liftle over half of the patients in all of the studies were male and
approximately two-thirds of patients were of non-white ethnic origin.
Duration of illness in the other studies ranged from 9.6 years (Kemp et a!. 1998) to 23.4
years (Macpherson et a!. 1996a). The duration of illness in this trial (13.08 years) was
towards the lower end of this range. The number of previous psychiatric admissions was
three, lower than the number reported in the earlier studies (4.3, Kemp et a!., 1998; 6.4,
Macpherson et al. 1 996a). The majority of patients in previous studies had schizophrenia
(58.2%, Kemp et a!. 1998; 100%, Macpherson eta!. 1996a). The proportion of patients in
this trial with a diagnosis of schizophrenia was within this range (85%).
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Because outcome measures vary across studies it is difficult to make mearnngful
comparisons in terms of patients' psychopathology. In this and previous trials, patients
were moderately symptomatic. Patients in the Compliance Therapy study (Kemp et a!.,
1998), however, were more symptomatic and were more likely to be under a section of
the Mental Health Act. This is because the trial was conducted in an inpatient, as opposed
to a community, setting with patients in an acute phase of their illness. Baseline scores on
the Drug Attitude Inventory, Expanded Schedule for the Assessment of Insight and
clinician rating of compliance were similar to the Kemp et al. (1998) trial. Randomisation
achieved groups that were well balanced on demographic and clinical variables and pre-
treatment scores.
The only substantial difference between the two groups was the training that the nurses
received. It is likely therefore, that any differences between the groups can be attributed
to the training intervention itself rather than to non-specific factors.
6.1.2 Trainee hypothesis: medication management training will enhance CPNs'
clinical skills and knowledge
The hypothesis that medication management training will enhance CPNs' clinical skills
and knowledge was tested by: 1. Examining within group changes using the paired
samples t-test; 2. Comparing the proportion of CPNs who were rated as having
satisfactory cognitive and compliance therapy skills (a score of 30 or more on the CTS)
pre- and post-training; and 3. Determining the proportion of trainees who were able to
rate a patient's mental state to a satisfactory standard.
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The hypothesis that medication management training would enhance CPNs' clinical skills
and knowledge were supported by the data.
Significant improvements in mean scores on both the Cognitive Therapy Scale and the
Knowledge about Medication Management Questionnaire were observed post-training.
The degree of improvement was similar in both the experimental and waiting list control
groups suggesting that the quality and standard of training were consistent over time.
Significantly more trainees were able to demonstrate satisfactory clinical skills, post
training, and over half of CPNs demonstrated that they were able to rate a video of a
patient being interviewed to an adequate standard.
The results are consistent with those reported in the pilot study (chapter 3) and suggest
that training is effective in enhancing CPNs' medication management skills.
6.1.3 Primary hypothesis: Medication management training will be superior to
standard care in improving patients' psychopathology
The hypothesis that medication management training will be superior to standard care in
improving patients' psychopathology was tested by using the ANCOVA to determine
mean response over time and comparing the proportion of patients in each group who
responded to training (a mean reduction in psychopathology of 10%).
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The hypothesis that medication management training would be superior to standard care
in improving patients' psychopathology (measured using the PANSS) was supported by
the data.
A comparison of mean scores at week 26 showed a 21% reduction in PANSS-total scores
in the experimental group compared with a 10% reduction in the control group. The
proportion of CPNs in each group whose patients responded to training also supported
the primary hypothesis. At the week 26 assessment the patients of 48% of CPNs in the
experimental group and 26% in the control group responded to training. The
improvements were not, however, clinically significant using Jacobson and Traux's
(1991) stringent criteria.
Within group analyses (of mean scores and response to training) also support the primary
hypothesis. When CPNs in the control group received training following the week 26
assessment a similar (15%) improvement in psychopathology was found over the
duration of the trial.
Improvements in psychopathology, the trials' primary aim, suggest that compliance with
antipsychotic medication has been enhanced. The improvements in compliance and
reduction in psychopathology may be because training has been effective and CPNs are
applying in clinical practice the new skills they have acquired. However, there are three
alternative explanations for the improvements in psychopathology. Firstly, that training
raised CPNs' awareness of the risk of relapse following non-compliance with
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antipsychotic medication and trainees have therefore paid more attention to ensuring that
patients are taking their medication. Secondly, it is possible that training resulted in CPNs
spending more time with patients and this increased contact improved psychopathology.
Finally, CPNs may have had a substantial influence on the way in which psychotropic
medication is prescribed.
6.1.4 Secondary hypotheses
6.1.4.1 Medication management training will be superior to standard care in improving
patients' compliance with antipsychotic medication?
The hypothesis that medication management training would be superior to standard care
in improving compliance with antipsychotic medication was supported by the data.
The ANCOVA showed that, at the week 26 assessment, medication management training
was superior to standard care in enhancing patients' attitudes towards treatment and
compliance. At the week 52 assessment improvements in patients' attitudes towards
treatment were maintained. Finally improvements in attitudes towards treatment and
compliance were shown to be clinically meaningful.
These fmdings support the conclusion that the improvements in psychopathology are as a
result of enhanced compliance with medication. They may also suggest that
improvements in patients' attitudes towards treatment are as a results of enhanced clinical
practice in CPNs who have received training. Indeed, training responders had lower
scores on the DAI-30 at the week 26 assessment and higher post-training scores on the
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CTS. However, exploratory stepwise regression did not support this conclusion. Scores
on the DAI-30 and clinician rating of compliance did not predict improvements in
psychopathology.
6.1.4.2 Medication management training will be superior to standard care in improving
patients' insight into their illness?
The hypothesis that medication management training would be superior to standard care
in improving patients' insight into their illness was not supported by the data.
There were no significant differences in scores within or between the groups on the
Expanded Schedule for the Assessment of Insight at week 26 or 52 assessments.
The absence of any effect on insight is surprising, given the improvements in insight
noted in two earlier trials (Macpherson et al., l996a; Kemp et al., 1996; 1998) and is
inconsistent with the conclusion that improvements in patients' psychopathology can be
explained by CPNs' enhanced clinical practice. However, the emphasis of the training
was on examining and testing patients' beliefs about medication and focusing on the use
of pharmacological treatments to manage specific symptoms or problems rather than
enhancing insight, for example, by helping patients to relabel symptoms as part of an
illness. An alternative explanation may be that patients already had a moderately good
level of insight that was unlikely to improve. Baseline scores on the SAI(E) were slightly
higher that those reported, pre-training, in the compliance therapy trial (43.2% vs. 37.6%
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(Kemp et a!., 1998)). Suggesting that there was less room for improvement in a stable
group of patients living in the community.
6.1.4.3 Medication management training will be superior to standard care in preventing
relapse?
The hypothesis that medication management training would be superior to standard care
in preventing relapse was not supported by the data.
Very few patients in either group experienced a relapse of their illness during the trial.
There were no significant differences between the experimental and control groups in the
proportion patients who relapsed (>10% increase in scores of the PANSS). In fact only
one patient in the control group experienced a relapse by the week 26 assessment.
Inpatient bed days were relatively low in both groups. There was no significant difference
in the number of inpatient bed days CPNs' patients used at either the week 26 or week 52
assessments.
The absence of any effect on relapse rates and inpatient bed days is surprising given the
differences in improvements in psychopathology and compliance observed between the
two groups. However, the findings are consistent with the results from the compliance
therapy study (Kemp et a!., 1998) which also reported no significant differences, at 18
months, in the overall time patients spent in hospital. It is possible that, because the
majority of patients were treated using long acting depot antipsychotic preparations, it
would take at least six months (Walburn et a!., under review) for a relapse to occur and
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that the re-emergence of symptoms would be progressive rather than abrupt. Thus,
making it too difficult to detect differences in relapse rates between the two groups. For
the anticipated differences to be observed, a substantially longer follow-up period would
be required without the confounding effect of a delayed training intervention in the
control group.
6.1.4.4 Medication management training will be superior to standard care in improving
the prescribing of antipsychotic medication?
The hypothesis that medication management training would be superior to standard care
in improving the prescribing of antipsychotic medication was not supported by the data.
There were no changes in the mean dose of antipsychotic medication prescribed in either
group at the week 26 or week 52 assessments. The stability of patients' psychotropic
medication in this trial suggests that the improvements in patients' psychopathology can
not be attributed to changes in treatment regimes. This lends further weight to the
conclusion that improvements in psychopathology are as a result of improved
compliance. However, the absence of any impact of training on the prescribing of
antipsychotic medication is surprising. At the baseline assessment the quality of
psychotropic prescribing was poor. Mean doses of antipsychotic medications were high,
there was a high proportion of patients (25%) on more than one antipsychotic, 49% of
patient were on long term anticholinergic medication, and very few patients were on
clozapine. It is widely assumed, although there are no data to support the idea, that CPNs
influence what and how psychiatrists choose to prescribe. A substantial component of the
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medication management training was therefore focused on psychopharmacology and the
use of evidence based guidelines as a basis for making treatment decisions. Training
appears to have had no effect on prescribing patterns and throughout the trial the mean
dose (in chlorpromazine equivalents) was stable. An explanation for the lack of
improvement in prescribing may be a perception among clinicians that, despite some
evidence to the contrary (Desai et al., 1999), changing or altering medication may risk or
precipitate a relapse. Such prescribing practices are undesirable if unwanted antipsychotic
side effects are to be managed and the longer term risk of tardive dyskinesia is to be
minimised (Gray 1 998a). To maximise the effect of training it would require genuine
multidisciplinary collaboration concerning prescribing decisions.
6.1.4.5 Medication management training will be superior to standard care in improving
side effects from antipsychotic medication?
The hypothesis that medication management training would be superior to standard care
in improving side effects from antipsychotic medication was not supported by the data.
The ANCOVA showed no significant differences between groups in the LUNSERS total
score at the week 26 assessment. There was little change in total scores over time in each
group, a fmding that is inconsistent with the conclusion that training led to enhanced
compliance with antipsychotic medication (side effects should get worse if patients are
more compliant). This lack of change may be because the LUNSERS is not sufficiently
sensitive to change over time.
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No differences were observed between the groups over time on any of the LUNSERS
sub-scales; anticholinergic, psychic, hormonal and miscellaneous side effects and allergic
reactions. However, there was a trend towards a reduction in EPS and red herrings. This
may indicate that training resulted in more appropriate use, by patients, of anticholinergic
medication to manage EPS.
Mean LUNSERS total scores at baseline suggest that patients were experiencing a
moderate level of side effects. The failure of training to improve the management of these
symptoms can most obviously be explained by the stability in psychotropic prescribing.
However, a range of non-pharmacological strategies (e.g. exercise and calorie restriction
to treat weight gain) for managing side effects were taught during the course. The failure
to detect any effect from these interventions requires alternative explanations. It is
possible that CPNs did not use the interventions. However, this is by no means certain.
Because the LUNSERS is a self-report measure of perceived side effects, training may
have made patients aware of symptoms that they did not know about or had not
previously attributed to their illness. This would increase LUNSERS scores and would
effectively cancel out any positive effect of training. The trend towards significant
differences in scores between the groups over time on the red herring sub-scale of the
LUNSERS lends support to this conclusion. Alternatively, side effects may still have
been rated by patients as being present even if trainees had been successful in teaching
them new coping strategies (e.g. a high fibre diet to treat constipation).
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6.2 TREATMENT OUTCOME FOR SKILLED AND UNSKILLED CPNs
Following training 14 (6 1%) CPNs in the experimental and 16 (55%) in the control group
were rated as having satisfactory clinical skills. If training had changed practice, CPNs'
knowledge and clinical skills should be predictive of clinical outcome. This was not the
case. Exploratory stepwise linear regression did not suggest that these factors were
important in determining response. However, trainees in the experimental group whose
patients responded were significantly more skilled than CPNs whose patients did not
respond. These inconclusive findings cast some doubt on the conclusion that
improvements in patients' psychopathology are as a result of enhanced clinical practice
by CPNs who had received training. The trial was not powered to explain which factors
predict response. Previous studies evaluating training have similarly not reported any
link between clinical skills and patient outcomes (Brooker 'et al., 1992a; Brooker et a!.,
1994; Lancashire et a!., under review). Larger trials will be needed to address this
important question.
The interplay between training, clinical practice, and patient outcomes is clearly very
complex and this trial may simply not have had enough statistical power to detect any
relationships that exist. This is, however, by no means certain. An alternative explanation
may be that training raised CPNs' awareness of compliance with antipsychotic
medication. This may mean that compliance improved because CPNs paid more attention
to whether or not patients were taking medication but did not apply the specific cognitive
behavioural skills they had acquired during training.
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6.3 DURABILITY OF IMPROVEMENTS IN THE EXPERIMENTAL GROUP AT
THE WEEK 52 ASSESSMENT
In the experimental group, within group analyses of mean scores showed that
improvements in psychopathology were maintained at the week 52 assessment but did
not continue to improve. This may suggest that CPNs continued to implement training
and maintain compliance in the patients they were treating. However, in the compliance
therapy trial (Kemp et al., 1998), patients' psychopathology, attitudes towards treatment,
compliance and insight were all stable between the six and twelve month follow-up
assessments despite receiving no additional intervention. An alternative explanation may
be that CPNs' practice was enhanced during and immediately following training but did
not continue for the duration of the trial. If this were the case degradation in
psychopathology would be predicted over time (i.e. the next three to four years).
Exploring this hypothesis is, however, beyond the scope of this trial.
6.4 OVERALL VALUE OF MEDICATION MANAGEMENT TRAINING
Although medication management training was superior to standard care in this trial, the
impact of training should not be overestimated. Although 48% of patients responded to
training there was no effect on patients' insight or side effects. Although patients
generally had a more positive attitude towards treatment, some ambivalence persisted.
This suggests that the risk of non-compliance and relapse in the future remains high.
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6.5 STABILITY OF THE CONTROL GROUP
Compliance has been observed to improve under scrutiny (Blackwell, 1996). There was a
significant improvement in patients' psychopathology in the control group prior to those
CPNs receiving training. A minority of patients (26%) responded to standard CPN
treatment and only one patient experienced a relapse of their illness. These results seem
to suggest that the process of CPNs being recruited to the trial and facilitating patient
interviews had a therapeutic effect. This phenomenon has been observed in other studies
(Wykes et a!., 1999). Alternatively, CPNs' practice may improve under scrutiny. Being
involved in a trial may make CPNs think about their practice and re-evaluate the care
they provide.
6.6 PATIENT VARIABLES ASSOCIATED WITH A GOOD OUTCOME
Variability of response to training is expected in patients with psychosis. In this trial
patients' age, duration of illness, and number of previous psychiatric admissions were
predicative of a better outcome. Although these finding have not been reported in
previous trials of compliance interventions, this may suggest that compliance
interventions will be more efficient if they are targeted at .patients with less chronic or
enduring symptoms where the course of their illness may be diverted.
6.7 COMPARISON WITH OTHER TRIALS
This is the first trial that has evaluated the impact of medication management training on
patient outcomes. As such there are no studies against which this trial can be directly
169
compared. However, it is important to place this trial in the context of controlled trials of
compliance interventions (Boczkowski et al., 1985; Macpherson et a!., 1996a; Kemp et
a!., 1998) and controlled and uncontrolled trials of CPN training (Brooker et a!., 1992a;
Brooker et a!., 1994; Lancashire et al., under review).
6.7.1 Comparison with other controlled trials of compliance interventions
As has already been discussed, the demographic and clinical characteristics of patients in
this trial are broadly comparable to other trials of compliance interventions (Boczkowski
eta!., 1985; Macpherson et a!., 1996a; Kemp et a!., 1998). The rates of trial drop-out and
trial refusal in this study are lower than that found in the compliance therapy study
(Kemp et a!., 1998).
Outcome measures vary across studies making it difficult to make meaningful
comparisons. For the purposes of discussion, the percentage changes in psychopathology
and attitudes towards treatment (probably the most valid and reliable measure of
compliance) from pre-training to final follow-up are shown in table 6.1 (where data are
available).
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Table 6.1 British controlled trials of interventions to enhance compliance in patients
with psychosis: mean score at pre-training and final follow-up, and percentage
change (raw data could not be extracted from one trial)
Is.esults expresseu as a percentage oi compiee compliance
2Attitudes towards medication questionnaire
3Raw score (-30 to +30 scale)
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In contrast to the findings of this trial, none of the previous studies demonstrated any
significant effect on patients' psychopathology at the final follow up assessment. This is
surprising given the improvements in compliance that were found, especially in the
compliance therapy trial (Kemp et a!., 1998). However, both studies were conducted in
an inpatient environment where psychopathology should have improved anyway
effectively swamping any experimental effect. Improvements in attitudes were similar to
Hayward et al. (1995) and greater than Kemp et al. (1998). In the control group
improvements were slightly greater (12%) than previous studies (Kemp et a!., 1998 and
Hayward et a!., 1995).
Improvements in patients' insight were found in the trials by Kemp et a!. (1998), who
observed a 31% improvement in insight and Macpherson et a!. (1 996a) who observed a
more modest improvement in insight. Hayward et a!. (1995) and the current trial failed to
show any significant change in patients' insight. Changes in insight in the control groups
range from a 1% reduction in the present trial, to a 20% increase in the compliance
therapy trial (Kemp et a!., 1998).
6.7.2 Explanations for difference in outcome - controlled trials of compliance
interventions
Some explanations for the conflicting results found by Hayward et a!., (1995) and
Macpherson et al. (1 996a) are advanced in chapter one.
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The two trials (Hayward et al., 1995; Macpherson et a!., 1996a) which reported no
significant impact on compliance were both brief interventions (respectively, 3 half hour
sessions and 1 to 3 sessions). In the compliance therapy trial, which found improvements
in compliance, patients received 4-6 sessions with an average of 3-3.5 hours face-to-face
contact, double that in the previous studies. It was anticipated, although not quantified,
that CPNs in this trial would have approximately 20 formal sessions with patients
discussing medication. Additionally, they would, as part of their work as a CPN, spend a
substantive amount of informal and unstructured time with patients discussing all aspects
of their treatment and care. Given the nature of psychotic illnesses such as schizophrenia
it is perhaps not surprising that interventions of a longer duration produce better
outcomes. There are a number of potential benefits of longer treatment. Firstly, there is
an opportunity for "over-learning" by repeating interventions to derive maximum benefit.
Secondly, there are opportunities for patients to learn by experience the effects of
changing or stopping medication. Longer treatment will also allow therapists to follow
through plans for addressing problems with medication making amendments and changes
with the patient as necessary. Similarly, patients may set long-term goals (such as getting
a job) that they want to achieve. A longer intervention will allow the therapist to follow
through, with the patient, any plan that had been worked out.
The effect of training on compliance in this trial is more substantial than in the study by
Kemp et a!. (1998). This would be predicted given the difference in the amount of both
structured and unstructured face-to-face contact between patients and therapists (10-20
hours in the present trial vs. 3-3.5 hours in the compliance therapy trial). One explanation
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may be that training has produced CPNs who are as skilled as the "expert" therapists in
the compliance therapy trial. They produce better results because they have more contact
with patients. There is, however, little evidence from the trial to support this conclusion.
An alternative explanation may be that more contact time with a less skilled therapist is
more effective than a few sessions with a highly skilled, trained (and expensive) research
psychiatrist.
Shared characteristics in the interventions used may explain the similarity of outcome
between this trial and the compliance therapy study (Kemp et a!., 1998). In both studies
the focus of the intervention was on working collaboratively with patients, exploring
ambivalence towards taking medication. Confrontation, lecturing and debating with
patients about medication was similarly avoided in both studies.
The differences in approaches may also explain the inconsistencies in results that were
observed with the patient education trial (Macpherson et a!., 1996a). In the patient
education study the emphasis of the intervention was on providing individually tailored
information, this led to improved knowledge but not compliance. Although patient
education does not appear to be effective in enhancing compliance, providing information
is an important component of good medication management because patients with
psychotic illnesses generally have such a poor understanding of their treatment
(Macpherson et a!., 1 996a; Gray et al., 1995). Within both compliance therapy (Kemp et
al., 1997) and medication management training, the importance of providing patients
with information about their illness and treatment is emphasised. However, neither study
174
attempted to measure the impact of the intervention on patients' knowledge. Future trials
should consider knowledge to be an important outcome to measure.
The three previous studies of interventions to enhance compliance failed to show any
impact on patients' psychopathology. As discussed in chapter one improving compliance
without improving clinical outcomes does not benefit the patient. However, in this trial
improvements in psychopathology were found and appear to be as a result of enhanced
compliance with medication. Since the Macpherson et a!. (1996a) study of patient
education and the Hayward et a!. (1995) study of medication self-management failed to
show enhanced compliance, improvements in psychopathology would not be predicted.
Kemp et al. (1998) did, however, show improvements in compliance and should
therefore be able to demonstrate improvements in psychopathology. In this trial the
PANSS, a very robust measure of patients' psychopathology, was used as the primary
outcome measure. In the Kemp et a!. (1998) trial, the 7-item version of the BPRS (Brief
Psychiatric Rating Scale, Lukoff et a!., 1996) was used. It is possible that the BPRS was
not sensitive enough to detect differences, primarily in positive symptoms between the
two groups. This is especially likely to be true considering that the trial was conducted in
an inpatient setting where actual compliance (as opposed to predicted future compliance
that the DAI-30 measures) is likely to be extremely good.
6.7.3 Comparison with other training trials
There have been three previous studies, all non-randomised controlled trials which have
evaluated the impact of training on clinical outcomes in patients with psychotic disorders
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(Brooker et a!., 1992a; Brooker et a!., 1994; Lancashire et a!., under review). Brooker ci
al. (1992) and Brooker et a!. (1994) were controlled trials of training CPNs in family
interventions and Lancashire et a!. (under review) was an uncontrolled trial of
psychosocial interventions training (the Thom programme). Although these studies had
different designs, interventions and assessments, comparison of the impact of training on
patients' psychopathology is useful (table 6.2). The percentage change is
psychopathology could not be calculated for the Brooker et a!. (1992) study.
Table 6.2 Studies of training interventions for CPNs that used changes in patients'
psychopathology as the main outcome deasure
All of the three training studies demonstrated significant improvements in patients'
psychopathology, even though the skills that were taught and the period of study that
trainees underwent, varied dramatically.
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6.7.4 Explanations for difference in outcome - studies of training interventions for
CPNs
Despite different training packages varying substantially in duration (8-40 days) and
content (medication management, schizophrenia family work, Thom training) all
reviewed studies led to improvements in patients' psychopathology. It seems reasonable
to propose that the longer the training, the more skilful the CPN and consequently the
better the patients' clinical outcome. In theory Thom training (Lancashire et al. under
review) should, because CPNs are trained in a range of techniques for a substantially
longer period of time, produce the best therapeutic outcomes. But in practice this does not
appear to be the case. The improvements in psychopathology in the Lancashire et al.
(under review) study and this trial were broadly similar. One explanation may be that as
the research methodology becomes more robust the degree of improvements found
reduces. The study that produced the largest improvements (Brooker et al., 1994) is
methodologically much weaker than Lancashire et a!., (under review) which in turn is
methodologically weaker than the present trial, which found more modest improvements
in psychopathology. The methodological merits of these trials are discussed in chapter
one.
Alternatively, it is possible that patients only have a limited potential to make
improvements in their psychopathology and there are no additive effects of using
different therapeutic approaches. It is also possible that the three training interventions
that have so far been tested had a similar placebo effect. Training, perhaps, engenders a
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more optimistic therapeutic attitude in trainees but does not lead to the delivery of the
intervention they have been trained to use. The results of the trial do seem to suggest that
this hypothesis warrants further investigation.
Finally the shared characteristics in the training packages may explain the similarity of
outcome. In all three studies, trainees were presented with a clear treatment rationale, and
rehearsed skills using role-play. All involved assessing patients using valid and reliable
assessment tools to produce a formulation. All involved the use of highly structured
clinical supervision. A number of important new questions are raised by this trial and
further research, for example controlling for training time, the attitudes and motivation of
CPNs and sufficiently powered to detect a link between clinicians skills and patient
outcome, is required.
6.8 IMPLICATIONS FOR TRAINING AND CLINICAL PRACTICE
J this trial, medication management training was acceptable to CPNs. Attendance at
training was good, satisfaction was high and knowledge and clinical skills improved
significantly. CPNs also appear to implement the knowledge and skills that they have
acquired in clinical practice, with the majority producing clinically meaningfully
improvements in their patients' psychopathology. Medication management training was
not harmful, no patient suicides or deaths occurred during the study. Any intervention
which attempts to raise patients' awareness of their illness may potentially increase the
risk of suicide (Amador eta!., 1996).
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The comparison of this trial with other controlled trials of interventions to enhance
compliance broadly suggests that working collaboratively with patients in a structured
way to explore ambivalence towards taking medication is the key to effective treatment.
The duration of treatment may also affect outcome. In this trial, patients received around
20 sessions plus additional informal work from CPNs. Very brief interventions appear to
be of little benefit.
This trial and the other studies evaluating clinical outcomes of training for CPNs suggest
that training in the use of valid and reliable assessment tools, a manualised approach to
treatment and the use of role-play to rehearse clinical skills are the key components of
effective training for CPNs. The duration of training does not appear to affect outcome.
In this trial CPNs received 80 hours of training delivered over ten days and produced
similar improvements in patients' psychopathology than more substantive programmes.
The medication management model (i.e. brief and focused) of training may be the
preferential model for disseminating interventions in the NHS.
6.9 LIMITATIONS OF THE TRIALS
The major weakness in the trial design was the use of standard care as the control
intervention. The lack of a credible (inert) control training condition of equal duration
means that improvements in the experimental group could be attributed to the attention
the CPNs received rather than the specifics of the intervention. The provision of training
in the control group following the week 26 assessment also make it impossible to make
between group comparisons at the week 52 assessments which would have allowed more
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robust analyses of the durability of training. However, unlike a drug trial, the ethics of
providing ineffective training to busy CPNs are dubious. It is likely that attendance to a
control training intervention would be poor. Further, if CPNs in the control group were
not offered training as an incentive to participate in the trial they would be unlikely to
facilitate patient interviews. Hence the design was chosen for ethical and pragmatic
reasons.
The use of highly experienced trainers and clinicians may weaken the argument that the
training package was effective. Much emphasis was placed on preparing the training
material in advance, delivering it in a structured format with a detailed treatment manual
for CPNs to follow. However, it remains a possibility that the use of a small number of
trainers, who had a vested interest in demonstrating the efficacy of training, may have
been more effective than an independent trainer working independently of the research
group. Although it seems unlikely that the motivation of the trainer can fully explain the
outcomes of this trial it is a consideration for future research.
The decision to ask CPNs to identify patients to participate in the trial after they had been
randomised was done for practical reasons. It enabled CPNs to organise study time once
they knew which group they were in and allowed the maximum amount of time for
patient interviews to be conducted. However, it is a potential source of bias as CPNs in
the experimental group may have identified patients who were easier to work with.
Patients in the experimental and control groups were, however, well balanced across a
range of variables. Outcomes in both groups following training were also very similar.
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Another methodological problem was the way in which compliance was measured. The
problems in measuring compliance have been outlined in chapter one. The Drug Attitude
Inventory and clinician rating are indirect proxy measure of patients' compliance. A more
direct measure may have been preferable, although, all current available methods of
measuring compliance with antipsychotic medication have substantial drawbacks. Pill
counting has been used in a number of previous studies but is obviously open to abuse
and is not suitable when a large proportion of patients are administered medication as a
depot. Serum assays are expensive, invasive and are not available for the full range of
antipsychotics (Kemp et a!., 1998). Urine tests for a drug or its metabolite may
overestimate compliance in antipsychotics with a long half-life (Churchill, 1985) and
may fail to detect low doses. Further, they only measure compliance within a few days
and are of limited value in assessing partial compliance. More robust and accurate
measures of adherence to treatment may need to be developed.
CPNs' knowledge and skills were measured at the beginning and end of training. It would
have been preferable for CPN assessments to be performed at the same time as their
patients. This would have allowed for a more robust comparison of the relationships
between skills and knowledge acquisition and patient outcome. However, some of the
assessments, specifically the video role-play, could not be administered in a clinical
setting because a suitable environment was needed, as was an actor to role-play the
patient.
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The study would have been improved by having direct measures of the amount of time
CPNs spent with their patients and the medication management interventions and skills
they used. One method of doing this would be to ask CPNs to submit audiotapes of their
sessions with patients. These tapes could then be independently rated. Brooker et al.
(1992) and Lancashire et a!. (under review) have attempted to use such methodology in
the past with some success. The proportion of submitted interactions tends to be low, for
example Brooker (1992b) reported that only a "minority" of tapes were submitted for
analysis, many of which were either blank or unclear. Rating audiotapes is both time
consuming and expensive (it takes approximately 3-5 hours to rate a single one hour
tape). Further, if CPNs think that they are going to be evaluated in practice then they are
likely to 'perform' well. However, once they are no longer under scrutiny then they
would revert back to their normal level of practice. Understanding how trainees integrate
skills into their practice is a major methodological challenge for future research.
This trial is the first randomised-controlled trial to examine the impact of CPN training
on patients' clinical outcomes. Despite the limitations that have been discussed, this trial
has several strengths. Randomisation was successful in achieving well balanced groups
across many variables that were not contaminated by CPNs in the experimental and
control groups working together. The study had sufficient power to detect a difference
between groups. The drop-out and refusal rates were respectable and assessments were
performed blind. Analysis was not restricted to mean scores but included categorical and




This trial represents a first attempt to evaluate the impact of CPN training using robust
randomised controlled methodology. As such it should be considered to be an exploratory
piece of work that will inform future definitive trials of both medication management and
other training interventions for CPNs. Further multi-centre research is needed to
determine the way in which training affects clinical outcomes. A controlled trial
comparing medication management with an inactive (or other focused) training
intervention would be useful in determining whether training gives CPNs new skills
which they put into practice or inspires and motivates them to work more closely with
their patients. Although this poses an ethical problem of providing CPNs with a training
programme which is known to be ineffective, it is a dilemma that must be addressed. One
option would be to compare medication management training with an alternative training
intervention which has been shown to benefit CPNs but should have little impact on
patients' compliance or psychopathology. An alternative training intervention may be in
the detection and management of side effects or delivering an educational intervention,
both of which would be beneficial to both CPNs and patients but should have minimal
effect on compliance. Such a trial could be used to begin to identify which aspects of
training are most effective in producing changes in specific aspects of psychopathology
and consider the duration of training courses and level of post training supervision that is
required.
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Although medication management training appears helpful in patients with psychotic
disorders, non-compliance is a major problem in patients with other psychiatric (such as
depression) and physical (such a hypertension and diabetes) illnesses. A controlled trial
comparing the impact of an adapted medication management training package for
primary care or district nurses with standard care would be an important progression of
this research.
6.11 WIDER IMPLICATIONS
This trial demonstrates that CPNs' medication management knowledge and skills can be
enhanced with training and that this results in lower levels of psychopathology in the
patients they are treating. Current care is fragmented with different professionals
responsible for different facets of care. The psychiatrist prescribes medication, the CPN
administers it and then monitors the patient for side effects and signs of relapse. CPN
prescribing may be a logical progression from the medication management training
described in this trial. Prescribing would allow the CPNs to respond quickly to untreated
symptoms, side effects or relapse. Such practice should maximise patients' compliance
with treatment and minimise the psychotic symptoms they experience.
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CHAPTER SEVEN: CONCLUSIONS
7.1 SUMMARY OF THESIS
Schizophrenia is a serious and enduring mental disorder that has a lifetime prevalence of
one percent. Antipsychotic medication has established efficacy in treating many of the
symptoms of schizophrenia. However, non-compliance is common and is observed in
around 42% of patients. The reasons for poor adherence are complex and an extensive list
of factors is reported within the literature. The most important appear to be patients'
insight into their illness, their beliefs about treatment and the side effects they experience
from their medication. A variety of interventions to improve compliance have been tested
and shown to be effective. These include compliance therapy (Kemp et al., 1996; 1998)
and behavioural tailoring (Boczkowski et al., 1985). The effective assessment and
management of antipsychotic side effects may also be effective in improving compliance
but this hypothesis has not been tested.
A substantial proportion of patients with schizophrenia are treated in the community by
mental health nurses (CPNs). A number of non-randomised controlled trials have
demonstrated that training is an effective method of providing CPNs with the skills they
need to deliver new interventions (such as family work; Brooker et al., 1994). Potentially
a training course that develops CPNs' knowledge and skills in helping patients manage
their medication more effectively may improve compliance with antipsychotic
medication. In turn improved compliance should result in patients experiencing fewer
psychotic symptoms.
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The most important research question to address was whether medication management
training would lead to a reduction in patients' psychopathology. However, a preliminary
investigation was first necessary to quantify deficits in current CPN practice and explore
the impact that recent training initiatives (such as Thorn) have had. If a need for training
was identified then a course could be developed and piloted to test the impact of training
on CPNs' clinical skills and knowledge. If this training was piloted and then shown to be
useful, further investigation of the impact of training on patients' clinical outcomes would
be warranted.
A national survey of 250 CPNs and Thorn graduates was conducted with an adjusted
response rate of 54%. Respondents were shown to be representative of CPNs currently
working in England and Wales at the time of the last national survey (Brooker and White,
1997). CPNs and Thorn graduates both reported that helping patients manage their
medication was an important part of their role. Significantly more Thorn graduates than
CPNs reported using valid measures of psychopathology and side effects. Both groups
identified a need for further training in medication management interventions such as
assessing side effects and enhancing compliance. The results of this survey were broadly
consistent with previous studies (Bennett et al., 1995; Gray 1998b) and suggest that
CPNs would benefit from and are receptive to training in medication management.
Based on the evidence presented in chapter one, data from the survey (chapter two), and
advice from a multidisciplinary group of experienced academics and clinicians, a
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curriculum for a brief 80 hour medication management course was developed. The core
components were:






This curriculum was piloted in a within subjects repeated measures uncontrolled study.
Fifteen CPNs attended an 80 hour ten day medication management course. Clinical skills
and knowledge were assessed pre- and post-training. The primary outcome measure was
the Cognitive Therapy Scale (CTS; Vallis et al., 1986; Dobson et a!., 1985) a ten item,
blind rated, measure of clinical skills. Trainees were broadly representative of CPNs
working in England and Wales. Post-training, there were significant improvements in
CTS total scores. Improvements in trainees' knowledge about medication management
were also found and it was reported that the course was acceptable and relevant to CPNs'
clinical practice.
From this pilot investigation and the findings presented in chapter two there was
sufficient evidence to warrant a randomised controlled trial to address the central research
question identified in chapter one:
187
• Does medication management training for CPNs improve patients' clinical outcomes?
Based on a power calculation, sixty CPNs were recruited to the trial, organised into
twelve geographical clusters to minimise contamination, and randomised into either an
experiential or waiting list control group. Each CPN identified two patients on their
caseload who met the inclusionlexclusion criteria. A research worker, who was blind to
the training condition, assessed these patients at baseline (week 0), and again after 26 and
52 weeks. CPNs in the experimental group received training after the baseline
assessment. CPNs in the waiting list control group continued with their standard practice
and then received training following the week 26 assessment. The primary aim was to
determine whether medication management training would produce significant
improvements in patients' psychopathology (as measured using the PANSS) because of
enhanced treatment adherence (as measured using the DAI-30).
Complete data were available for 52 trainees at baseline, 42 at the week 26 assessment
and 29 at the week 52 assessment. An analysis of the demographic and clinical profile of
the CPNs and patients who left the trial suggests that this happened by chance (e.g. CPNs
leaving the NHS Trust where the trial was conducted). CPNs who entered the trial were
representative of community nurses currently working in England and Wales (Brooker
and White 1997). Patients were also representative of those currently in receipt of mental
health services in the UK.
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The main findings of the randomised controlled trial were:
1. Training was effective in enhancing CPNs' medication management knowledge and
skills.
2. At the week 26 assessment, 48% of CPNs in the experimental group and 26% in the
waiting list control group showed improvements in the primary outcome measures.
Following training a similar proportion of CPNs in the control group showed
improvements in the primary outcome measures.
3. Improvements in psychopathology were maintained in the experimental group at the
week 52 assessment.
4. Training had no significant effect on patients' insight into their illness.
5. Mean prescribed dose of antipsychotic medication (in chiorpromazine equivalents)
was high throughout the trial and did not change significantly in either group.
6. Patients experienced a moderate degree of side effects for the duration of the trial.
This randomised controlled trial establishes for the first time, using robust methodology,
that CPNs can be trained to deliver an intervention derived from the research evidence.
The methodology used in this trial should form the foundation of more robust trials that
evaluate the impact of training interventions in many areas of health care. Only by
developing training interventions with established efficacy can evidence based
interventions be disseminated throughout the NHS allowing nurses to work effectively
towards improving the mental health of the nation.
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APPENDIX 1
COMMUNITY PSYCHIATRIC NURSING SURVEY












4. Other (specify) U
Age
How old are you? _______ years
Year of qualification




3. F LI	 7. Other specify
4.GU
Qualifications/experience
(Please tick all appropriate boxes)
1.SRN	 U
2.RGN	 U




7. RN (adult)	 LI
8. RN (mental health)
	 LI







Have you attended the THORN course?
1.Yes	 LI
2.No	 LI
Q2. ABOUT YOUR PRACTICE
How long have you worked as a CPN? __________ years
How many hours do you work each week? __________ hours
The different types of mental disorders commonly seen by CPNs are shown
below, divided into four groups. Please indicate how many patients on your
caseload have a main diagnosis of the following.
Number of
patients
Group 1	 Schizophrenia, dementia, bipolar disorder,
severe eating disorders
Group 2 Moderate to severe depression, pure
depression, panic disorder, obsessive
compulsive disorder
Group 3	 Phobia, somatoform disorder, mild eating
disorders, post-traumatic stress disorder
drug and alcohol problems, chronic fatigue
Group 4	 Bereavement, adjustment disorder, mild
depression/anxiety
TOTAL NUMBER OF PATIENTS ON YOU CASELOAD
Of the patients on your caseload taking antipsychotic medication, how
frequently do you monitor them for side effects?
1. More than once a week Li
2. Weekly	 LI
3. More than once a month LI
4. Monthly	 LI




Please list which, if any, assessment tools you routinely use to assess
antipsychotic side effects.
Please list the antipsychotic side effects that you monitor in your patients
(please be a through as possible).
Please list the outcome measures, if any, that you regularly use in your
clinical practice (please be as through as possible)
Q3. INTERVENTIONS
Below is list of interventions CPNs are often involved in delivering. Please
rate whether you think each is an important part of your role as a CPN.
1. Anxiety management
2. Crisis interventions
3. Monitoring patients' mental state
4. Counselling
5. Relaxation therapy
6. Suicide prevention/dealing with self harm
7. Monitoring the side effects of medication
8. Cognitive behaviour therapy (CBT)
9. Administering depot antipsychotics
10. Ensuring compliance with medication
11. Case management
12. Family work












































Do you give information to patients about schizophrenia?
1.Yes	 LI
2.No	 LI
Do you give information to patients about antipsychotic medication?
1.Yes	 LI
2.No	 LI
Do you give information to families about schizophrenia?
1.Yes	 Li
2.No	 LI




We would like to know your views on the treatment of schizophrenia. Could you
please state whether you agree, disagree or are not sure about the following
statements?
____________________________________________ Agree Disagree Not sure
1. Antipsychotic mediáation will generally help
patients_from_having_arelapse? 	 ________ _________ _________
2. Extrapyramidal symptoms are caused by the
blockade_of serotonin_receptors?	 ________ _________ _________
3. Newer (atypical or novel) antipsychotics are
better_tolerated_than_older_neuroleptics? 	 ________ _________ _________
4. Atypical antipsychotics have no affinity for
dopamine_receptors? 	 ________ _________ _________
5. If a patient has not responded to treatment
with an antipsychotic it is helpful to increase
the_dose?	 _________ __________ _________
6. Giving patients information about medication
will_improve_treatment_compliance. 	 _________ __________ _________
7. Atypical antipsychotics are effective in
treating the negative symptoms of
schizophrenia.________ _________ _________
8. Clozapine is the only antipsychotic effective
in patients with treatment resistant
schizophrenia.	 ________ _________ _________
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Q6. TRAINING
What training courses have you attended in the last five years?
Which of the following areas would you identify as the most important for
training? Please score each item. 9 being the most important, 1 the least
important, you may give more than one item the same score.
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
3 4 5 6 7
1. Anxiety management
2. Crisis interventions
3. Monitoring patients' mental state
4. Counselling
5. Relaxation therapy
6. Suicide prevention/dealing with self harm
7. Monitoring the side effects of medication
8. Cognitive behaviour therapy (CBT)
9. Administering depot antipsychotics
10. Ensuring compliance with medication
11. Case management
12. Family work
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Course aims
Overall aim
• By the end of the course the trainee will be proficient in delivering the medication
management intervention described in the treatment manual.
Specific course aims
• By the end of the course the trainee will be knowledgeable about the following: I.
The signs, symptoms and aetiology of schizophrenia; 2. Psychopharmacology; 3.
Factors affecting compliance; 4. Psychological interventions to enhance compliance.
• By the end of the course the trainees will be skilled in the following: 1. Assessing
patients' psychopathology, attitudes towards treatment, insight and antipsychotic side
effects; 2. Using a range of medication management and compliance therapy
techniques.
• By the end of the course the trainee will have presented one patient they are working
with for clinical supervision, demonstrating the application of medication
management knowledge and skills in practice.
Teaching methods




• Video-ratings of patients.




The course is formatively assessed in the following ways. 1. A multiple choice progress
test. 2. Performance on a standardised video role-play task. 3. Reliability in rating
patients' mental state.
The summative assessment for the course is a 3000 word case study.
Terms of Reference
1. To ensure the course falls within the remit of Kings College London in terms of its
academic profile and conforms to regulations.
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2. To ensure that the course is of a high academic standard and compares favourably
with its competitors.
3. To enhance and develop the curriculum in line with current trends in the field of
mental health research, service provision and policy.
4. To guarantee that entry requirements, teaching methods, assessment procedures and
provision of support services are suitable for both the course and the students.
5. To ensure the assessment procedures are fair and open and that marking schemes and
the classification system outlined in the course regulations are adhered to.
6. To certify that the award conferred is appropriate for the course and the performance
of the student justifies the award.
7. To assure the Education Committee that the management structure within the
Department and the course itself is sufficiently well established to address any
problems or issues that may arise.
8. To ensure that adequate resources are available for the course.
9. To evaluate current courses and make relevant changes.
10. To consider any other business pertinent to the course or required by the education
committee.
Structure and membership of exam boards
These will comply with the regulations of Kings College, London.
Arrangements for obtaining and using student feedback
1. Formal student evaluation of the course will be through an evaluation questionnaire
that will be completed at the end of the course.
2. Students will be asked to nominate and will be notified of the name and contact
number of a student representative whose role it will be to feedback student views at
the course management meetings.
3. At the end of each taught day of the course students will be asked for feedback.
4. Students will be encouraged to approach the Course Co-ordinator at any time with
feedback, problems or suggestions with regard to the course itself
Regulations
All courses conform to Kings College, London regulations. Copies are available on
request.
Entry requirements
Appropriate professional qualification i.e. registered nurse (RN), registered mental nurse
(RMN), occupational therapist (OT) or equivalent registered qualification in other
professions.
Assessment criteria.
Criteria for Marking Written Assignments.
All written submissions will include the following criteria:
• Include a critical review of the relevant literature.
• Focus on one patient the student has been working with.
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• Present an anonymous description of the patient so that patient's confidentiality is
preserved.
• Include all assessment measures as an appendix.
• Demonstrate the application of an assessment tool/intervention in clinical practice.
• Demonstrate the efficacy of the assessment/intervention in clinical practice.
• Provide evidence of a broad and up to date search of the literature with accurate
referencing (using the Harvard system).
• Develop a logical and balanced structure, present coherent lines of argument and
offer a conclusion.
• Show initiative in approach, clarity of argument and rigor in handling material.
• Offer analytical comment, critical evaluation and display originality.
The following outline criteria for grading written assessments will be used.
Grade	 Standard
70% and above	 Excellent. Fulfils the relevant criteria; an
______________________________________ exceptional piece of work.
60-69%	 Very good. Fulfils most of the relevant
____________________________________ criteria to a very high standard
50-59%	 Clear pass. Meets the relevant criteria to a
Satisfactory standard, or a paper of
variable quality which contains some
work of a high standard but some which
_______________________________________ is less than satisfactory
40-49%	 Pass. Meets the relevant criteria to a level
which is acceptable. Shows limited depth
___________________________________ and breadth of understanding
0-39% Fail. The criteria are not met to an
acceptable standard. Knowledge and
understanding are not demonstrated or
the material is inappropriate to the
______________________________________ question.
Failure of an assignment
Students who fail the written assessment will be offered remedial support as required.
They will be entitled to two further attempts at any single piece of assessed work. If they
are unsuccessful at the third attempt, this will constitute a fail and the practitioner will not
receive the award.
Completion of the course
To complete the course and receive an award, participants normally need to have:
1. Attended for the duration of the course. If time taken off for sickness etc, is in excess
of 20% of the attendance required, it will be necessary to review the participant's
place on the course.
2. Completed all course assessments - formative and summative.
3. Passed the summative assessments.
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Negotiated late submission
Students may negotiate with the course leader an extension of the submission date for an
assessment if:
1. They are still preparing for a re-attempt at a previous assessment.
2. They have been ill.
3. They have compassionate grounds.
4. They have experienced an emergency e.g. burglary, fire etc.
Requests for extended submission must be put in writing at least one week in advance
with an explanation as to why the extension is necessary. Negotiation for the new
submission date will be followed by written confirmation of the new deadline, which
must be adhered to.
Failure to submit assessments on time
If a student submit assessments late and has not negotiated a later submission date with
the course leader, then his/her work will not be marked; this assessment will be regarded
as a fail at the first attempt. If a student is unexpectedly absent from the course on the day
an assignment is due, it remains his/her responsibility to submit the assignment as soon as
possible, either by post, by fax or by hand.
Plagiarism
The offence of plagiarism of written work will result in a fail grade award. Students
assigned a fail grade due to plagiarism will be required to be reassessed on that particular
assignment.
Irregularities
Any irregularities relating to written assessments will be reported to the head of nursing
studies. The head of nursing studies shall consult as appropriate and practicable, for
example, with the external examiners and with learners. The head of nursing shall then
decide on the action to be taken, which may include reference to the examination board
for a decision or for commencement of disciplinary proceedings. The examination board
shall, except in cases considered trivial, have reported to them all irregularities and the
action taken upon them.
Appeals panel
Appeals related to the conduct of assessments will be examined in relation to and to
comply with the regulations of King's College London.
Evaluation of the Course
Internal evaluation.
Within the organisational structure in King's College London, the assessment review
group will monitor and ensure quality in all issues relating to the theoretical assessments.
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Methods of evaluation and monitoring
1. Written student evaluation, report from student representative, verbal evaluation after
taught days.
2. Organisational, using the methods recommended by Kings College, London.
Quality Assurance Mechanisms
Systematic monitoring and evaluation is an established part of practice within King's
College, London, as is student evaluation, individual performance appraisal, supervision,
peer review, and the organisational audit of educational and clinical standards.
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TIMETABLE
Cohort: Trust name, month, year
Dayl	 Day2
ddlmmll9yy	 ddlmmll9yy
9:30 Introductions and overview of course 9:30 Signs and symptoms of schizophrenia
10:00 Multiple choice questionnaire 	 11:00 Aetiology of schizophrenia
10:30 Video role play	 1:00 Assessing symptoms (video rating)
2:00 Reasons for non-compliance
3:00 Interventions to enhance compliance _____________________________________
Day3	 Day4
ddlmmll 9yy	 ddlmml 1 9yy
9:30 Assessing symptoms (video rating)	 9:30 Assessing side effects





9:30 Clinical supervision	 9:30 Clinical supervision
11:30 Psychopharmacology	 11:30 Psychopharmacology
2:00 Key skills in medication management 2:00 Key skills in medication management
role play (reviewing the patient's illness	 role play (exploring ambivalence)
history)	 _______________________________________
Day7	 Day8
ddlmmll 9yy	 ddlmmll 9yy
9:30 Clinical supervision	 9:30 Clinical supervision
11:30 Psychopharmacology	 11:30 User experiences
2:00 Key skills in medication management 2:00 Key skills in medication management
role play (testing patient's beliefs about






10:00 Clinical supervision	 9:30 Clinical supervision updates
11:30 Dual diagnosis 	 12:00 Evaluation of course
	
• •	 •	 2:00 Multiple choice questionnaire2:00 Key skills in medication management
	
•	 2:30 Video role play
role play (planning for the future)
229
Aims for the course
Spend five minutes thinking about what your personal aims for the course are and list
them below. At the start of the course you will be asked to state your aims and this will
allow the course content to be modified to meet your learning needs. At the end of the




Evaluation of the course
Were your personal aims achieved?
Clinical supervision




9:30 Introductions and overview of the course
10:00 Multiple choice questionnaire
10:3 0 Video role-play
2:00 Reasons for non-compliance
3:00 Interventions to enhance compliance
What is your personal aim for the day?
Aim:
Evaluation (include whether your aim was achieved):
Homework
It is essential that before next weeks session that you read the following:
Medication management treatment manual
Positive and Negative Syndrome Scale
These can be found in your course reading packs.








- Working as a team
- Making decision jointly





Rd On. . h.u.anofP.yci.ey.
What is the main cause of









Herz and Melville (1980) Patient inteiview
Carman neaL (1984) 	 Unne test
Kelley and Scott (1990) Pattern nterview
nuchanan (l992) Clinician judge.
Fliscliacakaretal. (1994) Clinucianjudge














Mean compliance rate approximately 50%
R,chd O. IP.ny. L,.,dw	 RhdG.y, Janm .(P.ydany. Li
Rd Ga 1.t* .IP..d,r U,.,&.,	 LMd C an.an ..(P.v..ey I
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Exercise one
List ten reasons why patients stop
taking medication
Is compliance better or worse
with antidepressants?
Non-compliance is the major
preventable cause of
psychiatric morbidity
How can compliance be enhanced?
synoD
,
S	 C...	 e	 955
Rd O.y. t.D.	 any. L	 Rd Cay.	 s(P.ysy.
Do side effects affect compliance?
Riehed Oe.y. Ieo,ano(P,h.i. Loreka
• Mutatava d aL in prom




• Pmt Ud. ethel, Od.I




• Hierarchy of side effects






• Study needs to be done but
requires large numben of
patients (n200-300)
Rekad O..y. Iseasin o(Pn' asy. Lead..
Other factors affecting compliance
• Gray et aL In submission; Kemp and David 1996
- Inseght (34'!. of variance)
• Kane(1983)
- amino. behaviour
• Applebaum and Gutheil (1980) Bartko Ct aL (1988)
- Psycbopathoto
• Hogan ci aL 1983
- Beliefs about treatment
• Heyscue et al. (1998)
- Substance misuse






R.ekad Osey I.s.o. ,(Por.sy. Leads.
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Exercise two
List techniques you have used to
improve compliance
Compliance Therapy






— * -- mix













• Wieden etaL (1986)
- 26% of patients with akathisia
- 59% of patients with parkinsonism
• BennettetaL (1995)
- CPNs ask about 3-4 side effects
• Gray (1998)
- CPNs didn't ask about important side effects which
affect compliance (e.g. sexual dysfunction)
Relwd amy, Ia	 (POay. L
Side effects
• Detection will be improved with the use of assessment
tools
- LUNSERS, S.npaon-Angu, AIMS, Banana
• Nurses aware of the need for more training
• Training limited
- Problem with Vmyersitieo
• Many side effects (e.g. El'S, symptomatic
hyperprolactinimeia) easily managed
- Novd/atypicl antipsycbotics
R.d amy.	 Poy, R
RCTs of educational interventions
n.d,ed amy, miss, o(P,yde.ay. Lo,dm
Author	 n rnt.rv.ntien Outo





al., (1996)	 patient	 knowledge not
education	 compliance
Gray (2000)	 44 Individual	 No effect on
patient	 compliance
education
Rkbod Guy. taa*adPgmi.ay. l
Behavioural interventions
Boczowski et aL (1985)
36 male chronic patients
90
with schizophrenia
	70	 -	 • RCT
	6 	 • Patients received one
	
.! 50	 session
	.10	 - Behavioural tailoring
	
3 30	 —	 - Patient education
	20	 - Control discussion about
	





Intud amy hara, .(Pany Lm.d..
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at end of session
• Understanding





- Punctloansg as a team






• Strategy for change
O,.d Ony.	 *(Pasy, 1d*.
Compliance therapy skills Avoid.......
• Normalising strategies
- Incidence of mental disorders/symptoms
- Analogies with physical illnesses
• Consequences of stopping medication
• Long term plans
• Information about illness and treatment
• Lecturing
• Preaching
• Insisting on diagnostic labeling
• Turning session into a debate
• Asking a series of questions
• Compliance is a major preventable cause of morbidity
• Medication management interventions are effective
- Ediicatio.
- Detection and management of side effects
- Careful prescrib.sg
- Compliance therapy
• Who can deliver medication management interventions
- CPNs ideally placed
- Dissenimation of research .sto practice
ld Gay. nuu( p S,5.. L
Compliance therapy skills
• Reviewing illness history
- Identifying pattern of illness
- Discuss negative experiences of treatment
• Beliefs about medication
- eg. medication is poison"; "1 don't need to take medication
once I feel better"; "medication doesn't help me"
- Rate belief (0-100%)
- ifltasthaa l00%testtbeevidence
- Re-rate the belief
IO,uvrP,S,h,.sS
Compliance therapy skills
• Consider pros and cons of treatment
- "it makia me sleepy .... but also less agitated"
• Target symptom
- Identified by patient
- Often indirect
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• Non-compliance is a major problem
- Need to think about concordance
• Interventions need to be structured and
targeted







A number of studies have implicated treatment non-compliance (defined as sub-optimal
treatment adherence) as a crucial factor in the relapse and rehospitalization of people with
schizophrenia (Green, 1998; Haywood et al., 1995). The incidence of non-compliance in
people with schizophrenia has been observed in 10% to 80% of patients with psychosis
(Babiker, 1986; Young et al., 1986). These variations can be attributed to different
treatment settings (e.g. inpatientloutpatient) and methods of measuring compliance.
However, it is generally accepted that around 50% of patients will stop taking their
medication within a year of antipsychotic medication being started. Interestingly, this is
not dissimilar to non-compliance rates in other chronic disorders such as depression
(Kemp and David, 1995).
Improved rates of compliance could dramatically reduce relapse. Kissling (1994)
suggests that good medication management may improve compliance and could
potentially reduce the relapse rates to about 15% (currently around 50% of patients
relapse within the first year of remission and about 85% do so within the first five years
(Kemp et al., 1997)). In order to develop effective medication management interventions
it is first necessary to examine why patients are non-compliant.
Factors affecting compliance
In a comprehensive review of factors associated with non-compliance in psychotic
patients, Kemp and David (1995) proposed that variables could be classified into those
related to the illness, the treatment and the person. Illness-related factors include lack of
insight (Bartko et al., 1988; Lin et al., 1979; McEvoy et al., 1989; van Putten et al.,
1976), aspects of psychopathology (for example, paranoia, thought disorder, hostility,
delusional beliefs about medication, grandiosity) (Appelbaum and Gutheil, 1980; Hoge et
al., 1990; Marder et al., 1983; van Putten, 1974) and cognitive impairment (Geller, 1982;
Macpherson et a!., 1996; Weiden et al., 1986). Factors associated with treatment include
the side-effects of antipsychotics, such as akathisia, akinesia, neuroleptic dysphoria,
sexual dysfunction, dystonias, tremor, rigidity and weight gain (Buchanan, 1992;
Michaux, 1961; Nelson, 1975; van Putten, 1974; van Putten et al., 1981; Weiden et al.,
1986). Person-related factors include the individual's personality and sociocultural
background. A number of studies have highlighted that antichemical and antipsychiatry
views are common (Angermeyer and Matschinger, 1994). Beliefs about the benefits of
'alternative' cures (such as diet) and the role of self-control and willpower in overcoming
the illness are also prevalent in our society (Weiden et al., 1986).
Interventions to enhance compliance
A number of studies have evaluated the use of interventions to increase compliance.
These include patient education (Gray 2000; Macpherson et al., 1996; Smith et al., 1992),
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behavioural tailoring (Boczkowski et a!., 1985) and compliance therapy (Kemp et a!.,
1996).
In a randomised controlled trial of education about drug treatment by Macpherson et al.
(1996), 64 patients with DSM IIIR schizophrenia were randomly assigned to receive
either:
- one session of education about medication;
- three sessions of education about medication; or
- Standard care.
The educational sessions were based on a specially designed booklet, drawn from
psychoeducational literature and principles of health education. Sessions lasted between
25 and 35 minutes. Techniques included rehearsal of material with questions and
feedback.
A range of measures were used, including the Knowledge about Medication
Questionnaire (KMQ) a tool designed to gauge patients' knowledge of antipsychotic
treatment. Patients were assessed at baseline, immediately post-intervention and at one-
month follow-up. Pre-intervention, patients showed a poor understanding of their
treatment. Both one and three sessions of education led to improvements in
understanding about medication compared to standard care. However, three sessions led
to significantly greater knowledge gain than one session.
Smith et al. (1992) and Gray (2000) also examined the effects of educational
interventions on-knowledge about medication, insight and attitudes towards treatment.
Smith et al. (1992) divided their intervention into four sessions, each session designed to
cover a different aspect of schizophrenia. Session 1 examined the concept of
schizophrenia, including possible causes and outcome; Session 2 focused on the
symptoms of schizophrenia; Session 3 emphasised the advantages, limitations, and side-
effects of the treatment of schizophrenia; Session 4 outlined basic symptom management
strategies. Twenty-eight patients participated in the study and significant gains in their
knowledge of treatment were observed post intervention. However, no significant
changes in insight or compliance with medication scores were reported.
Gray (2000) examined the effects of education about medication on patients who were
taking clozapine. Forty-four patients were randomly assigned to receive either three
sessions of education or standard care. As in the Smith et al. (1992) study, sessions
focused on the concept, the symptoms and the treatment of schizophrenia. Patients'
knowledge of the potential side effects of medication increased. However, no changes in
patients' attitudes towards treatment or insight were reported.
Boczkowski et al. (1985) took a very different approach to trying to improve compliance.
They assigned 36 male patients with chronic schizophrenia to receive one session of
either behavioural tailoring, patient education or a control intervention. Behavioural
tailoring involved informing patients of the importance of complying with their
medication and helping the patient to tailor their prescribed regimen so that it was better
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suited to their personal habits and routines. Compliance was measured via pill counts at
three time points: pre-intervention, one-month follow-up and three-month follow-up.
Results suggested that patients who received behavioural tailoring were more compliant
following treatment than were the other groups.
In a seminal study, Kemp et al. (1996) evaluated the effectiveness of compliance therapy,
a brief pragmatic intervention based on motivational interviewing and cognitive
behavioural therapy which aims to help patients work through ambivalence about
behaviour change. Key skills include the use of inductive questioning, reflective
listening, use of summarising, investigating the pros and cons of alternative courses of
action and homing in on and reinforcing adaptive attitudes and behaviours (Kemp et al.,
1997). Compliance therapy is divided into three distinct phases: phase 1 is concerned
with reviewing the patients' illness history, phase 2 explores ambivalence towards
treatment and phase 3 highlights the need for treatment maintenance.
In a randomised controlled trial 47 patients were randomly assigned to receive 4-6
sessions lasting 10-60 minutes each, of either compliance therapy or non-specific
counselling. Patients were assessed pre-intervention, post-intervention and at one, three,
and six-month follow-up using measures of insight into illness, attitudes towards
treatment and compliance. Patients who received compliance therapy showed
significantly greater improvements in attitudes towards treatment insight and compliance,
which were sustained at six-month follow-up.
The evidence suggest that an effective medication management intervention will include
the careful assessment of patients' psychopathology, beliefs about treatment, insight,
antipsychotic side effects, and other factors that may affect compliance. Is structured,
educative and collaborative. The therapist and patient work together to explore and
discuss concerns about treatment.
Overview of intervention and therapeutic techniques
Structure of sessions
Patients should ideally be seen individually, the duration and frequency of sessions will
need to be defined by individual therapists depending on the patient's level of cognitive
function. It is recommended that the intervention will initially involve approximately 10
hours individual work followed by ongoing top-up sessions. The aim of the medication
management intervention is not only to help the patient examine the use of
pharmacological interventions to treat their illness but also to provide them with the skills
to help them manage their medication in the future.
Baseline assessment
This is the first stage of the intervention, normally lasts several sessions and involves the
completion of formal clinical measures of:
• Psychopathology - using the PANSS (Kay et al., 1989)
• Beliefs about medication - using the Hogan drug attitude inventory (DAI-30, Hogan
etal., 1983)
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• Insight - using the Insight Scale for Psychosis (ISP, Birchwood et a!., 1994)
• Side effects - using the LUNSERS (Day et al., 1995)
During this stage of the intervention the therapist helps the patient to identify specific
problems and targets for treatment as well as engaging the patient in discussing their
medication. Once these problems have been identified they should be listed and ranked
by the patient. A clear treatment rationale, that the therapist wants to work collaboratively
with the patient in addressing issues around medication, is presented. A formulation and
plan of therapeutic tasks and homework is then discussed. Considerable time should be
devoted to the careful assessment and review of the patients' medication as this will not
only aid engagement but may also have some therapeutic benefit.
Structure of sessions and general therapeutic skills
The therapist should carefully plan and structure each session dependent on his or her
level of functioning. At the beginning of each session the therapist must set a clear
agenda with the patient with specific and relevant areas for discussion and set clear time
limits. General therapeutic approaches that should be used include carefully eliciting and
responding to verbal and non-verbal feedback; understanding the patients' views of
medication and treatment; and encouraging the patient to take an active role during the
sessions. Guided discovery is a central skill with the therapist helping the patient to
explore problems and draw their own conclusions. These general therapeutic approaches
form the foundation for the application of more specific medication management
techniques.
Medication management and compliance therapy techniques
Providing information
Providing patients with information about their illness and treatment is a central part of
the intervention and misconceptions and lack of understanding about any aspect of
treatment should be clarified at any opportunity.
The illness timeline
Patients identify when they, or significant others, first realised they had psychiatric
problems and then plot the course of their illness and the positive and negative effects of
treatment over time. Close attention should be paid to helping the patient identify when
their mental health has been particularly good and when it has been not so good. The
purpose of this exercise is two-fold; firstly it helps the patient make any links between
stopping medication and worsening psychopathology and secondly to identify and
examine negative experiences of treatment, particularly where medication had been
forcibly administered.
Normalising rationales
Drawing an illness timeline may be linked to the use of normalising rationales to explain
both psychotic pathology and the need for maintenance treatment. A rationale should be
discussed with the patient and the typical symptoms of, and possible genetic
predisposition to, schizophrenia are then described. The vulnerability-stress model
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(Zubin, 1987) should then be explained in detail, with the therapist making specific links
to the work done in reviewing the illness timeline, to help the patient identify that their
psychotic symptoms may be caused by an increased susceptible to stress. If the patient
accepts this rationale then further work could be undertaken with the therapist helping the
patient to draw analogies to other physical illnesses such as diabetes or asthma where
maintenance treatment is necessary to prevent relapse.
Drawing up a balance sheet
Patients are helped to draw up a balance sheet to highlight both the positive and negative
aspects of treatment. Emphasis should be placed on identifying the less obvious, or
indirect, effects of medication (staying out of hospital, getting into fewer arguments, less
problems with the neighbours). Dependent on the patients' level of functioning this
activity may be done as homework with the therapist expanding and clarifying the work
the patient had already undertaken.
Testing beliefs about illness and medication
Patients' beliefs about their illness and medication should be tested by using a modified
version of the cognitive behavioural procedures for examining delusions (Chadwick et
a!., 1996). Patients' beliefs about their illness and medication are identified from the drug
attitude inventory and listed. The patient then rates the beliefs in terms of their influence
on compliance. The beliefs are then rated on a percentage scale (0%=don't believe it at
all, 1 00%=belief held with complete conviction). If the belief is held with less than 100%
conviction it is gently challenged; the plausibility of the belief is questioned; and the
belief is reformulated as being an understandable response to, and way of making sense
of, specific experiences, and a personally meaningful alternative is constructed. Finally,
the patients' belief and the alternative are assessed (using the percentage scale) in the
light of the available information.
Specific problems with medication
Specific problems with medication, such as side effects, should be examined using a
problem solving strategy (Hawton and Kirk, 1989). A problem is selected and a target is
agreed. The broad steps necessary to achieve this goal are then identified and the patient
decides, in detail, the practical and realistic tasks that would be necessary to achieve this
goal. Progress is then reviewed in subsequent sessions
Examine the consequences of stopping medication
The Patients is asked to list the positive and negative aspects of stopping medication.
Again this is a potential homework task dependent on the patients' level of functioning.
Long term plans
Patients are asked to look six to twelve months into the future and identify a goal they
want to achieve. A problem solving strategy is utilised to identify broad and specific
tasks needed to achieve this objective.
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Medication review
The patients' medication is reviewed by the therapist and compared to the Bethiem and
Maudsley Prescribing Guidelines. Any discrepancies e.g. antipsychotic polypharmacy,
use of very high doses of antipsychotic or long term use of anticholinergics are discussed
with the patient and the prescriber. Practical solutions to tackling side effects, identified
by the patient as problematic, should be discussed at this time (for example, timing of
administration, route of administration). The aim of medication review is to ensure that
the patient is on the most effect treatment regime.
Behavioural tailoring
Much non-compliance may be accidental because patients simply forget to take
niedication. The therapist should identify how frequently this happens and simplify
dosing regimes, use visual prompts to remind patients to take medication, and make use
of doset boxes.
Re-assessments
Following the initial sessions with the patient the therapist should repeat the assessments.
This will allow the therapist to evaluate, in clinical supervision, if the work they have
been doing has been effective. It will also allow the therapist to identify areas where top
up sessions can be targeted.
Supervision
You should discuss the medication management work with you supervisor on a regular
basis. You will also have the opportunity to present one patient you are working with as
part. of the medication management course. You can also get online supervision by
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You have one hour to present a patient that you have been working with. You are advised
to spend the first 20 minutes presenting the patient using the framework below. You
MUST end your presentation with a supervision question. You should then spend 30
minutes discussing your supervision with the group and the final ten minutes deciding on





Compliance strategies used in the past
• Assessment
Psychopathology (using the PANSS)
Attitudes towards treatment (using the DAI-30)
Insight (using the ISP)
Side effects (using the LUNSERS)
• Patient formulation







9:30 Signs and symptoms of schizophrenia
11:00 Aetiology of schizophrenia
1:00 Assessing symptoms (video rating)
What is your personal aim for the day?
Aim:
Evaluation (include whether your aim was achieved):
Homework
It is essential that before next weeks session that you read the following:
Gray R. and Smedley N. (1997) Nursing Interventions with acutely ill clients. In: Thomas
B. et a!., (Eds) Stuart and Sundeen 's Mental Health Nursing. Mosby, London.
The Structure Clinical Interview (SCI)
Both are in your background reading pack.
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Schizophrenia
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Hallucinations	 Delusions
• Auditory	 • Paranoid
• Visual	 - Persecutory
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Thought disorder	 Passivity phenomena
• Formal though disorder 	 • Thought broadcasting
- Loosening of associations 	 • Thought insertion
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Abnormal affect
• Blunt of flat
• Inappropriate or incongruous





• Memory and learning
R.d Oy.	 Cn, I
	 nfP.. Lod
Motor abnormalities 	 Lack of volition
• Posturing	 • Lack of drive
• Waxy flexibility 	 • Diminished interest in the outside world
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Lack of insight	 Clinical phases
• Very common	 • Premorbid phase
• Associated with non-compliance 	 - Social and cognitive deficits traced to
childhood
• Prodromal
- Emergence of actual functional decline
• Insidious and gradual
Rd Gn	 Ld	 Ld
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Course
• Used to considered one of continuos
deterioration
• Seems to be a great degree of variability




• Level of social functioning
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• No previous psychiatric history






• Lifespan shortened by 10 years





• Occurs in all cultures
• Incidence 2-4 cases per 10,000 of the
population per year
• Lifetime risk 1%
Temporal variation
• Increased incidence in 19th Century
• May be declining
RIwd O
	 L.,d.	 G I(Pdy L.
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Social factors
• Schizophrenia more common in
industrialised countries
• More schizophrenic patients in lower
socioeconomic classes





• Fertility rates reduced by 25%
• Northern hemisphere more people with
schizophrenia (8%) born between
January and April
• Reversed in southern hemisphere
R.b.d Ge.y. I.*	 Ld
Immigration
• Higher incidence in recent immigrants
• Stress of leaving home country
• Not because of cultural intolerance
.iP.y. L.
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Aetiology of schizophrenia	 Exercise one
List what you think are the causes
of schizophrenia
R,bI O..y. IP.y	 L.,&.	 l.thdGy.	 'P.yy.
Aetiology	 Genetics
• Biological	 • Family studies
• Adoption studies
• Environmental	 - Adoptee studies
- Adoptee family studies
- Cross fostering studies
• Twin studies
• Molecular genetic studies
Genetics
• Schizophrenia does not follow a
Mendelian pattern
• Models





• More PBCs in patients with
schizophrenia
• Hypoxic/ischemic neuronal injury
• Cause or effect
Rcd G





• EE a robust predictor of relapse
• Low EE protective
• EE has any effect in other disorders
Prenatal exposure to viral
infection
• More schizophrenics born in late winter
and spring





• More life events than normal controls
prior to relapse




POSITIVE AND NEGATIVE SYNDROME
SCALE (PANSS)
Exercise
You will be shown a video of a patient being interviewed by a clinician who is experienced in using the
structured clinical interview (Sd). The video lasts 30-40 minutes. Watch the video carefully making notes
of the psychopathology that you observe. Once the video has finished complete the rating criteria below
using the rating criteria in your reading pack. REMEMBER you only rate what has been observed or
reported in the last seven days. REMEMBER you are looking for evidence. Once you have completed the
rating you will be asked to feedback to the group. If your score is substantially different form the other













N4 Passive/apathetic social withdrawal
N5 Difficulty in abstract thinking











G9 Unusual thought content
G 10 Disorientation
Gil Poor attention
G12 Lack ofjudgement and insight
G13 Disturbance of volition
G14 Poor impulse control
G 15 Preoccupation













9:30 Assessing symptoms (video rating)
2:00 Role play of structured clinical interview (SCI)
What is your personal aim for the day?
Aim:
Evaluation (include whether your aim was achieved):
Homework
By next weeks session you should have interviewed one patient using the structured
clinical interview and completed one PANS S rating. It is advisable that the patient you
interview should be the patient you present for clinical supervision.
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POSITIVE AND NEGATIVE SYNDROME
SCALE (PANSS)
Exercise
You will be shown another video of a patient being interviewed by a clinician who is experienced in using
the structured clinical interview (SC!). The video lasts 30-40 minutes. Watch the video carefully making
notes of the psychopathology that you observe. Once the video has finished complete the rating criteria
below using the rating criteria in your reading pack. REMEMBER you only rate what has been observed or
reported in the last seven days. REMEMBER you are looking for evidence. Once you have completed the
rating you will be asked to feedback to the group. If your score is substantially different form the other













N4 Passive/apathetic social withdrawal
N5 Difficulty in abstract thinking











G9 Unusual thought content
G 10 Disorientation
Gll Poor attention
Gi2 Lack ofjudgement and insight
Gi3 Disturbance of volition
G14 Poor impulse control
G 15 Preoccupation











Divide into pairs, one person should be a patient and the other interviewer. The person
who is going to role-play the patient should try to be a client that they know well (this
should make them more convincing). The interviewer should then conduct the structured
clinical interview. Think carefully about how the interview is presented to the patient and
how you will inform them of what you have found out about their experiences.
REMEMBER the aim of the exercise is to familiarise yourself with the interview.
When you have finished the patient should give the interviewer feedback about what they
did well and what they could have done differently.
Now reverse the roles so that the person that was the interviewer is the patient and the




9:30 Assessing side effects
11:00 Assessing patients' beliefs about medication
1:00 Assessing insight
What is your personal aim for the day?
Aim:
Evaluation (include whether your aim was achieved):
Homework
You must assess one patient using the self-report measures you have learnt to use. Again
this should be the patient you will present for you clinical supervision presentation.
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Liverpool University Neuroleptic Side Effect Rating Scale
LUNSERS
The following pages are a copy of the LUNSERS which is filly a validated and reliable
means of assessing neuroleptic side effects. It includes 41 known side effects of
neuroleptics and 10 "red herring" items such as 'hair loss' and 'chilblains' that are not
known side effects of neuroleptic medication. The red herring items are numbers 3, 8, 11,
12, 25, 28, 30, 33, 42 and 45. These should be scored separately as this score may
indicate individuals who overscore generally on the scale (a high score would be over 20
for example). The scoring is as follow:
Notatall	 =0
Very little	 = 1
Alittle	 =2
Quite a lot	 = 3
Very much













Assessment date	 Assessment no.
Please indicate how much you have experienced each of the following symptoms in the last month by






















	 Difficulty in concentrating
10. Constipation
11. Hair loss
12. Urine darker than usual
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Not	 Very	 A little	 Quite	 Very
at all
	










21.	 Difficulty in remembering things
22.	 Losing weight
23.	 Lack of emotions






29. Slowing of movements
30. Greasy skin
31. Sleeping too much
32. Difficulty passing water
33. Flushing of face
34. Muscle spasms
35. Sensitivity to sun
36. Diarrhoea
37. Over-wet or drooling mouth
38. Blurred vision









41.	 Difficulty getting to sleep
Very
much
















44. Pins and needles
45. Painful joints
46. Reduced sex drive
47. New or unusual skin marks
48. Parts of body moving on their own
49. Itchy skin
50. Periods less frequent
51. Passing a lot of water
Not	 Very	 A little	 Quite	 Very
at all	 little	 a lot	 much
_ 1 1 __ H
_ __ H





Extrapyramidal side effects 	 Anticholinergic side effects
19 Muscle stiffness 	 6. Dry mouth
29 Slowing of movements	 10. Constipation
34 Muscle spasms	 32. Difficulty passing water
40 Restiessness	 38. Blurred vision
43 Shakiness	 51. Passing a lot of water
48 Parts of the body moving on their own
37 Over-wet or drooling mouth
Possible range 0 - 28	 Possible range 0-20
Other autonomic	 Allergic reactions
15. Dizziness	 1. Rash
16. Feeling sick	 35. Sensitivity to sun
20. Palpitations	 47. New or unusual skin marks
27. Increased sweating	 49. Itchy skin
36. Diarrhoea
Possible range 0-20	 Possible range 0 - 16
Psychic side effects	 Hormonal side effects
2. Difficulty staying awake during the day 	 7. Swollen or tender chest
4 . Increased dreaming	 13. Period problems - women only
9. Difficulty in concentrating	 17. Increased sex drive
14. Tension	 24. Difficulty in achieving climax
18. Tiredness	 46. Reduced sex drive
21. Difficulty in remembering things	 50. Periods less frequent - women only
23. Lack of emotions
26. Depression
31. Sleeping too much
41. Difficulty getting to sleep
Possible range 0 - 40	 Possible range Women 0 - 24, Men 0- 16
Miscellaneous	 Red Herrings
5. Headaches	 3. Runny nose
22. Losing weight	 8. Chilblains
39. Putting on weight	 11. Hair loss
44. Pins and needles	 12. Urine darker than usual
25. Weak finger nails
28. Mouth ulcers
30. Greasy skin
33. Flushing of face
42. Neck muscles aching
45. Painful joints
Possible range 0- 16	 Possible range 0-40
Possible range for total scores
LIJNSERS side effect scores only	 LIJNSERS all 51 items
Women 0-164	 Women 0-204
Men	 0-156	 Men	 0-196
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Hogan Drug Attitude Inventory
Assessment date	 Assessment no.
The purpose of this questionnaire is to gain some understanding of how people view the use of psychiatric
medications and the nature of their experiences of these drugs. Your replies are used for research purposes
only, are strictly confidential, and will in no way affect your treatment.
Please read each of the following statements and decide whether it is true as applied to you or false as
applied to you. If the statement is false or usually false, circle the F following the statement. If the
statement is true or usually true, circle the T following the statement. If you want to change an answer,
mark an X over the incorrect answer and circle the correct answer.
Please answer every question. If a statement is worded not quite the way you would express it yourself,
decide whether it is mostly true or mostly false. Remember to give your own opinion- there are no right
or wrong answers. Do not spend too much time on any one item.
The medications referred to in the statements are psychiatric medications only.
1. I don't need to take medication once I feel better. T F
2. For me, the good things about medication outweigh the bad. T F
3. I feel weird, like a 'zombie', on medication. T F
4. Even when I am not in hospital I need medication regularly. I F
5. If! take medication its only because of pressure from other people. T F
6. I am more aware of what I am doing, of what is going on around me, when I am on medication. T F
7. Taking medications will do me no harm. T F
8. I take medications of my own free choice. T F
9. Medications make me feel more relaxed. T F
10. I am no different on or off medication. T F
11.The unpleasant effects of medication are always present. T F
12. Medication makes me feel tired and sluggish. T F
13. I take medication only when I am sick. I F
14. Medication is a slow-acting poison. T F
15. 1 get on better with people when I am on medication. T F
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16. 1 cant concentrate on anything when I am on medication. T F
17. 1 know better than the doctor when to go off medication. T F
18. 1 feel more normal on medication. T F
19. 1 would rather be sick than taking medication. T F
20. It is unnatural for my mind and body to be controlled by medication. T F
21. My thoughts are clearer on medication. T F
22. 1 should stay on medication even if! feel all right. T F
23. Taking medication will prevent me from having a breakdown. T F
24. It is up to the doctor when I go off medication. T F
25. Things that I could do easily are much more difficult when I am on medication. T F
26. I am happier, feel better, when taking medication. T F
27. I am given medication to control behaviour that other people (not myself) don't like. T F
28. I can't relax on medication. T F
29. I am in better control of myself when taking medications. T F
30. By staying on medications I can prevent getting sick. T F
If you have any further comments about medications or about this questionnaire, please write them
below.
Please do not write below this line
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SCORING CRITERIA
The scale has 15 items that will be scored as True and 15 items that will be scored as False in the case of a
fully compliant response. A correct answer to these items will be scored as plus 1. An incorrect answer will
be scored as minus 1. The total score is the sum of pluses and minuses. A positive total score means a
compliant response. A negative total score means a non-compliant response.






















































Insight scale for psychosis (ISP)
Assessment date	 Assessment no.
Please read the following statements carefully and then tick the box which best applies to you
	
Agree	 Disagree Unsure
I. Some of my symptoms are made by my mind
2. I am mentally well
3. I do not need medication 	 LII	 LI	 LI
4. My stay in hospital is necessary	 LI	 LI
5. The doctor is right in prescribing medication for me
6. I do not need to be seen by a doctor or psychiatrist	 LII	 LI
7. If someone said I have a nervous or a mental illness they would be
right













1. Some of my symptoms are made by my mind
2. I am mentally well	 LII
3. I do not need medication 	 LII
4. My stay in hospital is necessary
5. The doctor is right in prescribing medication for me
6. I do not need to be seen by a doctor or psychiatrist
7. If someone said I have a nervous or a mental illness they would be right
8. None of the unusual things I experience are due to an illness
Items
1+8 = Relable (total 4)
2+7 = Awareness of illness (total 4)
3+4+5+6/2 =Need for treatment (total 4)
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EXERCISE
In pairs (one person the therapist, one the patient) complete the self-report measures (if
necessary working through the measures with the patient). Think carefully about how you
present the assessments. Once they have been completed score them and try to work out,
with the patient, particular problems they have with medication e.g. specific side effects,
don't believe they need it, think that it is poison (patient formulation/problems and
targets). Think about the interventions that you would use to address these problems.







1:00 Key skills in medication management (reviewing the patients' illness history)
What is your personal aim for the day?
Aim:
Evaluation (include whether your aim was achieved):
Homework
You must read:
Taylor D. and Thomas B (1997) Psychopharmacology. In Thomas B. (ed) Stuart and
Sundeens Mental Health Nursing. Mosby, London
Kemp, R. Hayward P. and David A. (1997) The compliance therapy manual. The
Bethlem and Maudsey NHS Trust.
These papers/manuals are in your reading pack.
You should familiarise yourself with:
Taylor D. McConnell D. McConnell H. (1999) The Bethlem and Maudsley NHS Trust
Prescribing Guidelines 51h Edition. Martin DUnitZ, London.
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Schizophrenia
Psychopharmacology	 • Most serious of mental disorder
• Prevalence - approximately 1%
Ri.io..,.	 .(P.y. L	 llth.d .y.
	 t
Schizophrenia
• Positive symptoms e.g. hallucinations,
delusions, thought disorder
• Negative symptoms e.g. lack of
motivation, social withdrawal, emotional
blunting
I1th	 y.	 .(Ply. L.á
Dopamine hypothesis
• Increased dopaminergic





- All antipsychotics block post-synaptic
receptors
- PM - increase D2 - receptors
Dopamine hypothesis
• Evidence against
- In vivo scans shown no difference in D2
receptor density
- 20-30% treatment refractory













- Risk factor for tardive dyskinesia











• Efficacy vs. positive symptos





RidO, I*. (Py. L
Predictable adverse effects
• Hypotension, dizziness, sedation
• EPS, hyperprolactinaemia, TD, NMS
• Sedation
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Tardive dyskinesia
• No evidence for other atypicals
Id _-,. •	 .(P7. U
• Typical drugs - incidence 5% per year
• Clozapine improves symptoms
• Olanzapine - incidence 1% per year
Neuroleptic malignant
syndrome








- ft creatinine kinase
L.bd O..y.	 .(Py. L
Adverse effects	 Introduction of atypical drugs
• Use of typical antipsychotics limited by
adverse effects
• EPS
• Can be used to their advantage e.g.
chiorpromazine










• Atypical implies EPS sparing
• Lower propensity for EPS/no propensity
for EPS
• Does not necessarily mean better efficacy
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Hyperprolactinaemia	 Weight gain
• Haloperidol +++	 • Haloperidol +
• Clozapine	 0	 • Clozapine	 -4-e-+
• Risperidone ++	 • Risperidone +
• Sertindole 0	 • Sertindole ++
• Olanzapine +	 • Olanzapine +++
• Quetiapine 0	 • Quetiapine ++
• Zotepine	 +
	
RidO..y.	 .(hvNy. L	 IMd _.,.
Antipsychotic efficacy in
positive symptoms
• Clozapine superior for positive and
negative symptoms in non-refractory and
refractory schizophrenia
• All other antipsychotics - equal efficacy
RId O...	 .iPly. L.à.
Antipsychotic efficacy in
negative symptoms
• Equal efficacy for typical drugs
• Atypical have superior efficacy to typical,
but differences between them
- Clozapine +++
- Risperidone +
- Sertin dole (16mg)
- Olanzapine ++
—Quetiapine ?
rkd y,	 (Py. Ld
Antipsychotic efficacy in
refractory schizophrenia
• Clozapine - good evidence
• Risperidone - weak evidence
• Olanzapine - weak evidence
,.	 .IP*V. I
Choosing an antipsychotic






- Two drugs acting on the same physiological
systems
- Predict from pharmacology








.,.	 iP)iy. LM.dO..y,	 .(Py. L..á
Metabolism






Key skills in medication management
The illness timeline
Patients identify when they, or significant others, first realised they had psychiatric
problems and then plot the course of their illness and the positive and negative effects of
treatment over time. Close attention should be paid to helping the patient identify when
their mental health has been particularly good and when it has been not so good. The
purpose of this exercise is two-fold; firstly it helps the patient make any links between
stopping medication and worsening psychopathology, and secondly to identify and
examine negative experiences of treatment, particularly where medication had been
forcibly administered.
Time:	 5 minutes
Skills to be rated:	 Agenda setting, interpersonal effectiveness, guided discovery,
feedback
Agenda items:	 Reviewing the patients' experience of treatment
Current medication: 	 Sulpiride
Patient: You are 27 years old and have been taking antipsychotic
medication for the last five years. You do not believe that you
have a mental illness but you do acknowledge that you get
"stressed out". Medication helps reduce the voices you hear
but you stop taking it as soon as you leave hospital because
you don't like the idea of taking it and are worried that you
might be on it for life. You get some side effects which you






2:00 Key skills in medication management (exploring ambivalence)
What is your personal aim for the day?
Aim:
Evaluation (include whether your aim was achieved):
Homework
You must read:
Gournay K. Gray R. Taylor D. (1997) New Drug treatments for schizophrenia. Mental
Health Nursing 4,55-59.
Gray R. (in press) Effective dosing in the use of antipsychotics for the treatment of acute
schizophrenia. Mental Health Care
These papers are in your reading pack
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Key skills in medication management
Drawing up a balance sheet
Patients are helped to draw up a balance sheet to highlight both the positive and negative
aspects of treatment. Emphasis should be placed on identifying the less obvious, or
indirect, effects of medication (staying out of hospital, getting into fewer arguments, less
problems with the neighbours). Dependent on the patients' level of functioning this
activity may be done as homework with the therapist expanding and clarifying the work
the patient had already undertaken.
Time:




Agenda setting, interpersonal effectiveness, guided discovery,
feedback, pacing
Looking and the not so good and the good things about
medication
Sulpiride
Patient: You are 27 years old and have been taking antipsychotic
medication for the last five years. You do not believe that you
have a mental illness but you do acknowledge that you get
"stressed out". Medication helps reduce the voices you hear
but you stop taking it as soon as you leave hospital because
you don't like the idea of taking it and are worried that you
might be on it for life. You get some side effects which you
fmd distressing. This is the second session with the interviewer
with whom you are happy to talk. In the first session the







2:00 Key skills in medication management (testing patient's beliefs about treatment)
What is your personal aim for the day?
Aim:
Evaluation (include whether your aim was achieved):
Homework
Gray R. (1997) The administration of PRN medication by mental health nurses. Journal
of Psychiatric and Mental Health Nursing, 4, 55-57.
Gray R. (in press) Antipsychotics, side effects and effective management. Mental Health
Practice.
Both of these papers are in your reading pack.
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Key skills in medication management
Testing beliefs about illness and medication
Patients' beliefs about their illness and medication should be tested by using a modified
version of the cognitive behavioural procedures for examining delusions (Chadwick et
a!., 1996). Patients' beliefs about their illness and medication are identified from the drug
attitude inventory and listed. The patient then rates the beliefs in tenns of their influence
on complianc.e. The beliefs are then rated on a percentage scale (0%=don't believe it at
all 1 00%belief held with complete conviction). If the belief is held with less than 100%
conviction it is gently challenged; the plausibility of the belief is questioned; and the
belief is reformulated as being an understandable response to, and way of making sense
of, specific experiences, and a personally meaningful alternative is constructed. Finally,
the patients' belief and the alternative are assessed (using the percentage scale) in the
light of the available information.
Time:	 5 minutes
Skills to be rated:	 Guided discovery, interpersonal effectiveness
Agenda items:	 Look at beliefs about medication
Current medication:	 Sulpiride
Patient: You are 27 years old and have been taking antipsychotic
medication for the last five years. You do not believe that you
have a mental illness but you do acknowledge that you get
"stressed out". Medication helps reduce the voices you hear
but you stop taking it as soon as you leave hospital because
you don't like the idea of taking it and are worried that you
might be on it for life. You get some side effects which you
find distressing. This is your third session with the interviewer,
with whom you are happy to talk. In the first session the
interviewer helped you identify a pattern between stopping
medication and relapse. In the second you explored the not so






2:00 Key skills in medication management role play (problem solving)
What is your personal aim for the day?
Aim:
Evaluation (include whether your aim was achieved):
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Key skills in medication management
Specific problems with medication
Specific problems with medication, such as side effects, should be examined using a
problem solving strategy (Hawton and Kirk, 1989). A problem is selected and a target is
agreed. The broad steps necessary to achieve this goal are then identified and the patient
decides, in detail, the practical and realistic tasks that would be necessary to achieve this
goal. Progress is then reviewed in subsequent sessions
Time:	 5 minutes
Skills to be rated:	 Agenda setting, strategy for change
Agenda items:	 Sorting out the side effects of medication
Current medication: 	 Sulpiride
Patient: You are 27 years old and have been taking antipsychotic
medication for the last five years. You do not believe that you
have a mental illness but you do acknowledge that you get
"stressed out". Medication helps reduce the voices you hear
but you stop taking it as soon as you leave hospital because
you don't like the idea of taking it. This is the forth session
• - with the interviewer with whom you are happy to talk. You
think that medication might be helpful but are concerned about







2:00 Key skills in medication management (planning for the future)
What is your personal aim for the day?
Aim:
Evaluation (include whether your aim was achieved):
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Key skills in medication management
Long term plans
Patients are asked to look six to twelve months into the future and identify a goal the they
want to achieve. A problem solving strategy is utilised to identify broad and specific
tasks needed to achieve this objective.
Time:	 5 minutes
Skills to be rated: 	 Strategy for change
Agenda items:	 Planning for the future
Current medication:	 Sulpiride
Patient:	 You are 27 years old and have been taking antipsychotic
•	 medication for the last five years. You do not believe that you
•	 have a mental illness but you do acknowledge that you get
•	 "stressed out". Medication helps reduce the voices you hear
• but you stop taking it as soon as you leave hospital because
you don't like the idea of taking it. This is the fifth session
with the interviewer whom you are happy to talk to. You think
that medication might be helpful but are concerned about
taking it long term.
284
Day ten (follow-up day)
Agenda
SUBMISSION OF COURSE WORK
9:30 Clinical supervision updates
12:00 Course evaluation form
2:00 Multiple choice questionnaire
2:30 Video role-play
What is your personal aim for the day?
Aim:










What was rated: 1. Video role-play 0 2. Live session 0 3. Audio tape 0
Directions: For each item, assess the therapist on a scale from 0 to 6, and record the rating in the
space provided. Descriptions are given for even-numbered scale points. Ifyou believe the
therapist falls between two of the descriptions, select the intervening odd number (1, 3,
5). For example, if the therapist sets a very good agenda but did not establish priorities,
assign a rating of 5 rather than 4 or 6.
If the descriptions for a given item occasionally do not seem to apply to the session you are rating,
feel free to disregard them and use the more general scale below:
0	 1	 2	 3	 4	 5	 6














Therapist did not set an agenda
Therapist set an agenda that was vague or incomplete
Therapist worked with patient to set a mutually satisfactory agenda that included
specific areas for discussion.
Therapist worked with patient to set an appropriate agenda with specific and
relevant areas for discussion suitable for the time available. Established priorities

























Therapist did not ask for feedback to determine patient's understanding of, or
response to, the session.
Therapist elicited some feedback from the patient, but did not ask enough questions
to be sure the patient understood the therapist's line of reasoning during the session
or to ascertain whether the patient was satisfied with the session
Therapist asked enough questions to be sure that the patient understood the
therapist's line of reasoning throughout the session and to determine the patient's
reactions to the session. The therapists adjusted his/her behaviour in response to the
feedback, when appropriate.
Therapist was especially adept at eliciting and responding to verbal and non-verbal
feedback throughout the session (e.g. elicited reactions to session, regularly
checked for understanding, helped summarize main points at end of session).
Anchor points
Therapist repeatedly failed to understand what the patient explicitly said and thus
consistently missed the point. Poor empathic skills.
Therapist was usually able to reflect or rephrase what the patient explicitly said, but
repeatedly failed to respond to more subtle communication. Limited ability to listen
and empathize.
Therapist generally seemed to grasp the patient's "internal reality" as reflected by
both what the patient explicitly said and what the patient communicated in more
subtle ways. Good ability to listen and empathize
Therapist seemed to understand the patient's "internal reality" thoroughly and was
adept at communicating this understanding through appropriate verbal and non-
verbal responses to the patient (e.g. the tones of the therapist's response conveyed a





























Therapist had poor interpersonal skills. Seemed hostile, demeaning, or in some
other way destructive to the patient.
Therapist did not seem destructive, but had significant interpersonal problems. At
times, therapist appeared unnecessarily impatient, aloof, insincere or had difficulty
conveying confidence and competence.
Therapist displayed a satisfactory degree of warmth, concern, confidence,
genuineness, and professionalism. No significant interpersonal problems.
Therapist displayed optimal levels of warmth, concern, confidence, genuineness,
and professionalism, appropriate for this particular patient in this session.
Anchor points
Therapist did not attempt to set up collaboration with patient.
Therapist attempted to collaborate with patient, but had difficulty either defining a
problem that the patient considered important or establishing rapport.
Therapist was able to collaborate with patient, focus on a problem that both patient
and therapist considered important, and establish rapport.
Collaboration seemed excellent; therapist encouraged patient as much as possible
to take an active role during the session (e.g. by offering choices) so they could
function as a "team".








Therapist made no attempt to structure therapy time. Session seemed aimless.
Session had some direction, but the therapist had significant problems with
structuring or pacing (e.g., too little structure, inflexible about structure, too slowly
paced, too rapidly paced).
Therapist was reasonably successful at using time efficiently. Therapist maintained
appropriate control over flow of discussion and pacing
Therapist used time efficiently by tactfully limiting peripheral and unproductive
























Therapist relied primarily on debate, persuasion, or "lecturing". Therapist seemed
to be "cross-examining" patient, putting the patient on the defensive, or forcing
his/her point of view on the patient.
Therapist relied too heavily on persuasion and debate, rather than guided discovery.
However, therapist's style was supportive enough that patient did not seem to feel
attacked or defensive.
Therapist, for the most part, helped patient see new perspective through guided
discovery (e.g., examining evidence, considering alternative, weighing advantages
and disadvantages) rather than through debate. Used questioning appropriately.
Therapist was especially adept at using guided discovery during the session to
explore problems and help patient draw his/her own conclusions. Achieved an
excellent balance between skilful questioning and other modes of intervention
8. Strategy for change (Note: For this item, focus on the quality of the therapist's strategy for change, not












Therapist did not select compliance therapy techniques.
Therapist selected compliance therapy techniques; however, either the overall
strategy for bringing about change seemed vague or did not seem promising in
helping the patient.
Therapist seemed to have a generally coherent strategy for change that showed
reasonable promise and incorporated compliance therapy techniques.
Therapist followed a consistent strategy for change that seemed very promising and
incorporated the most appropriate compliance therapy techniques.
9. Application of compliance therapy/medication management techniques (Note: For this item, focus
on how skillfully the techniques were applied, not on how appropriate they were or whether change
actually occurred).
Anchor points
Therapist did not apply any compliance therapy or medication management
techniques.
Therapist used compliance therapy or medication management techniques, but
there were significant flaws in the way they were applied.
Therapist applied compliance therapy or medication management techniques with
moderate skill.
Therapist very skillfully and resourcefully employed compliance therapy
techniques.
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10. How would you rate the clinician in this session
Poor	 Barely	 Mediocre	 Satisfactory
	 Good	 Very Good	 Excellent
Adequate




You will enter a room where you will be introduced to a patient who wants to discuss
medication with you. They are concerned about the side effects they are experiencing
from the antipsychotic medication they are taking (sulpiride and procyclidine) and have
decided to stop taking it. You know from the notes that this is has happened before and
that when they stop they quickly become unwell again. In the past they have responded
well to medication that has got rid of very distressing voices and thoughts.
You have up to fifteen minutes to talk to the patient about their concerns. If you have not
finished the interview within fifteen minutes you will be stopped.
The interview is being video-taped and will be rated by an independent rater. It will be
destroyed at the end of the trial and will not be used for teaching or any other purpose
without your expressed permission in writing.
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APPENDIX 6
KNOWLEDGE ABOUT MEDICATION MANAGEMENT QUESTIONNIARE (KAMMQ)
Please answer each question on the work sheet by placing a against the answer that you think is correct.
Each question has only one correct answer. If you change your mind draw a line through the incorrect
answer and place a 0 against your new answer. Please answer all the questions on the work sheet. Any
questions that are unanswered will be scored as incorrect.
PATIENT PROFILE ONE
John is 38. He was diagnosed as suffering from schizophrenia 10 years ago. He has been prescribed
various antipsychotics over the years with limited effect and is currently maintained on zuclopenthixol
decanoate, administered every two weeks. He has only partially responded to this drug and continues to
complain of hallucinations and has marked negative symptoms.
1. John is receiving zuclopenthixol decanoate that is a conventional antipsychotic. Which of the following
best describes how these drugs work to relieve psychotic symptoms?
A. Block dopamine receptors 	 0
B. Block serotonin receptors	 0
C. Block histamine receptors 	 0
D. Inhibit the reuptake of dopamine	 0
E. Inhibit the reuptake or serotonin	 0
2. Conventional antipsychotics are most effective in treating
A. Positive symptoms	 0
B. Negative symptoms	 0
C. Cognitive functioning 	 0
D. Extrapyramidal symptoms	 0
E. Affective symptoms	 0
3. Like John, many patients with schizophrenia do not respond to conventional antipsychotics. What
proportion of patients do not respond to these drugs?
A. Approximately 80% 0
B. Approximately 50% 0
C. Approximately 20% 0
D. Approximately 100% 0
E. Approximately 10% 0
4. Conventional antipsychotics are associated with extrapyramidal symptoms (EPS). Which of the
following group of side-effects are commonly known as EPS?
A. Tardive dyskinesia, agranulocytosis, neuroleptic malignant syndrome, dystonias 	 0
B. Akathisia, tardive dyskinesia, agranulocytosis, parkinsonism	 0
C. Neuroleptic malignant syndrome. Dystonias, tardive dyskinesia, akathisia 	 0
D. Dystonias, parkinsonism, akathisia, tardive dyskinesia 	 0
E. Parkinsonism, tardive dyskinesia, agranulocytosis, dystonias 	 0
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5. Sexual dysfunction is a common side effect of antipsychotics why do patients experience these
symptoms?
A. Increased levels of serotonin	 0
B. Raised levels of prolactin	 0
C. Blockade of histamine receptors 	 0
D. Hyperdopaminergia	 0
E. Increased levels of GABA	 0
6. Clozapine belongs to the group of drugs termed atypical antipsychotics. What is one of the major
characteristics of an atypical drug?
A. Blockade of adrenergic receptors 	 0
B. Efficacy in improving cognitive functioning 	 0
C. It's new	 0
D. It's expensive	 0
E. It does not induce EPS at therapeutic doses 	 0
7. Clozapine has been shown to be effective for other patients like Mr. Smith who do not respond to






8. Novel antpsychotics (excluding clozapine) have been shown to be as effective as conventional drugs in a
number of ways. In which of the following are novel antipsychotics no different to conventional
treatments?
A. Inducing EPS	 0
B. Reducing negative symptoms	 0
C. Enhancing cognitive function	 0
D. Treating positive symptoms 	 0
E. Reducing affective symptoms	 0
PATIENT PROFILE TWO
Mary has had a diagnosis of schizophrenia for six years. She has had several relapses requiring
hospitalisation as she tended to stop taking her medication when discharged. Mary says the medication
makes her feel worse and her reason for smoking cannabis is to ease the side effects.





E. Around 70% 0
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10. Mary says the medication makes her feel worse and may be experiencing a negative subjective













12. Mary would be considered to have a dual diagnosis of schizophrenia and substance misuse. What
proportion of patients with a diagnosis of schizophrenia are reported to have a dual diagnosis in urban areas
of the UK?
A. Approximately 10% 0
B. Approximately 85% 0
C. Approximately 35% 0
D. Approximately 20% 0
E. Approximately 5% 0
13. Mary's poor compliance may be related to her lack of insight (awareness of illness). Which of the
following has not been shown to affect compliance?
A. Extrapyramidal symptoms	 0
B. Complex treatment regimes	 0
C. Lack of knowledge about medication	 0
D. Substance misuse	 0
E. Grandiose delusions	 0
14. Mary may benefit from compliance therapy. What are the components of this approach?
A. Cognitive behavioural therapy and psychoeducation	 0
B. Psychoeducation and behaviour therapy	 0
C. Motivational interviewing and psychoeducation 	 0
D. Cognitive behaviour therapy and motivational interviewing	 0
E. Psychodynamic psychotherapy and motivational interviewing	 0
15. What is one of the key principles of compliance therapy?
A. Confronting patients beliefs about medication	 0
B. Collaborating with patients on decisions about medication	 0
C. Encouraging the patient to stop medication	 0
D. Coercing the patient into taking medication	 0
E. Presenting information to patients using didactic methods. 	 0
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16. Mary has a very negative view of treatment and this may affect her long-term compliance. How might
you assess these views?
A. Use the KGV	 0
B. Use the Barnes scale	 0
C. Use the DAI-30	 0




Medication management course evaluation
For each of the key components of the course please state: 1. How satisfied you were
with way in which it was taught; 2. How relevant it was to your clinical practice; 3.
Whether you have been able to apply what you have learnt in practice.
1. Assessing symptoms
Satisfaction with how the component was taught
1. Satisfied	 LI
2. Neither satisfied or dissatisfied [1
3. Dissatisfied	 Li
Relevance to clinical practice
1. Relevant	 Li
2. Neither relevant or irrelevant	 [1
3. Irrelevant	 Li




2. Assessing factors affecting compliance
Satisfaction with how the component was taught
1. Satisfied	 Li
2. Neither satisfied or dissatisfied Li
3. Dissatisfied	 Li
Relevance to clinical practice
1. Relevant	 Li
2. Neither relevant or irrelevant	 Li
3. Irrelevant	 Li






Satisfaction with how the component was taught
1. Satisfied	 [1
2. Neither satisfied or dissatisfied LI
3. Dissatisfied	 LI
Relevance to clinical practice
1. Relevant	 LI
2. Neither relevant or irrelevant 	 [I
3. Irrelevant	 Li





Satisfaction with how the component was taught
1. Satisfied	 Li
2. Neither satisfied or dissatisfied U
3. Dissatisfied	 El
Relevance to clinical practice
1. Relevant	 El
2. Neither relevant or irrelevant	 LI
3. Irrelevant	 El




4. Medication management key skills role play
Satisfaction with how the component was taught
1. Satisfied	 U
2. Neither satisfied or dissatisfied El
3. Dissatisfied	 El
Relevance to clinical practice
1. Relevant	 El
2. Neither relevant or irrelevant	 El
3. Irrelevant	 El
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4. The medication management course overall
Satisfaction with how the component was taught
1. Satisfied	 El
2. Neither satisfied or dissatisfied El
3. Dissatisfied	 El
Relevance to clinical practice
1. Relevant	 El
2. Neither relevant or irrelevant	 El
3. Irrelevant	 El



















































































































































































































































































































































































































































































E = experimental group; C = control group

























We would like to invite you to participate in a research study. We are interested to find
out whether we can improve your care by giving extra training to your community
psychiatric nurse (CPN) on various aspects of your treatment, especially medication. All
we ask of you is that you complete some questionnaires and be interviewed by a
researcher now, after about six months and again after 12 months. The questionnaires
will take approximately half an hour and cover how you are managing, how you are
feeling and how the medication suits you. The interview will take approximately 40
minutes. If you do not wish to participate or if you do but then change your mind, this
will not affect you treatment or care in any way.
If you have any concerns about the study contact:
RICHARD GRAY
Tutor-Practitioner






Patients name	 Patient ID code
1. I voluntarily agree to take part in the study.
2. I am over 18 years of age.
3. I have been given a full explanation of the purpose of the study.
4. I am aware of what is expected of me by agreeing to participate in this study.
5. I am aware that I can refuse to participate in this study and that by not agreeing to
take part my care and treatment will not be affected in any way.
6. 1 understand that I can withdraw my consent from the study at any time.
7. I understand that I will not be referred to by name in any report concerning this study.























Duration of illness (in years)
Age at onset of illness (in years)
Number of previous psychiatric admissions
Number of detentions under MHA






























Since the last assessment how many days has the patient spent in psychiatric hospital.
days
Week 52 assessment




Histogram — PANSS-total	 Histogram — DAI-30
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Trainee satisfaction with training
f
Ii I I 1 .Zii) ii p11) itI Ii FI11 Ii 4jJ pl(I)pi
Satisfaction with how the
	 Relevance to clinical practice Ability to apply in practice
component was taught
Satisfied	 37 (84%) Relevant	 32 (73%) Completely	 29 (66%)




Dissatisfied	 0 (0%)	 Irrelevant	 0 (0%)	 Not at all	 0 (0%)I
I1 I I 'f-lI)ii1 III) II	 iii!1i pi4I),1I,)(H1 ItJ
-	 I
Satisfaction with how the
	 Relevance to clinical practice Ability to apply in practice
component was taught
Satisfied	 35 (80%) Relevant	 34 (77%) Completely 	 34 (77%)
Neither	 9 (20%)	 Neither	 10 (23%) Partially	 11(23%)
satisfied or	 relevant or
dissatisfied	 irrelevant
Dissatisfied	 0 (0%)	 Irrelevant	 0 (0%)	 Not at all	 0 (0%)
Satisfaction with how the
	 Relevance to clinical practice Ability to apply in practice
component was taught
Satisfied	 43 (98%) Relevant	 44	 Completely	 27 (61%)
(100%)




Dissatisfied	 0 (0%)	 Irrelevant	 0 (0%)	 Not at all	 0 (0%)
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Iii I 'fZ hII) iii p Ill iF) l	 Ifl1!1 ¶il I iII Ij fl [l]iU
Satisfaction with how the
	 Relevance to clinical practice Ability to apply in practice
component was taught
Satisfied	 31 (70%) Relevant	 29 (66%) Completely	 24 (5 5%)




Dissatisfied	 0 (0%)	 Irrelevant	 0 (0%)	 Not at all
	 0 (0%)
Satisfaction with how the
	 Relevance to clinical practice Ability to apply in practice
component was taught
Satisfied	 26 (59%) Relevant	 31(70%) Completely	 23 (52%)
Neither	 18 (41%) Neither




Dissatisfied	 0 (0%)	 Irrelevant	 0 (0%)	 Not at all	 0 (0%)
I	 I
Satisfaction with how the
	 Relevance to clinical practice Ability to apply in practice
component was taught
Satisfied	 40 (90%) Relevant
	 37 (84%) Completely	 28 (64%)
Neither	 4 (10%)	 Neither	 7 (6%)	 Partially	 16 (36%)
satisfied or	 relevant or
dissatisfied	 irrelevant
Dissatisfied	 0 (0%)	 Irrelevant	 0 (0%)	 Not at all	 0 (0%)
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